

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Peer-mediated assisted partner notification services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041083
Article Type:	Protocol
Date Submitted by the Author:	29-May-2020
Complete List of Authors:	<p>Monroe-Wise, Aliza; University of Washington, Mbogo, Loice; Kenyatta National Hospital  Guthrie, Brandon; University of Washington  Bukusi, David; Kenyatta National Hospital  Sambai, Betsy; Kenyatta National Hospital  Chohan, Bhavna; University of Washington; Kenya Medical Research Institute  Scott, John; University of Washington  Cherutich, Peter; Kenya Ministry of Health  Musyoki, Helgar; Kenya Ministry of Health  Bosire, Rose; Kenya Medical Research Institute; University of Washington  Dunbar, Matthew; University of Washington  Macharia, Paul; Kenya Ministry of Health  Masyuko, Sarah; Kenya Ministry of Health; University of Washington  Wilkinson, Eduan; University of KwaZulu-Natal  De Oliveira, Tulio; University of KwaZulu-Natal  Ludwig-Barron, Natasha; University of Washington  Sinkele, Bill; Support for Addiction Prevention and Treatment in Africa  Herbeck, Joshua; University of Washington School of Public Health,  Farquhar, Carey; University of Washington</p>
Keywords:	<p>HIV &amp; AIDS &lt; INFECTIOUS DISEASES, Hepatology &lt; INTERNAL MEDICINE, International health services &lt; HEALTH SERVICES ADMINISTRATION &amp; MANAGEMENT, Epidemiology &lt; INFECTIOUS DISEASES, Molecular diagnostics &lt; INFECTIOUS DISEASES, VIROLOGY</p>

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Peer-mediated assisted partner notification services to identify and link to care HIV-**  
4 **positive and HCV-positive people who inject drugs: a cohort study protocol**  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14

15 Aliza Monroe-Wise<sup>a</sup>, Loice Mbogo<sup>b</sup>, Brandon Guthrie<sup>a,c</sup>, David Bukusi<sup>b</sup>, Betsy Sambai<sup>b</sup>, Bhavna  
16 Chohan<sup>a,d</sup>, John Scott<sup>e</sup>, Peter Cherutich<sup>f</sup>, Helgar Musyoki<sup>f</sup>, Rose Bosire<sup>d</sup>, Matthew Dunbar<sup>g</sup>, Paul  
17 Macharia<sup>f</sup>, Sarah Masyuko<sup>a,f</sup>, Eduan Wilkinson<sup>h</sup>, Tulio de Oliveira<sup>h</sup>, Natasha Ludwig-Barron<sup>b</sup>,  
18  
19  
20 Bill Sinkele<sup>i</sup>, Joshua Herbeck<sup>a\*</sup>, Carey Farquhar<sup>a,b,e\*</sup>  
21  
22  
23  
24  
25  
26  
27  
28

29 <sup>a</sup>University of Washington Department of Global Health, <sup>b</sup>Kenyatta National Hospital,  
30  
31 <sup>c</sup>University of Washington Department of Epidemiology, <sup>d</sup>Kenya Medical Research Institute,  
32  
33 <sup>e</sup>University of Washington Department of Medicine, <sup>f</sup>Kenya's Ministry of Health, <sup>g</sup>Center for  
34  
35 Studies in Demography and Ecology, University of Washington, <sup>h</sup>KwaZulu-Natal Research and  
36  
37 Innovation Sequencing Platform, University of KwaZulu-Natal, <sup>i</sup>Support for Addiction  
38  
39 Prevention and Treatment in Africa  
40  
41  
42  
43  
44  
45  
46

47 Corresponding author: Aliza Monroe-Wise, MD, MSc. Email: alizamw@uw.edu  
48  
49

50 University of Washington, 325 Ninth Avenue, Box 359909, Seattle, WA 98104-2499  
51  
52

53 \*These authors share senior authorship.  
54  
55  
56  
57  
58  
59  
60

## **Abstract**

### **Introduction**

Targeted, tailored interventions to test high-risk individuals for HIV and hepatitis C (HCV) are vital to achieving HIV control and HCV micro-elimination in Africa. Compared with the general population, people who inject drugs (PWID) are at increased risk of HIV and HCV and are less likely to be tested or successfully treated. Assisted partner notification services (APNS) increases HIV testing among partners of people living with HIV and improves case-finding and linkage to care. We describe a study in Kenya examining whether APNS can be adapted to find, test, and link to HIV and HCV care the sexual and injecting partners of HIV-positive PWID using a network of community-embedded peer educators (PEs).

### **Methods and analysis**

This prospective cohort study leverages a network of PEs to identify 1,000 HIV-positive PWID for enrollment as index participants. Each index completes a questionnaire and provides names and contact information of all sexual and injecting partners from the past 3 years. PEs then use a stepwise locator protocol to engage partners in the community and bring them to study sites for enrollment, questionnaire completion and rapid HIV and HCV testing. Outcomes include number and type of partners per index who are mentioned, enrolled, tested, diagnosed with HIV and HCV and linked to care.

### **Ethics and dissemination**

All potential index participants are screened for intimate partner violence (IPV) and those at high risk are not eligible to enroll. Those at medium risk are monitored for IPV following enrollment.

1  
2  
3 A community advisory board (CAB) meets biennially to engage in feedback and discussion  
4  
5 between the community and the research team. A safety monitoring board (SMB) meets biennially  
6  
7 to discuss study progress and review data, including IPV monitoring data. Dissemination plans  
8  
9 include presentations at quarterly Ministry of Health (MoH) working group meetings, local and  
10  
11 international conferences, and publications.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Strengths and limitations of this study**

- This cohort study investigates the use of assistant partner notification services (APNS) for HIV and hepatitis C (HCV) to find, test, and link to care the sexual and injection partners of people who inject drugs (PWID) in Kenya—a high risk, difficult to reach population.
- Community embedded peer educators who are former drug users trained to provide harm reduction services and are known and trusted within the PWID community conduct partner tracing, and typically serve as the first point of contact with potential partner participants.
- An iris scanning biometric identification system ensures that each index participant enrolled is a unique individual and confirms that individual partner participants who enroll more than once in relation to different index participants are the same individual.
- Phylogenetic analysis of HIV and HCV viral sequences combined with APNS provides additional information about transmission dynamics within the cohort, including risk of onward transmission for different clusters and geographic regions.

### **Introduction**

Of the UNAIDS 90-90-90 goals,<sup>1</sup> diagnosing 90% of those living with HIV remains the most elusive target worldwide,<sup>2</sup> and strategies to reach high-risk individuals who have never been tested for HIV is increasingly important.<sup>3</sup> Sharing needles and other drug paraphernalia is the most efficient mode of HIV transmission, and accounts for 13% of new infections globally.<sup>4,5</sup> In Kenya, prevalence of HIV among people who inject drugs (PWID) has been estimated at 15 – 50%<sup>5–9</sup>—significantly higher than the general population prevalence of 4.9%,<sup>10</sup> and up to 30% of PWID in Kenya have never tested for HIV.<sup>11,12</sup> Multiple studies have demonstrated low knowledge of HIV

1  
2  
3 status and low engagement in care among Kenya's PWID.<sup>12,13</sup> Retention in care and adherence to  
4  
5 ART are also both lower among drug users as compared with non-drug users worldwide,<sup>2</sup> and sub-  
6  
7 Saharan Africa (SSA) has the lowest rates of ART use among HIV-positive PWID anywhere in  
8  
9 the world.<sup>14</sup>  
10  
11

12  
13 In addition to HIV, PWID are at high risk for hepatitis C virus (HCV) globally and have the highest  
14  
15 HCV prevalence of any group studied in Kenya, between 13-40%<sup>15-17</sup> compared with the general  
16  
17 population prevalence of <1-4%.<sup>18,19</sup> However, multiple barriers exist at individual, provider and  
18  
19 system levels resulting in low rates of testing, engagement in care, and completion of treatment  
20  
21 courses for PWID.<sup>20-22</sup> Although less than 20% of PWID with chronic HCV worldwide have  
22  
23 undergone antibody screening, the number who have completed PCR confirmatory testing is even  
24  
25 lower.<sup>23</sup> Despite the introduction of highly effective direct acting antivirals (DAAs) into Kenya in  
26  
27 2016, only a small fraction of HCV-infected individuals have been treated, prompting attention to  
28  
29 micro-elimination strategies.  
30  
31  
32  
33

34  
35 Assisted partner notification services (APNS) for HIV is an evidence-based partner notification  
36  
37 strategy in which providers elicit information about the sexual or injecting partners of an HIV-  
38  
39 positive index client, and then contact, HIV test and link to care any partners found to be positive.<sup>24</sup>  
40  
41 APNS has been shown to significantly and safely increase the uptake of HIV testing services  
42  
43 (HTS), case finding, and linkage to care for partners of HIV-positive people.<sup>24-26</sup> APNS can also  
44  
45 reduce barriers to disclosing HIV status<sup>27</sup> and is cost-effective.<sup>28</sup> APNS has been successfully  
46  
47 implemented among HIV-positive patients from the general population in the USA,<sup>29</sup>  
48  
49 Mozambique,<sup>30</sup> Malawi,<sup>31,32</sup> and Kenya,<sup>26</sup> and has recently been incorporated into the World  
50  
51 Health Organization (WHO) guidelines for routine care for HIV-positive people worldwide.<sup>33</sup>  
52  
53  
54  
55 While programs have introduced the practice of APNS in high-risk key populations (KPs) such as  
56  
57  
58  
59  
60



1  
2  
3 female sex workers (FSW)<sup>34</sup> and men who have sex with men (MSM),<sup>35,36</sup> this intervention has  
4 not been well-studied among PWID, an extremely high risk group.<sup>24,37</sup> Similar to FSW and MSM,  
5 PWID engage in behavior that is criminalized<sup>38</sup> while experiencing high rates of marginalization  
6 and displacement,<sup>39</sup> making them difficult to study. These factors and others also contribute to  
7 significant barriers in the implementation of health programs targeting PWID.<sup>40–42</sup>  
8  
9  
10  
11  
12  
13

14  
15  
16 Phylogenetic analysis is a method of identifying the role of specific risk groups and risk factors  
17 for onward transmission of HIV and HCV using the genetic sequence of each virus.<sup>43–45</sup> Viral  
18 phylogenetics can provide additional information on patterns of transmission,<sup>46–48</sup> epidemic  
19 growth,<sup>49,50</sup> risk groups,<sup>51–53</sup> and risk factors associated with onward transmission.<sup>45,54–56</sup>  
20  
21  
22  
23  
24  
25

26 Here we describe a prospective cohort study that seeks to determine whether and how APNS can  
27 be implemented to find, test, and link to care the injection and sexual partners of HIV-positive  
28 PWID in Kenya. Simultaneously, our study will use phylogenetic analysis to study genetic  
29 sequences of HIV and HCV within our cohort to further understand transmission patterns and risk  
30 for onward transmission. All index and partner participants are tested for HCV in addition to HIV.  
31  
32 In Kenya, the large majority of PWID do not have regular access to cellular telephones, which are  
33 the typical communication modality for APNS in other populations. As such, our APNS model  
34 relies on the utilization of community-embedded peer educators (PEs) to locate and communicate  
35 with members of this difficult to reach population. We hypothesize that we will be able to employ  
36 these customized APNS procedures to reach a large number of injection and sexual partners, and  
37 that we will see differences in HIV and HCV testing, HIV and HCV prevalence, and engagement  
38 in care between sexual and injection partners. Additionally, we hypothesize that we will identify  
39 unique transmission patterns and risks for onward transmission in phylogenetic analysis.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Methods and analysis**

### *Approach*

APNS is a practice through which healthcare providers facilitate the notification, testing and linkage to care for partners who have been exposed to HIV or other sexually transmitted infections by an individual known to be positive. Typically, APNS is conducted by healthcare providers who elicit information about partners from an “index” patient and then call the partners over the telephone to alert them to their exposure and arrange testing. We have designed customized procedures to ensure and improve the safety and efficacy of APNS in the unique population of PWID in Kenya. Because PWID and their partners in Kenya rarely own cellular phones, we work with community-embedded peer educators (PEs) to find and engage with partners. Additionally, our protocol includes different APNS procedures among injection partners and for sexual partners, as these groups have different risk profiles and different relationships to index participants.

### *Study design*

Our study is a prospective cohort study with two groups: index and partner participants (“indexes” and “partners”). We use tailored APNS procedures to identify, find, test and link to care the sexual and injection partners of HIV-positive PWID. All participants who are either HIV-positive or HCV-infected then complete a 6-month follow-up visit to assess linkage to and engagement in care.

### *Study sites/setting*

Study procedures take place in eight main sites including public health centers, medically assisted therapy (MAT) centers, and needle and syringe programs (NSPs) in Nairobi, Kilifi, and Mombasa

1  
2  
3 Counties in Kenya (Figure 1). Each site is staffed by at least one clinical officer (mid-level  
4 clinician) who works with the study team to ensure that indexes are HIV-positive. In Nairobi  
5  
6 County, the activities are centered at two NSP sites and one MAT center in the Mathare North  
7  
8 area. The NSP sites, run by Support for Addiction Prevention and Treatment in Africa (SAPTA),  
9  
10 offer routine HIV counseling and testing. Referrals are made to local clinics providing care for  
11  
12 those who test positive for HIV or HCV. We also recruit indexes from a government-run  
13  
14 methadone clinic in Nairobi in the Ngara area. The Ngara Health Center MAT clinic offers HIV  
15  
16 testing, care and treatment in addition to daily methadone administration, psychosocial services  
17  
18 and treatment for other health conditions. In Kilifi county, participant recruitment and enrollment  
19  
20 takes place at three needle and syringe program centers and one government hospital. The Omari  
21  
22 Project is located in Malindi town and offers HIV counseling, testing, care and treatment in  
23  
24 addition to harm reduction services. Malindi Sub-County Hospital's MAT center is a recruitment  
25  
26 site in Kilifi County within a mid-sized government hospital that offers a large range of medical  
27  
28 and social services. Malindi Sub-County Hospital also has a large laboratory that houses the  
29  
30 study's samples collected in both Kilifi and Mombasa Counties. The Muslim Education and  
31  
32 Welfare Association (MEWA) NSP sites in Kilifi and Mtwapa towns offer HIV counseling and  
33  
34 testing, in addition to HIV care and treatment and harm reduction services. In Mombasa county,  
35  
36 participants are recruited from the ReachOut Center, an NSP site in Mombasa city that offers a  
37  
38 full range of harm reduction services in addition to HIV counseling, testing, care and treatment.  
39  
40 All recruitment sites offer HCV testing when kits are available through specific donor-driven  
41  
42 projects.  
43  
44  
45  
46  
47  
48  
49  
50

### 51 52 Population 53 54 55 56 57 58 59 60

1  
2  
3 This study includes index participants and their sexual and injecting partners . All indexes are HIV-  
4 positive PWID. Partners are either sexual partners or injecting partners of indexes. As such,  
5  
6 partners need not be PWID or HIV-positive but are defined by their relationships with indexes.  
7  
8  
9

10  
11 Indexes are largely recruited from organizations and clinics that provide services to PWID  
12  
13 populations, although they may also come from outreach efforts or informal referrals from other  
14  
15 participants. Partners are identified and recruited through peer-mediated APNS and may come  
16  
17 from any geographic area or community.  
18  
19  
20

### 21 Study procedures

#### 22 1. Peer educator recruitment and training

23  
24  
25  
26  
27  
28 PEs are recovering PWID with established relationships in the PWID communities that they serve.  
29  
30 The majority are between the ages of 25 and 50, are enrolled in Kenya's methadone program and  
31  
32 have stopped injecting drugs, byself-report. These men and women have been identified by the  
33  
34 individual organizations at which they work as being key community members, and have  
35  
36 undergone extensive training for their roles as PEs. Training is an intensive 5-day course with  
37  
38 modules covering a broad spectrum of content including basics of drugs and drug-related harms,  
39  
40 harm reduction efforts including NSP and MAT, abscess prevention and management, overdose  
41  
42 prevention and management and behavior change communication. PEs have access to relatively  
43  
44 hidden PWID community spaces, and provide health counseling, linkage to support organizations,  
45  
46 information, and other services to this vulnerable population.  
47  
48  
49

50  
51  
52 For this study, PEs who were actively carrying out basic duties were chosen by the leadership at  
53  
54 each organization based on several factors including awareness and knowledge of HIV in the  
55  
56  
57  
58  
59

1  
2  
3 community and access to unique target populations (for instance, women who inject drugs are  
4 more easily accessed by women PEs). Once identified, PEs underwent an intensive 1-day training  
5  
6 more easily accessed by women PEs). Once identified, PEs underwent an intensive 1-day training  
7  
8 to educate them on the practice and ethics of research, study procedures, and their role in the study.  
9  
10 PEs participate in regular health education and harm reduction training and engage in quarterly  
11  
12 sessions with study leadership wherein PEs present barriers and lessons learned to the study team  
13  
14 so that study-related issues can be addressed.  
15

## 16 17 18 2. Inclusion & exclusion criteria

19  
20  
21 Inclusion and exclusion criteria are different for indexes and partners (Table 1). Any interested  
22  
23 individuals who are under the age of 18 are referred to the site clinicians for routine counseling  
24  
25 and harm reduction services.  
26  
27

## 28 29 3. Index recruitment and enrollment

30  
31  
32 PEs work with clinicians at each site to identify potential indexes at NSP sites, MAT centers and  
33  
34 other areas where PWID congregate. Clinicians are employed by the sites, and are trained as  
35  
36 clinical officers (COs), or mid-level providers. For this study, HIV rapid testing is performed by  
37  
38 COs and takes place as part of standard clinic procedures. All potential indexes are re-tested using  
39  
40 HIV rapid tests (as per the national guidelines) to confirm HIV status prior to enrollment. If HIV-  
41  
42 seropositive, either newly diagnosed or known to be positive, clinicians either discuss the study  
43  
44 directly with potential participants or engage PEs to find individuals and bring them to the study  
45  
46 office. Importantly, PEs are not told whether participants are being traced as an index or a partner,  
47  
48 protecting the confidentiality of indexes' HIV status.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Study staff health advisors (HAs) are the individuals responsible for conducting study procedures  
4 including data collection, HIV and HCV testing, and the coordination of APNS efforts (Figure 2).  
5  
6 All HAs were trained and experienced in HIV counseling and testing prior to working for the  
7  
8 study, and many had previous experience working with PWID. All HAs underwent a week-long  
9  
10 training course at the beginning of the study in which they learned the basics and purpose of  
11  
12 research, research ethics, study procedures, unique ethical and logistical issues to consider when  
13  
14 working with PWID, and other topics. All HAs also completed the Collaborative Institutional  
15  
16 Training Initiative (CITI) course on Human Subjects Research and the Responsible Conduct of  
17  
18 Research. HAs explain the benefits and rationale for providing APNS, discuss the importance of  
19  
20 learning more about HIV and HCV, and describe the process of notifying partners without  
21  
22 revealing the identity of the index. They ask participants to provide written informed consent and  
23  
24 use an iris-scanning biometric device to record a unique identifier for each participant, thus  
25  
26 enabling the study team to confirm that a person does not enroll into the program as an index more  
27  
28 than once.  
29  
30  
31  
32  
33  
34  
35

36 Indexes undergo a structured questionnaire administered by the HA using open data kit (ODK)  
37  
38 software on tablet devices (ODK, 2017, Seattle, WA, USA). Questionnaires cover a variety of  
39  
40 topics including demographics, sexual and injecting behaviors, drug use history, and HIV testing  
41  
42 and engagement history. Participants are then asked to recall all of their sexual and injecting  
43  
44 partners over the past three years, naming these partners one by one and assigning each partner a  
45  
46 letter (“A,” “B,” etc). Indexes are asked to give as much locator information as possible for each  
47  
48 partner, including names (which may be nicknames), phone numbers, and location of employment  
49  
50 or residence. Locator information is written on a paper form for each partner. Indexes then  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 complete a short ODK questionnaire about each partner mentioned, which includes information  
4  
5 about the relationship between the index and the partner.  
6  
7

8  
9 Indexes then undergo rapid HCV antibody testing as part of routine study procedures. HAs conduct  
10  
11 pre- and post- test counseling and ensure individuals who test positive are available for follow-up  
12  
13 visits to discuss confirmatory HCV PCR testing and enrolling in a treatment program administered  
14  
15 by the Ministry of Health. All indexes then undergo phlebotomy with a sample of 10mL of blood  
16  
17 drawn for further testing (see section 6 below). Indexes receive 400 Kenya Shillings (KES,  
18  
19 equivalent to about \$4) as compensation for travel and time spent in the study procedures.  
20  
21  
22

#### 23 4. Peer-educator mediated assisted partner services and partner recruitment

24  
25  
26 For those partners who have phone numbers listed, HAs attempt phone communication first.  
27  
28 However, the vast majority of partners mentioned by indexes do not have working cellular phones;  
29  
30 therefore, with very few exceptions, PEs locate and conduct the study's first interaction with  
31  
32 identified partners. PEs are given paper forms containing names and locator information for  
33  
34 identified partners. They are never told which index referred the team to each partner, and that  
35  
36 information is not listed on locator forms or any other accessible file. PEs then locate and approach  
37  
38 potential participants in the community. Using a standardized script, PEs inform potential  
39  
40 participants that they have been identified as an individual who might be eligible for a research  
41  
42 study on HIV and HCV. They then accompany interested individuals to the nearest research office,  
43  
44 where the study's HAs conduct informed consent.  
45  
46  
47  
48  
49

#### 50 5. Partner enrollment

1  
2  
3 After informed consent and biometric identification, partners complete a structured questionnaire  
4 similar to that of indexes, administered by HAs on a handheld device using ODK software.  
5  
6 Following the questionnaire, all partners undergo rapid antibody testing for both HIV and HCV.  
7  
8 Testing and counseling services are provided in accordance with national HIV testing and  
9 counseling guidelines. Any partner found to be positive for either HIV or HCV antibodies  
10 undergoes a 10mL blood draw. Those partners who test negative for both HIV and HCV are  
11 finished with study procedures at this time, and are counseled on risk reduction measures and  
12 linked to HIV and HCV prevention services before leaving the study site. All partners receive 400  
13 Kenya Shillings (KES, equivalent to about \$4) as compensation for travel and time spent in the  
14 study procedures.  
15  
16

17 HIV-positive partners are invited to undergo screening as an index once data collection procedures  
18 for their partner enrollment are complete. If they meet eligibility criteria as an index, they may  
19 enroll as an index. Study procedures are slightly amended for indexes that have previously enrolled  
20 as partners. After undergoing informed consent and completing a short questionnaire that only  
21 includes questions that were not a part of the partner enrollment questionnaire, they complete the  
22 identification and data collection on each of their sexual and injection partners, identical to partner  
23 identification procedures for indexes described above.  
24  
25

## 26 6. Laboratory Procedures

27 Blood samples from both index and partner enrollment visits are collected in EDTA vacutainer  
28 tubes. Blood is mixed with the anticoagulant by inversion and the anticoagulated blood is stored  
29 at room temperature at the sites for less than 4 hours. A motorcycle courier picks samples from  
30 each site daily and brings them to the University of Nairobi Pediatric Research Laboratory in  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Nairobi or the Malindi Sub-County Hospital Laboratory for coast sites. At each laboratory,  
4 samples are first used to prepare two Whatman 903 Protein Saver dried blood spot (DBS) cards  
5 with 50ul of whole blood on each spot. Blood samples are then centrifuged and used to prepare 2  
6 to 3 aliquots of 1ml of plasma in labeled serum vials. Plasma aliquots and air-dried DBS cards  
7 (with desiccant in sealed Ziploc bags) are then stored at -80° Celsius and shipped on dry ice to the  
8 University of KwaZulu-Natal laboratory. There, samples undergo HIV and HCV viral load testing  
9 and amplification for sequencing.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

## 20 7. Participant follow-up

21  
22  
23 All index and partner participants who were positive for HIV or HCV complete a six-month  
24 follow-up visit. HAs identify which participants are due for follow-up visits on a weekly basis and  
25 give PEs as list of these names. PEs then trace participants and bring them back to clinics where  
26 data collection procedures are conducted.  
27  
28  
29  
30  
31  
32  
33

34 Six-month visits are short, and involve only a brief questionnaire covering questions on testing for  
35 HIV or HCV (if not infected with both on enrollment), enrollment in care and treatment,  
36 engagement in care, and follow-up testing. The purpose of this visit is to assess whether  
37 engagement in care has changed following APNS procedures.  
38  
39  
40  
41  
42  
43

## 44 8. Intimate partner violence (IPV) monitoring

45  
46  
47 Given historical concerns that APS may increase one's risk of experiencing intimate partner  
48 violence, all potential participants undergo screening for IPV before enrollment. IPV is defined as  
49 any physical, sexual or psychological harm inflicted on a person by a current or former sexual  
50 partner. After answering a standardized set of six questions about physical, emotional and sexual  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 IPV and the timing of any previous experience of IPV based on published screening tools reviewed  
4 by the Centers for Disease Control and Prevention,<sup>57</sup> potential participants are classified as low,  
5 medium or high risk for IPV. Individuals are classified as at high risk for IPV if they report IPV  
6 within the last month. Any potential index who is classified as high IPV risk is excluded from  
7 study participation and provided with IPV counseling and resources. Any potential partner who is  
8 classified as high IPV risk is allowed to enroll, but then receives special monitoring for IPV  
9 following enrollment.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 Potential participants are classified as at moderate risk for IPV if they report 1) IPV during their  
21 lifetime either from a current or past partner; and/or 2) fear of IPV if they participate in the study.  
22 All index or partner participants classified as moderate IPV risk receive special monitoring for  
23 IPV following their enrollment in the study.  
24  
25  
26  
27  
28  
29

30 Potential participants are classified as at low risk for IPV if they report 1) no IPV during their  
31 lifetime ; and 2) no fear of IPV if they participate in the study. These individuals undergo standard  
32 study procedures which include completing the baseline IPV case report form and a follow-up IPV  
33 case report to capture reports of any interim IPV.  
34  
35  
36  
37  
38  
39

#### 40 9. Confidentiality and safety

41  
42  
43

44 *Participants:* All study procedures take place in private rooms at each study facility. To ensure the  
45 safety and confidentiality of indexes, PEs who are tasked with finding partners are blinded to the  
46 identity of the linked index through the use of partner locator forms that do not contain identifying  
47 information about the index participant. Locator forms do contain a printed barcode label that are  
48 then used by study staff to link the partner with the index who referred the partner.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Sexual partners are brought to independent facilities for enrollment rather than to centers that serve  
4  
5 PWID, in order to further protect the identity of the index participant who referred them. The  
6  
7 independent facilities are local healthcare clinics that serve the general population.  
8  
9

10  
11 *Peer educators:* PEs have frequent interactions with police, and can be victims of harassment or  
12  
13 violence, both by police and by PWID. To reduce the risk of law enforcement troubles, PEs carry  
14  
15 identification showing that they are working on a study being conducted by the Ministry of Health.  
16  
17 Local law enforcement officials have also attended ongoing sensitization trainings by the Ministry  
18  
19 of Health and by organizations working with PWID.  
20  
21

## 22 23 10. Referrals to care

24  
25  
26  
27 *HIV Counseling and Care:* Participants are provided with their HIV test results in the context of  
28  
29 post-test counseling, and are then referred to available medical and psychosocial care and support  
30  
31 facilities either within the research site or in close proximity to the research site or the participant's  
32  
33 home. Additionally, HIV-positive individuals are offered individual or group support sessions as  
34  
35 available within each site.  
36  
37

38  
39  
40 *HCV Counseling and Care:* Participants who test positive for HCV antibodies using rapid testing  
41  
42 are provided with their HCV antibody test results in the context of pre- and post-test counseling.  
43  
44 They are informed that they may have active HCV infection; however, further confirmatory testing  
45  
46 must be done prior to establishing the diagnosis. Confirmatory polymerase chain reaction (PCR)  
47  
48 testing is done in batches of samples at our partnering laboratory at the University of KwaZulu-  
49  
50 Natal, South Africa, and participants with active infection are later contacted for results and  
51  
52 counseling. Once notified, those with active infection are paired with a PE at their site to ensure  
53  
54  
55  
56  
57  
58  
59

1  
2  
3 close contact is maintained. Study participants with active HCV infections will be eligible to  
4 receive free treatment with direct acting antivirals, which the Kenyan MoH has procured.  
5  
6

### 7 8 9 Data management

10  
11  
12 After each study visit, HAs review their work for omissions or errors and all data are uploaded  
13 into the study database. Electronic data are stored securely in an encrypted database on servers  
14 using Open Data Kit Aggregate, within Kenya's Ministry of Health (MoH). All errors or omissions  
15 identified at any step in the quality assurance/quality control process are revised by the staff  
16 member who originally completed the document. All additions and corrections are initialed and  
17 dated by the staff member who records the entry.  
18  
19  
20  
21  
22  
23  
24

25  
26  
27 A link-log is separately encrypted to further ensure that data remains secure. Any data transferred  
28 to investigators or MoH are de-identified and encrypted during the process of transfer from the  
29 server. Each investigator maintains and stores secure, complete, accurate and current study records  
30 throughout the study. A database manager performs regular data cleaning and resolves any  
31 discrepancies that occur. Study sites also conduct quality control and quality assurance procedures.  
32  
33  
34  
35  
36  
37  
38

### 39 Outcome measures

40  
41  
42 The primary outcomes of interest to assess the success of the APNS intervention are: a) number  
43 of partners tested for HIV and HCV through APNS, identified by each index participant over the  
44 course of the study period; b) number of partners newly testing positive for HIV and HCV, per  
45 index participant; c) number of known HIV or HCV cases identified through APNS who are not  
46 engaged in care; d) number of index and partner participants with HIV and/or HCV infection who  
47 are linked to care; e) number of index and partners with HIV and/or HCV infection who remain in  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 care and are receiving appropriate treatment at 6 months after testing positive. Secondary outcomes  
4  
5 are linked to inclusion in phylogenetic clusters identified as high risk for onward transmission of  
6  
7 HIV and HCV.  
8  
9

### 10 11 Sample size and power analysis 12

13  
14 We are enrolling 1000 HIV-positive indexes and their sexual and injecting partners . Based on  
15  
16 HCV data from MoH and our preliminary results, we estimate that 20% of PWID with HIV will  
17  
18 be co-infected with HCV and that each index will identify on average two partners who will accept  
19  
20 HIV and HCV testing, 20% of whom will be HIV-positive, and 20% of whom will be HCV-  
21  
22 infected. Thus, with provision of APNS to 1,000 HIV-positive indexes and testing of 2,000  
23  
24 partners, we will identify an estimated 600 indexes and partners infected with HCV and 400 HIV-  
25  
26 positive partners.  
27  
28  
29

### 30 31 Statistical methods and analysis 32

33  
34 To determine efficacy of the APNS intervention, we will use generalized estimating equations  
35  
36 (GEE) models with a Poisson link to compare the two arms of the study using the following  
37  
38 variables and offsets: 1) rate of HIV and HCV testing of partners: number of individuals tested for  
39  
40 HIV or HCV, offset by the number of partners located with locator information provided by the  
41  
42 index participant; 2) prevalence of HIV and HCV infection: number of individuals identified as  
43  
44 HIV or HCV-positive, offset by the number of individuals who were HIV tested; and 3) rate of  
45  
46 linkage to HIV and HCV care: individuals who test HIV or HCV-positive and link to care, offset  
47  
48 by the total number of individuals who test HIV or HCV-positive.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Additionally, using both GEE and phylogenetic analysis, we will determine the following: 1)  
4 identifiable and individual risk factors linked to high rates of HIV and HCV transmission, 2) risk  
5 factors linked to both needle-sharing and sexual transmission, and 3) identification of transmission  
6 clusters among PWID for both HIV and HCV.  
7  
8  
9  
10  
11

### 12 Phylogenetic analysis

13  
14  
15  
16 HIV and HCV gene sequencing is attempted for all study participants who test positive for either  
17 virus. Sequencing will be performed at the KwaZulu-Natal Research Innovation and Sequencing  
18 Platform (KRISP) at the University of KwaZulu-Natal in Durban, South Africa. For HIV we will  
19 subsequently combine our data with additional, publicly available, HIV sequences from Kenya  
20 and perform phylogenetic and phylodynamic analyses to describe patterns and rates of viral  
21 transmission among key populations in Kenya and identify traits associated with relative  
22 infectiousness. For HCV we will use phylogenetic methods to characterize the modes and risk  
23 factors for onward transmission among PWID.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 Ethics and Dissemination

#### 37 General ethical considerations

38  
39  
40  
41  
42 This study is registered at [clinicaltrials.gov](http://clinicaltrials.gov) and has ethical approval from both the University of  
43 Washington Human Subjects Division and the Kenyatta National Hospital Ethics and Research  
44 Committee. It also has approval from Kenya's National Commission for Science, Technology and  
45 Innovation.  
46  
47  
48  
49  
50

51  
52  
53 Risks to study participants are minimal, as neither obtaining blood nor HIV testing is likely to  
54 cause serious harm to the study participant. While IPV has the potential to cause harm, it has not  
55  
56  
57  
58  
59

1  
2  
3 increased in other US or African studies when this intervention has been implemented.<sup>24,58,59</sup> Study  
4  
5 staff are highly trained in counseling about risk behaviors, implications of testing HIV-positive,  
6  
7 and protecting confidentiality to avoid potential social harms. In addition, staff have undergone  
8  
9 extensive training on IPV counseling and ensure that resources have been identified in all sites so  
10  
11 we can safely refer participants who report abuse or are concerned for their safety. To further  
12  
13 monitor and protect against IPV, we collect IPV data on case report forms during interviews with  
14  
15 participants as described above.  
16  
17  
18  
19

20  
21 A safety monitoring board composed of researchers and policy makers in both Kenya and the US  
22  
23 reviews study data twice per year. The board monitors enrollments, deaths, loss to follow up,  
24  
25 adverse events, and IPV monitoring data and makes recommendations of whether to continue  
26  
27 study procedures.  
28  
29

30  
31 Ethical considerations surrounding the use of biometric identification systems among vulnerable  
32  
33 key populations in Kenya have been discussed extensively.<sup>60</sup> Despite early opposition from the  
34  
35 Key Populations Consortium and other organizations to the government's use of fingerprint-based  
36  
37 biometric data collection, the organizations and individuals working with PWID communities  
38  
39 continued to report no opposition to iris scanning for research purposes among PWID. In  
40  
41 November 2019, Kenya passed the Data Protection Bill, rendering it legal to collect biometric data  
42  
43 as long as the use of such data does not violate the subjects' rights.<sup>61</sup> The use of biometrics is now  
44  
45 standard practice in many research and clinical settings, and has been found to be acceptable to  
46  
47 participants.<sup>62</sup> Our participants have not reported any concerns, fears, or hesitations regarding the  
48  
49 use of an iris scanning biometric identification system.  
50  
51  
52  
53

#### 54 Dissemination plan

55  
56  
57  
58  
59  
60

1  
2  
3 Results from the study are presented on an ongoing basis at Kenya's quarterly MoH harm reduction  
4 and key population technical working group meetings, and discussed at biannual community  
5 advisory board meetings. Our study team includes several officials from the MoH. Ongoing study  
6 analyses are also presented at national conferences annually, including Kenya's HIV clinicians'  
7 society meeting, the Infectious Disease Society of Kenya (IDSK) biennial conference, or the  
8 Annual University of Nairobi STD/HIV/SRH Collaborative Conference. Additionally, study  
9 results are presented in at least one international conference per year, including the Conference on  
10 Retroviruses and Opportunistic Infections (CROI), the International AIDS Conference, and the  
11 College on Problems of Drug Dependence (CPDD) annual conference. Finally, the study team  
12 reviews data on a weekly basis and any changes in data trends or other concerns are discussed  
13 directly with the organizations through which study procedures take place.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Authors' contributions**

30  
31  
32 CF and JH conceived of the study; AMW, BG, BC, MD, PM, JH and CF contributed to the study  
33 design and data collection structure; AMW, LM, DB, BSa, BC, JS, PC, HM, RB, PM, SM, EW,  
34 TDO, JH and CF contributed to data collection; AMW, LM, BG, DB, BSa, PC, HM, RB, SM,  
35 EW, TDO, NLB, JH and CF contributed to data analysis and dissemination; AMW, BG, JH and  
36 CF wrote the manuscript; all authors reviewed the manuscript for content.  
37  
38  
39  
40  
41  
42  
43  
44

### 45 **Funding**

46  
47  
48 This work was supported by National Institutes of Drug Abuse, grant number R01 DA043409.  
49  
50

### 51 **Competing interests**

52  
53  
54  
55 All authors state that they have no competing interests.  
56  
57  
58  
59  
60



## Patient and Public Involvement

Members of the community of PWID being researched were consulted in the development of research questions and design of the study. The study is supported by a Community Advisory Board (CAB) composed of members of the community, peer educators and employees of organizations that provide services to the population. The CAB meets with the study team regularly and helps inform dissemination plans.

## References

1. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Published October 2014. Accessed March 7, 2018. [http://www.unaids.org/sites/default/files/media\\_asset/90-90-90\\_en.pdf](http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf)
2. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. *BMJ Glob Health*. 2016;1(2):e000010. doi:10.1136/bmjgh-2015-000010
3. Staveteig S, Croft TN, Kampa KT, Head SK. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries. *PLOS ONE*. 2017;12(10):e0186316. doi:10.1371/journal.pone.0186316
4. Brodish P, Singh K, Rinyuri A, et al. Evidence of high-risk sexual behaviors among injection drug users in the Kenya PLACE study. *Drug Alcohol Depend*. 2011;119(1-2):138-141. doi:10.1016/j.drugalcdep.2011.05.030
5. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet Lond Engl*. 2008;372(9651):1733-1745. doi:10.1016/S0140-6736(08)61311-2
6. M. Odek-Ogunde, B. Lore, F. Owiti, S. Munywoki, J. Moor. Seroprevalence of HIV, HBC and HCV in injecting drug users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II findings. In ; 2004.
7. National AIDS Control Council NS and ACP. Kenya HIV Prevention Revolution Road Map: Count Down to 2030. Published online June 2014.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
8. Kurth AE, Cleland CM, Des Jarlais DC, et al. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya. *J Acquir Immune Defic Syndr* 1999. 2015;70(4):420-427. doi:10.1097/QAI.0000000000000769
9. Ndetei, David M. A study on the linkages between drug abuse, injecting drug use and HIV/AIDS in Kenya: a rapid situation assessment. *U N Off Drugs Crime.*:45.
10. National AIDS Control Council. *Kenya HIV Estimates Report 2018*. Accessed February 21, 2019. <https://nacc.or.ke/wp-content/uploads/2018/11/HIV-estimates-report-Kenya-20182.pdf>
11. Tun W, Sheehy M, Broz D, et al. HIV and STI Prevalence and Injection Behaviors Among People Who Inject Drugs in Nairobi: Results from a 2011 Bio-behavioral Study Using Respondent-Driven Sampling. *AIDS Behav*. 2015;19(Suppl 1):24-35. doi:10.1007/s10461-014-0936-3
12. Lizcano, J. Testing and Linkage to Care for Injecting Drug Users. In: ; 2016.
13. Githuka G, Hladik W, Mwalili S, et al. Populations at Increased Risk for HIV Infection in Kenya: Results From a National Population-Based Household Survey, 2012. *J Acquir Immune Defic Syndr* 1999. 2014;66(Suppl 1):S46-S56. doi:10.1097/QAI.0000000000000137
14. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. *Lancet Lond Engl*. 2010;375(9719):1014-1028. doi:10.1016/S0140-6736(10)60232-2
15. Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. *Lancet Infect Dis*. 2019;19(11):1255-1263. doi:10.1016/S1473-3099(19)30264-6
16. Muasya T, Lore W, Yano K, et al. Prevalence of Hepatitis C Virus and its genotypes among a cohort of drug users in Kenya. *East Afr Med J*. 2008;85(7). doi:10.4314/eamj.v85i7.9649
17. Odek-Ogunde M, Okoth, F, Lore, W, Owiti, F.R. Seroprevalence of HIV, HBC and HCV in Injecting Drug Users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II Findings. In: ; 2004.
18. Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. *Pan Afr Med J*. 2019;34. doi:10.11604/pamj.2019.34.31.17885
19. Loarec A, Carnimeo V, Molfino L, et al. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. *AIDS Lond Engl*. 2019;33(2):353-355. doi:10.1097/QAD.0000000000002070
20. Litwin AH, Jost J, Wagner K, et al. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. *Contemp Clin Trials*. 2019;87:105859. doi:10.1016/j.cct.2019.105859

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
21. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. *Drug Alcohol Rev.* 2012;31(7):918-924. doi:10.1111/j.1465-3362.2012.00468.x
22. Enkelmann J, Gassowski M, Nielsen S, et al. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing. *Harm Reduct J.* 2020;17(1):7. doi:10.1186/s12954-019-0338-y
23. Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. *Liver Int Off J Int Assoc Study Liver.* 2019;39(1):20-30. doi:10.1111/liv.13949
24. Dalal S, Johnson C, Fonner V, et al. Improving HIV test uptake and case finding with assisted partner notification services. *AIDS Lond Engl.* 2017;31(13):1867-1876. doi:10.1097/QAD.0000000000001555
25. Kahabuka C, Plotkin M, Christensen A, et al. Addressing the First 90: A Highly Effective Partner Notification Approach Reaches Previously Undiagnosed Sexual Partners in Tanzania. *AIDS Behav.* 2017;21(8):2551-2560. doi:10.1007/s10461-017-1750-5
26. Cherutich P, Golden MR, Wamuti B, et al. Assisted partner services for HIV in Kenya: a cluster randomised controlled trial. *Lancet HIV.* 2017;4(2):e74-e82. doi:10.1016/S2352-3018(16)30214-4
27. Plotkin M, Kahabuka C, Christensen A, et al. Outcomes and Experiences of Men and Women with Partner Notification for HIV Testing in Tanzania: Results from a Mixed Method Study. *AIDS Behav.* 2018;22(1):102. doi:10.1007/s10461-017-1936-x
28. Sharma M, Smith JA, Farquhar C, et al. Assisted partner notification services are cost-effective for decreasing HIV burden in western Kenya. *AIDS Lond Engl.* 2018;32(2):233-241. doi:10.1097/QAD.0000000000001697
29. Landis SE, Schoenbach VJ, Weber DJ, et al. Results of a randomized trial of partner notification in cases of HIV infection in North Carolina. *N Engl J Med.* 1992;326(2):101-106. doi:10.1056/NEJM199201093260205
30. Myers RS, Feldacker C, Cesár F, et al. Acceptability and Effectiveness of Assisted Human Immunodeficiency Virus Partner Services in Mozambique: Results From a Pilot Program in a Public, Urban Clinic. *Sex Transm Dis.* 2016;43(11):690-695. doi:10.1097/OLQ.0000000000000529
31. Brown LB, Miller WC, Kamanga G, et al. HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. *J Acquir Immune Defic Syndr* 1999. 2011;56(5):437-442.
32. Brown LB, Miller WC, Kamanga G, et al. Predicting partner HIV testing and counseling following a partner notification intervention. *AIDS Behav.* 2012;16(5):1148-1155. doi:10.1007/s10461-011-0094-9

- 1
- 2
- 3 33. World Health Organization. WHO | WHO recommends assistance for people with HIV to notify
- 4 their partners. WHO. Accessed February 22, 2019. <http://www.who.int/hiv/pub/vct/who-partner->
- 5 notification-policy/en/
- 6
- 7 34. Quinn C, Nakyanjo N, Ddaaki W, et al. HIV partner notification values and preferences among sex
- 8 workers, fishermen, and mainland community members in Rakai, Uganda: a qualitative study. *AIDS*
- 9 *Behav.* 2018;22(10):3407-3416. doi:10.1007/s10461-018-2035-3
- 10
- 11 35. Rane V, Tomnay J, Fairley C, et al. Opt-Out Referral of Men Who Have Sex With Men Newly
- 12 Diagnosed With HIV to Partner Notification Officers: Results and Yield of Sexual Partners Being
- 13 Contacted. *Sex Transm Dis.* 2016;43(6):341-345. doi:10.1097/OLQ.0000000000000449
- 14
- 15 36. Halkitis PN, Kupprat SA, McCree DH, et al. Evaluation of the relative effectiveness of three HIV
- 16 testing strategies targeting African American men who have sex with men (MSM) in New York City.
- 17 *Ann Behav Med Publ Soc Behav Med.* 2011;42(3):361-369. doi:10.1007/s12160-011-9299-4
- 18
- 19 37. Malik M, Jamil MS, Johnson CC, Pasha MS, Hermez J, Qureshi S ul H. Integrating assisted partner
- 20 notification within HIV prevention service package for people who inject drugs in Pakistan. *J Int*
- 21 *AIDS Soc.* 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25317
- 22
- 23 38. DeBeck K, Cheng T, Montaner JS, et al. HIV and the criminalisation of drug use among people who
- 24 inject drugs: a systematic review. *Lancet HIV.* 2017;4(8):e357-e374. doi:10.1016/S2352-
- 25 3018(17)30073-5
- 26
- 27 39. United Nations, Office on Drugs and Crime. *World Drug Report 2016.*; 2016.
- 28
- 29 40. Molinaro S, Resce G, Alberti A, et al. Barriers to effective management of hepatitis C virus in
- 30 people who inject drugs: Evidence from outpatient clinics. *Drug Alcohol Rev.* 2019;38(6):644-655.
- 31 doi:10.1111/dar.12978
- 32
- 33 41. Phillips KT. Barriers to practicing risk reduction strategies among people who inject drugs. *Addict*
- 34 *Res Theory.* 2016;24(1):62-68. doi:10.3109/16066359.2015.1068301
- 35
- 36 42. Heath AJ, Kerr T, Ti L, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand.
- 37 *J Public Health Oxf Engl.* 2016;38(3):e301-e308. doi:10.1093/pubmed/fdv143
- 38
- 39 43. Frost SDW, Pillay D. Understanding Drivers of Phylogenetic Clustering in Molecular Epidemiological
- 40 Studies of HIV. *J Infect Dis.* 2015;211(6):856-858. doi:10.1093/infdis/jiu563
- 41
- 42 44. Brenner BG, Wainberg MA. Future of phylogeny in HIV prevention. *J Acquir Immune Defic Syndr*
- 43 *1999.* 2013;63 Suppl 2:S248-254. doi:10.1097/QAI.0b013e3182986f96
- 44
- 45 45. Jacka B, Applegate T, Kraiden M, et al. Phylogenetic clustering of hepatitis C virus among people
- 46 who inject drugs in Vancouver, Canada. *Hepatology Baltim Md.* 2014;60(5):1571-1580.
- 47 doi:10.1002/hep.27310
- 48
- 49 46. Grabowski MK, Lessler J, Redd AD, et al. The Role of Viral Introductions in Sustaining Community-
- 50 Based HIV Epidemics in Rural Uganda: Evidence from Spatial Clustering, Phylogenetics, and
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 Egocentric Transmission Models. Hallett T, ed. *PLoS Med.* 2014;11(3):e1001610.  
4 doi:10.1371/journal.pmed.1001610  
5
- 6  
7 47. Worobey M, Gemmel M, Teuwen DE, et al. Direct Evidence of Extensive Diversity of HIV-1 in  
8 Kinshasa by 1960. *Nature.* 2008;455(7213):661-664. doi:10.1038/nature07390  
9
- 10  
11 48. de Oliveira T, Pillay D, Gifford RJ. The HIV-1 Subtype C Epidemic in South America Is Linked to the  
12 United Kingdom. *PLoS ONE.* 2010;5(2). doi:10.1371/journal.pone.0009311  
13
- 14  
15 49. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ. Molecular Phylodynamics of  
16 the Heterosexual HIV Epidemic in the United Kingdom. *PLoS Pathog.* 2009;5(9).  
17 doi:10.1371/journal.ppat.1000590  
18
- 19  
20 50. Hué S, Clewley JP, Cane PA, Pillay D. Investigation of HIV-1 transmission events by phylogenetic  
21 methods: requirement for scientific rigour. *AIDS Lond Engl.* 2005;19(4):449-450.  
22 doi:10.1097/01.aids.0000161778.15568.a1  
23
- 24  
25 51. Dennis AM, Hué S, Hurt CB, et al. Phylogenetic insights into regional HIV transmission. *AIDS Lond*  
26 *Engl.* 2012;26(14):1813-1822. doi:10.1097/QAD.0b013e3283573244  
27
- 28  
29 52. Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the  
30 molecular epidemiology of newly diagnosed HIV infections. *AIDS Lond Engl.* 2012;26(16):2079-  
31 2086. doi:10.1097/QAD.0b013e32835805b6  
32
- 33  
34 53. Kouyos RD, Rauch A, Böni J, et al. Clustering of HCV coinfections on HIV phylogeny indicates  
35 domestic and sexual transmission of HCV. *Int J Epidemiol.* 2014;43(3):887-896.  
36 doi:10.1093/ije/dyt276  
37
- 38  
39 54. Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with  
40 men: a combined clinical, epidemiological and phylogenetic approach. *AIDS.* 2010;24(11):1739-  
41 1747. doi:10.1097/QAD.0b013e32833ac9e6  
42
- 43  
44 55. Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early  
45 HIV-1 infection. *J Infect Dis.* 2007;195(7):951-959. doi:10.1086/512088  
46
- 47  
48 56. Kramer MA, Cornelissen M, Paraskevis D, et al. HIV transmission patterns among The Netherlands,  
49 Suriname, and The Netherlands Antilles: a molecular epidemiological study. *AIDS Res Hum*  
50 *Retroviruses.* 2011;27(2):123-130. doi:10.1089/aid.2010.0115  
51
- 52  
53 57. Centers for Disease Control and Prevention (CDC). Intimate Partner Violence and Sexual Violence  
54 Victimization Assessment Instruments for Use in Healthcare Settings: (410572008-001). Published  
55 online 2007. doi:10.1037/e410572008-001  
56
- 57  
58 58. Monroe-Wise A, Maingi Mutiti P, Kimani H, Moraa H, Bukusi DE, Farquhar C. Assisted partner  
59 notification services for patients receiving HIV care and treatment in an HIV clinic in Nairobi,  
60 Kenya: a qualitative assessment of barriers and opportunities for scale-up. *J Int AIDS Soc.*  
2019;22(Suppl Suppl 3). doi:10.1002/jia2.25315


- 1  
2  
3 59. Goyette MS, Mutiti PM, Bukusi D, et al. Hiv Assisted Partner Services Among Those with and  
4 Without A History of Intimate Partner Violence in Kenya. *J Acquir Immune Defic Syndr* 1999.  
5 Published online February 5, 2018. doi:10.1097/QAI.0000000000001638  
6  
7 60. KELIN and the Kenya Key Populations Consortium. "Everyone Said No:" *Biometrics, HIV and Human*  
8 *Rights – A Kenya Case Study*. KELIN; 2018. Accessed April 10, 2020.  
9 <https://www.kelinkkenya.org/everyonesaidno/>  
10  
11 61. Gathura G. Biometrics system for identifying people living with HIV ready. *The Standard*.  
12 [https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready)  
13 [living-with-hiv-ready](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready). Published November 17, 2019. Accessed April 10, 2020.  
14  
15 62. Anne N, Dunbar MD, Abuna F, et al. Feasibility and acceptability of an iris biometric system for  
16 unique patient identification in routine HIV services in Kenya. *Int J Med Inf*. 2020;133:104006.  
17 doi:10.1016/j.ijmedinf.2019.104006  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 **Table 1. Inclusion and Exclusion Criteria**

<u>Group</u>	<u>Inclusion</u>	<u>Exclusion</u>
<i>Index</i>	<ul style="list-style-type: none"> <li>• 18 years of age or older</li> <li>• Recent intravenous drug use as defined by injecting at least once in the past year</li> <li>• HIV-positive</li> </ul>	<ul style="list-style-type: none"> <li>• Classified as at high risk for IPV (described below)</li> </ul>


	<ul style="list-style-type: none"><li>• Willing and able to provide locator information for sexual and/or injecting partners</li><li>• Willing and able to provide informed consent</li></ul>	
<b><i>Partner</i></b>	<ul style="list-style-type: none"><li>• 18 years of age or older</li><li>• identified by an index as either having injected with the index in the past 3 years or had sexual intercourse with the index in the past three years HIV-positive</li><li>• Willing and able to provide informed consent</li></ul>	None

**Figure 1. Map of Study Sites**





**Figure 2. Study Flow Diagram**



# BMJ Open

## Peer-mediated assisted partner notification services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041083.R1
Article Type:	Protocol
Date Submitted by the Author:	23-Oct-2020
Complete List of Authors:	<p>Monroe-Wise, Aliza; University of Washington, Mbogo, Loice; Kenyatta National Hospital  Guthrie, Brandon; University of Washington  Bukusi, David; Kenyatta National Hospital  Sambai, Betsy; Kenyatta National Hospital  Chohan, Bhavna; University of Washington; Kenya Medical Research Institute  Scott, John; University of Washington  Cherutich, Peter; Kenya Ministry of Health  Musyoki, Helgar; Kenya Ministry of Health  Bosire, Rose; Kenya Medical Research Institute; University of Washington  Dunbar, Matthew; University of Washington  Macharia, Paul; Kenya Ministry of Health  Masyuko, Sarah; Kenya Ministry of Health; University of Washington  Wilkinson, Eduan; University of KwaZulu-Natal  De Oliveira, Tulio; University of KwaZulu-Natal  Ludwig-Barron, Natasha; University of Washington  Sinkele, Bill; Support for Addiction Prevention and Treatment in Africa  Herbeck, Joshua; University of Washington School of Public Health,  Farquhar, Carey; University of Washington</p>
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Addiction, Epidemiology, Evidence based practice, Global health, Gastroenterology and hepatology
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Hepatology < INTERNAL MEDICINE, International health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Epidemiology < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, VIROLOGY

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Peer-mediated assisted partner notification services to identify and link to care HIV-**  
4 **positive and HCV-positive people who inject drugs: a cohort study protocol**  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14

15 Aliza Monroe-Wise<sup>a</sup>, Loice Mbogo<sup>b</sup>, Brandon Guthrie<sup>a,c</sup>, David Bukusi<sup>b</sup>, Betsy Sambai<sup>b</sup>, Bhavna  
16 Chohan<sup>a,d</sup>, John Scott<sup>e</sup>, Peter Cherutich<sup>f</sup>, Helgar Musyoki<sup>f</sup>, Rose Bosire<sup>d</sup>, Matthew Dunbar<sup>g</sup>, Paul  
17 Macharia<sup>f</sup>, Sarah Masyuko<sup>a,f</sup>, Eduan Wilkinson<sup>h</sup>, Tulio de Oliveira<sup>h</sup>, Natasha Ludwig-Barron<sup>b</sup>,  
18  
19  
20 Bill Sinkele<sup>i</sup>, Joshua Herbeck<sup>a\*</sup>, Carey Farquhar<sup>a,b,e\*</sup>  
21  
22  
23  
24  
25  
26  
27  
28

29 <sup>a</sup>University of Washington Department of Global Health, <sup>b</sup>Kenyatta National Hospital,

30 <sup>c</sup>University of Washington Department of Epidemiology, <sup>d</sup>Kenya Medical Research Institute,

31 <sup>e</sup>University of Washington Department of Medicine, <sup>f</sup>Kenya's Ministry of Health, <sup>g</sup>Center for

32 <sup>h</sup>Studies in Demography and Ecology, University of Washington, <sup>h</sup>KwaZulu-Natal Research and

33 <sup>i</sup>Innovation Sequencing Platform, University of KwaZulu-Natal, <sup>i</sup>Support for Addiction

34 <sup>Prevention and Treatment in Africa</sup>

35  
36  
37  
38  
39  
40  
41  
42  
43  
44 Corresponding author: Aliza Monroe-Wise, MD, MSc. Email: alizamw@uw.edu

45  
46  
47 University of Washington, 325 Ninth Avenue, Box 359909, Seattle, WA 98104-2499

48  
49  
50 \*These authors share senior authorship.

51  
52  
53 V2.0 13/10/20  
54  
55  
56  
57  
58  
59  
60

## **Abstract**

### **Introduction**

Targeted, tailored interventions to test high-risk individuals for HIV and hepatitis C (HCV) are vital to achieving HIV control and HCV micro-elimination in Africa. Compared with the general population, people who inject drugs (PWID) are at increased risk of HIV and HCV and are less likely to be tested or successfully treated. Assisted partner notification services (APNS) increases HIV testing among partners of people living with HIV and improves case-finding and linkage to care. We describe a study in Kenya examining whether APNS can be adapted to find, test, and link to HIV and HCV care the sexual and injecting partners of HIV-positive PWID using a network of community-embedded peer educators (PEs). Our study also uses phylogenetic analysis to determine risk factors for onward transmission of both viruses.

### **Methods and analysis**

This prospective cohort study leverages a network of PEs to identify 1,000 HIV-positive PWID for enrollment as index participants. Each index completes a questionnaire and provides names and contact information of all sexual and injecting partners. PEs then use a stepwise locator protocol to engage partners in the community and bring them to study sites for enrollment, questionnaire completion and rapid HIV and HCV testing. Outcomes include number and type of partners per index who are mentioned, enrolled, tested, diagnosed with HIV and HCV and linked to care.

### **Ethics and dissemination**

1  
2  
3 Potential index participants are screened for intimate partner violence (IPV) and those at high risk  
4 are not eligible to enroll. Those at medium risk are monitored for IPV following enrollment. A  
5  
6 community advisory board engages in feedback and discussion between the community and the  
7  
8 research team. A safety monitoring board discusses study progress and reviews data, including  
9  
10 IPV monitoring data. Dissemination plans include presentations at quarterly Ministry of Health  
11  
12 working group meetings, local and international conferences, and publications.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Strengths and limitations of this study**

- This cohort study investigates the use of assisted partner notification services (APNS) for HIV and hepatitis C (HCV) to find, test, and link to care the sexual and injection partners of people who inject drugs (PWID) in Kenya—a high risk, difficult to reach population. The study offers APNS to HIV-positive index participants; partner services were not offered to HIV-negative, HCV-positive clients to identify those exposed to HCV but not HIV.
- Community embedded peer educators formerly used drugs and have been trained to provide harm reduction services. They are known and trusted within the PWID community conduct partner tracing, and typically serve as the first point of contact with potential partner participants. While this approach has proved largely successful, there are limitations including logistical challenges and concerns for client confidentiality and safety of both the client and peer educator.
- An iris scanning biometric identification system ensures that each index participant enrolled is a unique individual and confirms that individual partner participants who enroll more than once in relation to different index participants are the same individual.
- Phylogenetic analysis of HIV and HCV viral sequences combined with APNS provides additional information about transmission dynamics within the cohort, including risk of onward transmission for different clusters and geographic regions.



## **Introduction**

Of the UNAIDS 90-90-90 goals,<sup>1</sup> diagnosing 90% of those living with HIV remains the most elusive target worldwide,<sup>2</sup> and strategies to reach individuals at high-risk for HIV who have never been tested is increasingly important.<sup>3</sup> Sharing needles and other drug paraphernalia is the most efficient mode of HIV transmission, and accounts for 13% of new infections globally.<sup>4,5</sup> In Kenya, prevalence of HIV among people who inject drugs (PWID) has been estimated at 15 – 50%<sup>5-9</sup>— significantly higher than the general population prevalence of 4.9%,<sup>10</sup> and up to 30% of PWID in Kenya have never tested for HIV.<sup>11,12</sup> Multiple studies have demonstrated low knowledge of HIV status and low engagement in care among Kenya's PWID.<sup>12,13</sup> Retention in care and adherence to ART are also both lower among PWID as compared with others worldwide.<sup>2</sup>

In addition to HIV, PWID are at high risk for hepatitis C virus (HCV) globally and have the highest HCV prevalence of any group studied in Kenya at 13-40%<sup>9,14,15</sup>. This is especially high when compared to the general population HCV prevalence in Kenya of <1-4%.<sup>16,17</sup> However, multiple barriers exist at individual, provider and system levels resulting in low rates of testing, engagement in care, and completion of treatment courses for PWID.<sup>18-20</sup> Although less than 20% of PWID with chronic HCV worldwide have undergone antibody screening, the number who have completed PCR confirmatory testing is even lower.<sup>21</sup> Despite the introduction of highly effective direct acting antivirals (DAAs) into Kenya in 2016, only a small fraction of individuals living with HCV have been treated, prompting attention to micro-elimination strategies.

Assisted partner notification services (APNS) for HIV is an evidence-based partner notification strategy in which providers elicit information about the sexual or injecting partners of an HIV-positive index client, and then contact, HIV test and link to care any partners found to be positive.<sup>22</sup>

1  
2  
3 APNS has been shown to significantly and safely increase the uptake of HIV testing services  
4 (HTS), case finding, and linkage to care for partners of HIV-positive people.<sup>22-24</sup> APNS can also  
5 reduce barriers to disclosing HIV status<sup>25</sup> and is cost-effective.<sup>26</sup> APNS has been successfully  
6 implemented among HIV-positive patients from the general population in the USA,<sup>27</sup>  
7 Mozambique,<sup>28</sup> Malawi,<sup>29,30</sup> and Kenya,<sup>24</sup> and has recently been incorporated into the World  
8 Health Organization (WHO) guidelines for routine care for HIV-positive people worldwide.<sup>31</sup>  
9 While programs have introduced the practice of APNS in high-risk key populations (KPs) such as  
10 female sex workers (FSW)<sup>32</sup> and men who have sex with men (MSM),<sup>33,34</sup> this intervention has  
11 not been well-studied among PWID,<sup>35</sup> an extremely high risk group.<sup>22,36</sup> Similar to FSW and  
12 MSM, PWID engage in behavior that is criminalized<sup>37</sup> while experiencing high rates of  
13 marginalization and displacement,<sup>38</sup> making them difficult to study. These factors and others also  
14 contribute to significant barriers in the implementation of health programs targeting PWID.<sup>39-41</sup>

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Phylogenetic analysis is a method of identifying the role of specific risk groups and risk factors  
for onward transmission of HIV and HCV using the genetic sequence of each virus.<sup>42-44</sup> Viral  
phylogenetics can provide additional information on patterns of transmission,<sup>45-47</sup> epidemic  
growth,<sup>48,49</sup> risk groups,<sup>50-52</sup> and risk factors associated with onward transmission.<sup>44,53-55</sup>

Here we describe a prospective cohort study that seeks to determine whether and how APNS can  
be implemented to find, test, and link to care the injection and sexual partners of HIV-positive  
PWID in Kenya. Simultaneously, our study will use phylogenetic analysis to study genetic  
sequences of HIV and HCV within our cohort to further understand transmission patterns and risk  
for onward transmission. All index and partner participants are tested for HCV in addition to HIV.  
While many partner contact methods for conducting APNS have been used,<sup>22</sup> cellular telephones  
are the most common first-line communication modality for reaching partners in other

1  
2  
3 populations.<sup>23,24,28,56</sup> In Kenya, however, the large majority of PWID do not have regular access to  
4  
5 cellular telephones. As such, our APNS model relies on the utilization of community-embedded  
6  
7 peer educators (PEs) to locate and communicate with members of this difficult to reach population.  
8  
9 We hypothesize that we will be able to employ these customized APNS procedures to reach a large  
10  
11 number of injection and sexual partners, and that we will see differences in HIV and HCV testing,  
12  
13 HIV and HCV prevalence, and engagement in care between sexual and injection partners.  
14  
15 Additionally, we hypothesize that we will identify unique transmission patterns and risks for  
16  
17 onward transmission in phylogenetic analysis.  
18  
19  
20  
21

## 22 **Methods and analysis**

### 23 *Approach*

24  
25  
26 APNS is a practice through which healthcare providers facilitate the notification, testing and  
27  
28 linkage to care for partners who may have been exposed to HIV or other sexually transmitted  
29  
30 infections by an individual known to be positive. Typically, APNS is conducted by healthcare  
31  
32 providers who elicit information about partners from an “index” patient and then call the partners  
33  
34 over the telephone to alert them to their exposure and arrange testing. We have designed  
35  
36 customized procedures to ensure and improve the safety and efficacy of APNS in the unique  
37  
38 population of PWID in Kenya. Because PWID and their partners in Kenya rarely own cellular  
39  
40 phones, we work with community-embedded peer educators (PEs) to find and engage with  
41  
42 partners. Additionally, our protocol involves referrals to different facilities for injection partners  
43  
44 and for sexual partners, as a precaution to ensure safety and confidentiality of index participants.  
45  
46  
47  
48  
49  
50  
51

### 52 *Study design*

1  
2  
3 Our study is a prospective cohort study with two groups: index and partner participants (“indexes”  
4 and “partners”). We use tailored APNS procedures to identify, find, test and link to care the sexual  
5 and injection partners of HIV-positive PWID. All participants who are diagnosed with either HIV  
6 or HCV- then complete a 6-month follow-up visit to assess linkage to and engagement in care.  
7  
8  
9

### 10 11 12 13 *Study sites/setting* 14

15  
16 Study procedures take place in eight main sites including public health centers, medically assisted  
17 therapy (MAT) centers, and needle and syringe programs (NSPs) in Nairobi, Kilifi, and Mombasa  
18 Counties in Kenya (Figure 1). Each site is staffed by at least one clinical officer (mid-level  
19 clinician) who works with the study team to ensure that indexes are HIV-positive. In Nairobi  
20 County, the activities are centered at two NSP sites and one MAT center in the Mathare North  
21 area. The NSP sites, run by Support for Addiction Prevention and Treatment in Africa (SAPTA),  
22 offer routine HIV testing services. Referrals are made to local clinics providing care for those who  
23 test positive for HIV or HCV. We also recruit indexes from a government-run methadone clinic in  
24 Nairobi in the Ngara area. The Ngara Health Center MAT clinic offers HIV testing, care and  
25 treatment in addition to daily methadone administration, psychosocial services and treatment for  
26 other health conditions. In Kilifi county, participant recruitment and enrollment takes place at three  
27 needle and syringe program centers and one government hospital. The Omari Project is located in  
28 Malindi town and offers HIV counseling, testing, care and treatment in addition to harm reduction  
29 services. Malindi Sub-County Hospital’s MAT center is a recruitment site in Kilifi County within  
30 a mid-sized government hospital that offers a large range of medical and social services. Malindi  
31 Sub-County Hospital also has a large laboratory that houses the study’s samples collected in both  
32 Kilifi and Mombasa Counties. The Muslim Education and Welfare Association (MEWA) NSP  
33 sites in Kilifi and Mtwapa towns offer HIV counseling and testing, in addition to HIV care and  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 treatment and harm reduction services. In Mombasa county, participants are recruited from the  
4 ReachOut Center, an NSP site in Mombasa city that offers a full range of harm reduction services  
5  
6 in addition to HIV counseling, testing, care and treatment. All recruitment sites offer routine HCV  
7  
8 testing when kits are available through specific donor-driven projects.  
9  
10  
11

### 12 13 *Population*

14  
15  
16 This study includes index participants and their sexual and injecting partners . All indexes are HIV-  
17  
18 positive PWID. Partners are either sexual partners or injecting partners of indexes. As such,  
19  
20 partners need not be PWID or HIV-positive but are defined by their relationships with indexes.  
21  
22

23  
24 Indexes are largely recruited from organizations and clinics that provide services to PWID  
25  
26 populations, although they may also come from outreach efforts or informal referrals from other  
27  
28 participants. Partners are identified and recruited through peer-mediated APNS and may come  
29  
30 from any geographic area or community.  
31  
32

### 33 34 *Patient and Public Involvement*

35  
36  
37 Members of the community of PWID being researched were consulted in the development of  
38  
39 research questions and design of the study. The study is supported by a Community Advisory  
40  
41 Board (CAB) composed of members of the community, peer educators and employees of  
42  
43 organizations that provide services to the population. The CAB meets with the study team regularly  
44  
45 and helps inform dissemination plans.  
46  
47  
48

### 49 50 *Study procedures*

#### 51 52 53 1. Peer educator recruitment and training

1  
2  
3 PEs are recovering PWID with established relationships in the PWID communities that they serve.  
4  
5 The majority are between the ages of 25 and 50, are enrolled in Kenya's methadone program and  
6  
7 report having stopped injecting drugs.. These men and women have been identified by the  
8  
9 individual organizations at which they work as being key community members, and have  
10  
11 undergone extensive training for their roles as PEs. Training is an intensive 5-day course with  
12  
13 modules covering a broad spectrum of content including basics of drugs and drug-related harms,  
14  
15 harm reduction efforts including NSP and MAT, abscess prevention and management, overdose  
16  
17 prevention and management and behavior change communication. PEs have access to relatively  
18  
19 hidden PWID community spaces, and provide health counseling, linkage to support organizations,  
20  
21 information, and other services to this vulnerable population.  
22  
23  
24  
25  
26

27 For this study, PEs who were actively carrying out basic duties were chosen by the leadership at  
28  
29 each organization based on several factors including awareness and knowledge of HIV in the  
30  
31 community and access to unique target populations (for instance, women who inject drugs are  
32  
33 more easily accessed by women PEs). Once identified, PEs underwent an intensive 1-day training  
34  
35 to educate them on the practice and ethics of research, study procedures, and their role in the study.  
36  
37 PEs participate in regular health education and harm reduction training and engage in quarterly  
38  
39 sessions with study leadership where they present barriers and lessons learned to the study team  
40  
41 so that study-related issues can be addressed.  
42  
43  
44  
45  
46

## 47 2. Inclusion & exclusion criteria

48  
49

50 Inclusion and exclusion criteria are different for indexes and partners (Table 1). Any interested  
51  
52 individuals who are under the age of 18 are referred to the site clinicians for routine counseling  
53  
54 and harm reduction services.  
55  
56  
57

### 3. Index recruitment and enrollment

Enrollment began in March 2018. Clinicians at each site identify potential indexes using existing clinical data on known HIV-positive clients. Additionally, any client who tests positive for HIV during routine testing is invited to participate. Clinicians are employed by the sites, and are trained clinical officers (COs), or mid-level providers. For this study, HIV rapid testing is performed by COs and takes place as part of standard clinic procedures. All potential indexes are re-tested using HIV rapid tests (as per the national guidelines) to confirm HIV status prior to enrollment. If HIV-seropositive, either newly diagnosed or known to be positive, clinicians either discuss the study directly with potential participants or engage PEs to find individuals and bring them to the study office if they are not regular clients at the site. Importantly, PEs are not told whether participants are being traced as an index or a partner, protecting the confidentiality of indexes' HIV status.

Study staff health advisors (HAs) are the individuals responsible for conducting study procedures including data collection, HIV and HCV testing, and the coordination of APNS efforts (Figure 2). All HAs were trained and experienced in HIV testing services prior to working for the study, and many had previous experience working with PWID. All HAs underwent a week-long training course at the beginning of the study in which they learned the basics and purpose of research, research ethics, study procedures, unique ethical and logistical issues to consider when working with PWID, and other topics. All HAs also completed the Collaborative Institutional Training Initiative (CITI) course on Human Subjects Research and the Responsible Conduct of Research. HAs explain the benefits and rationale for providing APNS, discuss the importance of learning more about HIV and HCV, and describe the process of notifying partners without revealing the identity of the index. They ask participants to provide written informed consent for study participation, APNS, and future use of biological specimens and future contact for additional

1  
2  
3 studies, using an iris-scanning biometric device to record a unique identifier for each participant,  
4 thus enabling the study team to confirm that a person does not enroll into the program as an index  
5 more than once.  
6  
7  
8  
9

10  
11 Indexes undergo a structured questionnaire administered by the HA using open data kit (ODK)  
12 software on tablet devices (ODK, 2017, Seattle, WA, USA). Questionnaires cover a variety of  
13 topics including demographics, sexual and injecting behaviors, drug use history, and HIV testing  
14 and engagement history. Participants are then asked to recall all of their sexual and injecting  
15 partners over the three years prior to enrollment, naming these partners one by one and assigning  
16 each partner a letter (“A,” “B,” etc). Indexes are asked to give as much locator information as  
17 possible for each partner, including names (which may be nicknames), phone numbers, and  
18 location of employment or residence. Locator information is written on a paper form for each  
19 partner. Indexes then complete a short ODK questionnaire about each partner mentioned, which  
20 includes information about the relationship between the index and the partner. Indexes who wish  
21 to notify partners themselves are given a 2-week window in which to do so, after which partners  
22 are contacted by study staff.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Indexes then undergo rapid HCV antibody testing as part of routine study procedures. HAs conduct  
41 pre- and post- test counseling and ensure individuals who test positive are available for follow-up  
42 visits to discuss confirmatory HCV PCR testing and enrolling in a treatment program administered  
43 by the Ministry of Health. All indexes then undergo phlebotomy with a sample of 10mL of blood  
44 drawn for further testing (see section 6 below). Indexes receive 400 Kenya Shillings (KES,  
45 equivalent to about \$4) as compensation for travel and time spent in the study procedures.  
46  
47  
48  
49  
50  
51  
52  
53

#### 54 4. Peer-educator mediated assisted partner services and partner recruitment

55  
56  
57



1  
2  
3 For those partners who have phone numbers listed, HAs attempt phone communication first.  
4  
5 However, the vast majority of partners mentioned by indexes do not have working cellular phones;  
6  
7 therefore, with few exceptions, PEs locate and conduct the study's first interaction in person with  
8  
9 identified partners. PEs are given paper forms containing names and locator information for  
10  
11 identified partners. They are never told which index referred the team to each partner, and that  
12  
13 information is not listed on locator forms or any other accessible file. PEs then locate and approach  
14  
15 potential participants in the community. Using a standardized script, PEs inform potential  
16  
17 participants that they have been identified as an individual who might be eligible for a research  
18  
19 study on HIV and HCV. PEs do not notify partners of their exposure during initial contact for  
20  
21 several reasons: 1) to protect the HIV status of indexes, PEs are not told whether they are recruiting  
22  
23 an index or a partner, and 2) PEs have not felt comfortable discussing HIV or HCV exposure with  
24  
25 potential participants. Once PEs have notified potential participants of their possible eligibility,  
26  
27 they then accompany interested individuals to the nearest research office, where the study's HAs  
28  
29 conduct informed consent. Informed consent includes consent to future use of biological  
30  
31 specimens and future contact for additional studies. In the rare event that a potential participant  
32  
33 does not agree to come to the study office, an HA returns to the site with the PE and notifies the  
34  
35 individual of the exposure.  
36  
37  
38  
39  
40  
41  
42

### 43 5. Partner enrollment

44  
45  
46 After informed consent and biometric identification, partners complete a structured questionnaire  
47  
48 similar to that of indexes, administered by HAs on a handheld device using ODK software.  
49  
50 Following the questionnaire, all partners undergo rapid antibody testing for both HIV and HCV.  
51  
52 HIV testingservices are provided in accordance with national HIV testing guidelines. Any partner  
53  
54 found to be positive for either HIV or HCV antibodies undergoes a 20mL blood draw. Those  
55  
56  
57

1  
2  
3 partners who test negative for both HIV and HCV are finished with study procedures at this time  
4  
5 and are counseled on risk reduction measures and linked to HIV and HCV prevention services  
6  
7 before leaving the study site. All partners receive 400 Kenya Shillings (KES, equivalent to about  
8  
9 \$4) as compensation for travel and time spent in the study procedures.  
10  
11

12  
13 HIV-positive partners are invited to undergo screening as an index once data collection procedures  
14  
15 for their partner enrollment are complete. If they meet eligibility criteria as an index, they may  
16  
17 enroll as an index. Study procedures are slightly amended for indexes that have previously enrolled  
18  
19 as partners. After undergoing informed consent and completing a short questionnaire that only  
20  
21 includes questions that were not a part of the partner enrollment questionnaire, they complete the  
22  
23 identification and data collection on each of their sexual and injection partners, identical to partner  
24  
25 identification procedures for indexes described above.  
26  
27  
28  
29

### 30 6. Laboratory Procedures

31  
32  
33 Blood samples from both index and partner enrollment visits are collected in EDTA vacutainer  
34  
35 tubes. Blood is mixed with the anticoagulant by inversion and the anticoagulated blood is stored  
36  
37 at room temperature at the sites for less than 4 hours. A motorcycle courier picks samples from  
38  
39 each site daily and brings them to the University of Nairobi Pediatric Research Laboratory in  
40  
41 Nairobi or the Malindi Sub-County Hospital Laboratory for coast sites. At each laboratory,  
42  
43 samples are first used to prepare two Whatman 903 Protein Saver dried blood spot (DBS) cards  
44  
45 with 50ul of whole blood on each spot. Blood samples are then centrifuged and used to prepare 2  
46  
47 to 3 aliquots of 1ml of plasma in labeled serum vials. Plasma aliquots and air-dried DBS cards  
48  
49 (with desiccant in sealed Ziploc bags) are then stored at -80° Celsius and shipped on dry ice to the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 University of KwaZulu-Natal laboratory. There, samples undergo HIV and HCV viral load testing  
4 and amplification for sequencing.  
5  
6

### 7 7. Participant follow-up

8  
9  
10 All indexes and any partners who were positive for HIV or HCV complete a six-month follow-up  
11 visit. HAs identify which participants are due for follow-up visits on a weekly basis and give PEs  
12 as list of these names. PEs then trace participants and bring them back to clinics where data  
13 collection procedures are conducted. PEs make several attempts to find participants in the  
14 community before considering them lost to follow-up.  
15  
16  
17  
18  
19  
20  
21  
22

23  
24 Six-month visits involve a brief questionnaire covering questions on testing for HIV or HCV (if  
25 not infected with both on enrollment), enrollment in care and treatment, engagement in care, and  
26 follow-up testing. The purpose of this visit is to assess whether engagement in care has changed  
27 following APNS procedures. We do not collect additional data from those lost to follow up.  
28  
29  
30  
31  
32

### 33 8. Intimate partner violence (IPV) monitoring

34  
35  
36  
37 Given historical concerns that APS may increase one's risk of experiencing intimate partner  
38 violence, all potential participants undergo screening for IPV before enrollment. IPV is defined as  
39 any physical, sexual or psychological harm inflicted on a person by a current or former sexual  
40 partner. After answering a standardized set of six questions about physical, emotional and sexual  
41 IPV and the timing of any previous experience of IPV based on published screening tools reviewed  
42 by the Centers for Disease Control and Prevention,<sup>57</sup> potential participants are classified as low,  
43 medium or high risk for IPV. Individuals are classified as at high risk for IPV if they report IPV  
44 within the last month. Any potential index who is classified as high IPV risk is excluded from  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 study participation and provided with IPV counseling and resources. Any potential partner  
4 participant who is classified as high IPV risk is allowed to enroll, but then receives special  
5 monitoring for IPV following enrollment.  
6  
7  
8  
9

10  
11 Potential participants are classified as at moderate risk for IPV if they report 1) IPV during their  
12 lifetime either from a current or past partner; and/or 2) fear of IPV if they participate in the study.  
13  
14 All index or partner participants classified as moderate IPV risk receive special monitoring for  
15 IPV following their enrollment in the study.  
16  
17  
18  
19

20  
21 Potential participants are classified as at low risk for IPV if they report 1) no IPV during their  
22 lifetime ; and 2) no fear of IPV if they participate in the study. These individuals undergo standard  
23 study procedures which include completing the baseline IPV case report form and a follow-up IPV  
24 case report to capture reports of any interim IPV.  
25  
26  
27  
28  
29

### 30 31 9. Confidentiality and safety 32 33

34  
35 *Participants:* All study procedures take place in private rooms at each study facility. To ensure the  
36 safety and confidentiality of indexes, PEs who are tasked with finding partners are blinded to the  
37 identity of the linked index through the use of partner locator forms that do not contain identifying  
38 information about the index participant. Locator forms do contain a printed barcode label that are  
39 then used by study staff to link the partner with the index who referred the partner.  
40  
41  
42  
43  
44  
45

46  
47 Sexual partners are brought to independent facilities for enrollment rather than to centers that serve  
48 PWID, in order to further protect the identity of the index participant who referred them. The  
49 independent facilities are local healthcare clinics that serve the general population.  
50  
51  
52  
53  
54  
55

1  
2  
3 *Peer educators*: PEs have frequent interactions with police, and can be victims of harassment or  
4 violence, both by police and by PWID. To reduce the risk of law enforcement troubles, PEs carry  
5 identification showing that they are working on a study being conducted by the Ministry of Health.  
6  
7  
8  
9  
10 Local law enforcement officials have also attended ongoing sensitization trainings by the Ministry  
11 of Health and by organizations working with PWID.  
12  
13

## 14 15 10. Referrals to care

16  
17  
18  
19 *HIV Counseling and Care*: Participants are provided with their HIV test results in the context of  
20 post-test counseling, and are then referred to available medical and psychosocial care and support  
21 facilities either within the research site or in close proximity to the research site or the participant's  
22 home. Additionally, HIV-positive individuals are offered individual or group support sessions as  
23 available within each site.  
24  
25  
26  
27  
28  
29

30  
31  
32 *HCV Counseling and Care*: Participants who test positive for HCV antibodies using rapid testing  
33 are provided with their HCV antibody test results in the context of pre- and post-test counseling.  
34 They are informed that they may have active HCV infection; however, further confirmatory testing  
35 must be done prior to establishing the diagnosis. Confirmatory polymerase chain reaction (PCR)  
36 testing is done in batches of samples at our partnering laboratory at the University of KwaZulu-  
37 Natal, South Africa, and participants with active infection are later contacted for results and  
38 counseling. Turnaround time from enrollment to PCR result notification varies, but is typically  
39 between 1 and 4 months. Once notified, those with active infection are paired with a PE at their  
40 site to ensure close contact is maintained. Study participants with active HCV infections will be  
41 eligible to receive free treatment with direct acting antivirals, which the Kenyan MoH has  
42 procured.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

### Data management

After each study visit, HAs review their work for omissions or errors and all data are uploaded into the study database. Electronic data are stored securely in an encrypted database on servers using Open Data Kit Aggregate, within Kenya's Ministry of Health (MoH). All errors or omissions identified at any step in the quality assurance/quality control process are revised by the staff member who originally completed the document. All additions and corrections are initialed and dated by the staff member who records the entry.

A link-log is separately encrypted to further ensure that data remains secure. Any data transferred to investigators or MoH are de-identified and encrypted during the process of transfer from the server. Each investigator maintains and stores secure, complete, accurate and current study records throughout the study. A database manager performs regular data cleaning and resolves any discrepancies that occur. Study sites also conduct quality control and quality assurance procedures. All co-investigators have access to the final dataset and this is not limited by contractual agreements. Study data will be available upon request at the completion of the study.

### Outcome measures

The primary outcomes of interest to assess the success of the APNS intervention are: a) number of sexual and injection partners tested for HIV and HCV through APNS, identified by each index participant over the course of the study period; b) number of sexual and injection partners newly testing positive for HIV and HCV, per index participant; c) number of known HIV or HCV cases identified through APNS who are not engaged in care; d) number of index and partner participants with HIV and/or HCV infection who are linked to care; e) number of index and partners with HIV and/or HCV infection who remain in care and are receiving appropriate treatment at 6 months after

1  
2  
3 testing positive. Secondary outcomes are linked to inclusion in phylogenetic clusters identified as  
4  
5 high risk for onward transmission of HIV and HCV.  
6  
7

### 8 9 Sample size

10  
11 We are enrolling 1000 HIV-positive indexes and their sexual and injecting partners. Based on  
12  
13 HCV data from MoH and our preliminary results, we estimate that 20% of PWID with HIV will  
14  
15 be co-infected with HCV and that each index will identify on average two partners who will accept  
16  
17 HIV and HCV testing, 20% of whom will be HIV-positive, and 20% of whom will be HCV-  
18  
19 infected. Thus, with provision of APNS to 1,000 HIV-positive indexes and testing of 2,000  
20  
21 partners, we will identify an estimated 600 indexes and partners infected with HCV and 400 HIV-  
22  
23 positive partners. This study was designed to have high precision in estimating the prevalence of  
24  
25 HIV and HCV infection among partners, providing valuable input for modeling the impact of  
26  
27 APNS in the population. For an observed HIV or HCV prevalence of 10% among partners,  
28  
29 precision is estimated at 1.9%; with an observed HIV or HCV prevalence of 30% among partners,  
30  
31 precision is estimated at 2.9%. Statistical methods and analysis  
32  
33  
34  
35  
36  
37

38 To determine efficacy of the APNS intervention, we will use generalized estimating equations  
39  
40 (GEE) models with a Poisson link using the following variables and offsets: 1) rate of HIV and  
41  
42 HCV testing of partners: number of individuals tested for HIV or HCV, offset by the number of  
43  
44 partners located with locator information provided by the index participant; 2) prevalence of HIV  
45  
46 and HCV infection: number of individuals identified as HIV or HCV-positive, offset by the  
47  
48 number of individuals who were HIV tested; and 3) rate of linkage to HIV and HCV care:  
49  
50 individuals who test HIV or HCV-positive and link to care, offset by the total number of  
51  
52 individuals who test HIV or HCV-positive.  
53  
54  
55  
56  
57

1  
2  
3 Additionally, using both GEE and phylogenetic analysis, we will determine the following: 1)  
4 identifiable and individual risk factors linked to high rates of HIV and HCV transmission, 2) risk  
5 factors linked to both needle-sharing and sexual transmission, and 3) identification of transmission  
6 clusters among PWID for both HIV and HCV.  
7  
8  
9  
10  
11

### 12 Phylogenetic analysis

13  
14  
15  
16 HIV and HCV gene sequencing are attempted for all study participants who test positive for either  
17 virus. Sequencing will be performed at the KwaZulu-Natal Research Innovation and Sequencing  
18 Platform (KRISP) at the University of KwaZulu-Natal in Durban, South Africa. For HIV we will  
19 subsequently combine our data with additional, publicly available, HIV sequences from Kenya  
20 and perform phylogenetic and phylodynamic analyses to describe patterns and rates of viral  
21 transmission among key populations in Kenya and identify traits associated with relative  
22 infectiousness. For HCV we will use phylogenetic methods to characterize the modes and risk  
23 factors for onward transmission among PWID.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

### 36 Ethics and Dissemination

#### 37 General ethical considerations

38  
39  
40  
41  
42 This study is registered at [clinicaltrials.gov](http://clinicaltrials.gov) and has ethical approval from both the University of  
43 Washington Human Subjects Division and the Kenyatta National Hospital Ethics and Research  
44 Committee. It also has approval from Kenya's National Commission for Science, Technology and  
45 Innovation.  
46  
47  
48  
49  
50

51  
52  
53 There are a number of potential risks to participants. Risks of conducting APNS include  
54 psychological distress, social or economic hardship, criminal penalties, and loss of privacy and/or  
55  
56  
57



1  
2  
3 confidentiality. Study procedures, including confidentiality and counseling procedures, are  
4 specifically designed to minimize these risks to participants. While IPV has the potential to cause  
5 harm, it has not increased in other US or African studies when this intervention has been  
6 implemented in the general population.<sup>22,58,59</sup> We recognize that risks may be different when  
7 implementing APNS among key populations and study staff are highly trained in counseling about  
8 risk behaviors, implications of testing HIV-positive, and protecting confidentiality to avoid  
9 potential social harms. In addition, staff have undergone extensive training on IPV counseling and  
10 ensure that resources have been identified in all sites so we can safely refer participants who report  
11 abuse or are concerned for their safety. Participants reporting moderate IPV are monitored as  
12 described in Section 8; they are counseled and referred for services if IPV is reported at any of  
13 these follow-up visits.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 A safety monitoring board composed of researchers and policy makers in both Kenya and the US  
30 reviews study safety data twice per year. The board monitors enrollments, deaths, loss to follow  
31 up, adverse events, including social harms, and IPV monitoring data and makes recommendations  
32 regarding study procedures.  
33  
34  
35  
36  
37  
38

39 Ethical considerations surrounding the use of biometric identification systems among key  
40 populations in Kenya have been discussed extensively.<sup>60</sup> Despite early opposition from the Key  
41 Populations Consortium and other organizations to the government's use of fingerprint-based  
42 biometric data collection, the organizations and individuals working with PWID communities  
43 continued to report no opposition to iris scanning for research purposes among PWID. In  
44 November 2019, Kenya passed the Data Protection Bill, rendering it legal to collect biometric data  
45 as long as the use of such data does not violate the subjects' rights.<sup>61</sup> The use of biometrics is now  
46 standard practice in many research and clinical settings, and has been found to be acceptable to  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 participants.<sup>62</sup> Our participants have not reported any concerns, fears, or hesitations regarding the  
4  
5 use of an iris scanning biometric identification system.  
6  
7

### 8 9 Dissemination plan

10  
11 Results from the study and changes to the study are presented on an ongoing basis at Kenya's  
12  
13 quarterly MoH harm reduction and key population technical working group meetings, and  
14  
15 discussed at biannual meetings by the Community Advisory Board that was established for this  
16  
17 study. Our study team includes several collaborators from the MoH. Ongoing study analyses are  
18  
19 also presented at national conferences annually, including Kenya's HIV clinicians' society  
20  
21 meeting, the Infectious Disease Society of Kenya (IDSK) biennial conference, or the Annual  
22  
23 University of Nairobi STD/HIV/SRH Collaborative Conference. Additionally, study results are  
24  
25 presented in at least one international conference per year, including the Conference on  
26  
27 Retroviruses and Opportunistic Infections (CROI), the International AIDS Conference, and the  
28  
29 College on Problems of Drug Dependence (CPDD) annual conference. Finally, the study team  
30  
31 reviews data on a weekly basis and any changes in data trends or other concerns are discussed  
32  
33 directly with the organizations through which study procedures take place.  
34  
35  
36  
37  
38  
39

### 40 41 Authors' contributions

42  
43 CF and JH conceived of the study; AMW, BG, BC, MD, PM, BSi, JH and CF contributed to the  
44  
45 study design and data collection structure; AMW, LM, DB, BSa, BC, JS, PC, HM, RB, PM, SM,  
46  
47 EW, TDO, BSi, JH and CF contributed to data collection; AMW, LM, BG, DB, BSa, PC, HM,  
48  
49 RB, SM, EW, TDO, NLB, JH and CF contributed to data analysis and dissemination; AMW, BG,  
50  
51 JH and CF wrote the manuscript; all authors reviewed the manuscript for content.  
52  
53  
54  
55  
56  
57

## **Funding**

This work was supported by the Division of AIDS, National Institutes of Drug Abuse, grant number R01 DA043409. 301 North Stonestreet Ave, Bethesda, MD 20892. +1 301-443-1124.

## **Competing interests**

All authors state that they have no competing interests.

Figure 1. Map of Study Sites

Figure 2. Study Flow Diagram

## **References**

1. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Published October 2014. Accessed March 7, 2018. [http://www.unaids.org/sites/default/files/media\\_asset/90-90-90\\_en.pdf](http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf)
2. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. *BMJ Glob Health*. 2016;1(2):e000010. doi:10.1136/bmjgh-2015-000010
3. Staveteig S, Croft TN, Kampa KT, Head SK. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries. *PLOS ONE*. 2017;12(10):e0186316. doi:10.1371/journal.pone.0186316
4. Brodish P, Singh K, Rinyuri A, et al. Evidence of high-risk sexual behaviors among injection drug users in the Kenya PLACE study. *Drug Alcohol Depend*. 2011;119(1-2):138-141. doi:10.1016/j.drugalcdep.2011.05.030
5. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet Lond Engl*. 2008;372(9651):1733-1745. doi:10.1016/S0140-6736(08)61311-2
6. National AIDS Control Council NS and ACP. Kenya HIV Prevention Revolution Road Map: Count Down to 2030. Published online June 2014.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
7. Kurth AE, Cleland CM, Des Jarlais DC, et al. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya. *J Acquir Immune Defic Syndr* 1999. 2015;70(4):420-427. doi:10.1097/QAI.0000000000000769
8. Ndetei, David M. A study on the linkages between drug abuse, injecting drug use and HIV/AIDS in Kenya: a rapid situation assessment. *U N Off Drugs Crime*.:45.
9. Odek-Ogunde M, Okoth, F, Lore, W, Owiti, F.R. Seroprevalence of HIV, HBC and HCV in Injecting Drug Users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II Findings. The XV International AIDS Conference, Bangkok, Thailand: ; 2004.
10. National AIDS Control Council. *Kenya HIV Estimates Report 2018*. Accessed February 21, 2019. <https://nacc.or.ke/wp-content/uploads/2018/11/HIV-estimates-report-Kenya-20182.pdf>
11. Tun W, Sheehy M, Broz D, et al. HIV and STI Prevalence and Injection Behaviors Among People Who Inject Drugs in Nairobi: Results from a 2011 Bio-behavioral Study Using Respondent-Driven Sampling. *AIDS Behav*. 2015;19(Suppl 1):24-35. doi:10.1007/s10461-014-0936-3
12. Lizcano, J. Testing and Linkage to Care for Injecting Drug Users. 11th International Conference on HIV Treatment and Prevention Adherence, Ft. Lauderdale, FL, USA ; 2016.
13. Githuka G, Hladik W, Mwalili S, et al. Populations at Increased Risk for HIV Infection in Kenya: Results From a National Population-Based Household Survey, 2012. *J Acquir Immune Defic Syndr* 1999. 2014;66(Suppl 1):S46-S56. doi:10.1097/QAI.0000000000000137
14. Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. *Lancet Infect Dis*. 2019;19(11):1255-1263. doi:10.1016/S1473-3099(19)30264-6
15. Muasya T, Lore W, Yano K, et al. Prevalence of Hepatitis C Virus and its genotypes among a cohort of drug users in Kenya. *East Afr Med J*. 2008;85(7). doi:10.4314/eamj.v85i7.9649
16. Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. *Pan Afr Med J*. 2019;34. doi:10.11604/pamj.2019.34.31.17885
17. Loarec A, Carnimeo V, Molfino L, et al. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. *AIDS Lond Engl*. 2019;33(2):353-355. doi:10.1097/QAD.0000000000002070
18. Litwin AH, Jost J, Wagner K, et al. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. *Contemp Clin Trials*. 2019;87:105859. doi:10.1016/j.cct.2019.105859
19. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. *Drug Alcohol Rev*. 2012;31(7):918-924. doi:10.1111/j.1465-3362.2012.00468.x

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
20. Enkelmann J, Gassowski M, Nielsen S, et al. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing. *Harm Reduct J*. 2020;17(1):7. doi:10.1186/s12954-019-0338-y
21. Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. *Liver Int Off J Int Assoc Study Liver*. 2019;39(1):20-30. doi:10.1111/liv.13949
22. Dalal S, Johnson C, Fonner V, et al. Improving HIV test uptake and case finding with assisted partner notification services. *AIDS Lond Engl*. 2017;31(13):1867-1876. doi:10.1097/QAD.0000000000001555
23. Kahabuka C, Plotkin M, Christensen A, et al. Addressing the First 90: A Highly Effective Partner Notification Approach Reaches Previously Undiagnosed Sexual Partners in Tanzania. *AIDS Behav*. 2017;21(8):2551-2560. doi:10.1007/s10461-017-1750-5
24. Cherutich P, Golden MR, Wamuti B, et al. Assisted partner services for HIV in Kenya: a cluster randomised controlled trial. *Lancet HIV*. 2017;4(2):e74-e82. doi:10.1016/S2352-3018(16)30214-4
25. Plotkin M, Kahabuka C, Christensen A, et al. Outcomes and Experiences of Men and Women with Partner Notification for HIV Testing in Tanzania: Results from a Mixed Method Study. *AIDS Behav*. 2018;22(1):102. doi:10.1007/s10461-017-1936-x
26. Sharma M, Smith JA, Farquhar C, et al. Assisted partner notification services are cost-effective for decreasing HIV burden in western Kenya. *AIDS Lond Engl*. 2018;32(2):233-241. doi:10.1097/QAD.0000000000001697
27. Landis SE, Schoenbach VJ, Weber DJ, et al. Results of a randomized trial of partner notification in cases of HIV infection in North Carolina. *N Engl J Med*. 1992;326(2):101-106. doi:10.1056/NEJM199201093260205
28. Myers RS, Feldacker C, Cesár F, et al. Acceptability and Effectiveness of Assisted Human Immunodeficiency Virus Partner Services in Mozambique: Results From a Pilot Program in a Public, Urban Clinic. *Sex Transm Dis*. 2016;43(11):690-695. doi:10.1097/OLQ.0000000000000529
29. Brown LB, Miller WC, Kamanga G, et al. HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. *J Acquir Immune Defic Syndr* 1999. 2011;56(5):437-442.
30. Brown LB, Miller WC, Kamanga G, et al. Predicting partner HIV testing and counseling following a partner notification intervention. *AIDS Behav*. 2012;16(5):1148-1155. doi:10.1007/s10461-011-0094-9
31. World Health Organization. WHO | WHO recommends assistance for people with HIV to notify their partners. WHO. Accessed February 22, 2019. <http://www.who.int/hiv/pub/vct/who-partner-notification-policy/en/>

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
32. Quinn C, Nakyanjo N, Ddaaki W, et al. HIV partner notification values and preferences among sex workers, fishermen, and mainland community members in Rakai, Uganda: a qualitative study. *AIDS Behav.* 2018;22(10):3407-3416. doi:10.1007/s10461-018-2035-3
33. Rane V, Tomnay J, Fairley C, et al. Opt-Out Referral of Men Who Have Sex With Men Newly Diagnosed With HIV to Partner Notification Officers: Results and Yield of Sexual Partners Being Contacted. *Sex Transm Dis.* 2016;43(6):341-345. doi:10.1097/OLQ.0000000000000449
34. Halkitis PN, Kupprat SA, McCree DH, et al. Evaluation of the relative effectiveness of three HIV testing strategies targeting African American men who have sex with men (MSM) in New York City. *Ann Behav Med Publ Soc Behav Med.* 2011;42(3):361-369. doi:10.1007/s12160-011-9299-4
35. Levy JA, Fox SE. The outreach-assisted model of partner notification with IDUs. *Public Health Rep Wash DC 1974.* 1998;113 Suppl 1:160-169.
36. Malik M, Jamil MS, Johnson CC, Pasha MS, Hermez J, Qureshi S ul H. Integrating assisted partner notification within HIV prevention service package for people who inject drugs in Pakistan. *J Int AIDS Soc.* 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25317
37. DeBeck K, Cheng T, Montaner JS, et al. HIV and the criminalisation of drug use among people who inject drugs: a systematic review. *Lancet HIV.* 2017;4(8):e357-e374. doi:10.1016/S2352-3018(17)30073-5
38. United Nations, Office on Drugs and Crime. *World Drug Report 2016.*; 2016.
39. Molinaro S, Resce G, Alberti A, et al. Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. *Drug Alcohol Rev.* 2019;38(6):644-655. doi:10.1111/dar.12978
40. Phillips KT. Barriers to practicing risk reduction strategies among people who inject drugs. *Addict Res Theory.* 2016;24(1):62-68. doi:10.3109/16066359.2015.1068301
41. Heath AJ, Kerr T, Ti L, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand. *J Public Health Oxf Engl.* 2016;38(3):e301-e308. doi:10.1093/pubmed/fdv143
42. Frost SDW, Pillay D. Understanding Drivers of Phylogenetic Clustering in Molecular Epidemiological Studies of HIV. *J Infect Dis.* 2015;211(6):856-858. doi:10.1093/infdis/jiu563
43. Brenner BG, Wainberg MA. Future of phylogeny in HIV prevention. *J Acquir Immune Defic Syndr 1999.* 2013;63 Suppl 2:S248-254. doi:10.1097/QAI.0b013e3182986f96
44. Jacka B, Applegate T, Krajden M, et al. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. *Hepatal Baltim Md.* 2014;60(5):1571-1580. doi:10.1002/hep.27310
45. Grabowski MK, Lessler J, Redd AD, et al. The Role of Viral Introductions in Sustaining Community-Based HIV Epidemics in Rural Uganda: Evidence from Spatial Clustering, Phylogenetics, and Egocentric Transmission Models. Hallett T, ed. *PLoS Med.* 2014;11(3):e1001610. doi:10.1371/journal.pmed.1001610

- 1
- 2
- 3
- 4 46. Worobey M, Gemmel M, Teuwen DE, et al. Direct Evidence of Extensive Diversity of HIV-1 in
- 5 Kinshasa by 1960. *Nature*. 2008;455(7213):661-664. doi:10.1038/nature07390
- 6
- 7 47. de Oliveira T, Pillay D, Gifford RJ. The HIV-1 Subtype C Epidemic in South America Is Linked to the
- 8 United Kingdom. *PLoS ONE*. 2010;5(2). doi:10.1371/journal.pone.0009311
- 9
- 10 48. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ. Molecular Phylodynamics of
- 11 the Heterosexual HIV Epidemic in the United Kingdom. *PLoS Pathog*. 2009;5(9).
- 12 doi:10.1371/journal.ppat.1000590
- 13
- 14 49. Hué S, Clewley JP, Cane PA, Pillay D. Investigation of HIV-1 transmission events by phylogenetic
- 15 methods: requirement for scientific rigour. *AIDS Lond Engl*. 2005;19(4):449-450.
- 16 doi:10.1097/01.aids.0000161778.15568.a1
- 17
- 18 50. Dennis AM, Hué S, Hurt CB, et al. Phylogenetic insights into regional HIV transmission. *AIDS Lond*
- 19 *Engl*. 2012;26(14):1813-1822. doi:10.1097/QAD.0b013e3283573244
- 20
- 21 51. Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the
- 22 molecular epidemiology of newly diagnosed HIV infections. *AIDS Lond Engl*. 2012;26(16):2079-
- 23 2086. doi:10.1097/QAD.0b013e32835805b6
- 24
- 25
- 26 52. Kouyos RD, Rauch A, Böni J, et al. Clustering of HCV coinfections on HIV phylogeny indicates
- 27 domestic and sexual transmission of HCV. *Int J Epidemiol*. 2014;43(3):887-896.
- 28 doi:10.1093/ije/dyt276
- 29
- 30 53. Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with
- 31 men: a combined clinical, epidemiological and phylogenetic approach. *AIDS*. 2010;24(11):1739-
- 32 1747. doi:10.1097/QAD.0b013e32833ac9e6
- 33
- 34 54. Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early
- 35 HIV-1 infection. *J Infect Dis*. 2007;195(7):951-959. doi:10.1086/512088
- 36
- 37
- 38 55. Kramer MA, Cornelissen M, Paraskevis D, et al. HIV transmission patterns among The Netherlands,
- 39 Suriname, and The Netherlands Antilles: a molecular epidemiological study. *AIDS Res Hum*
- 40 *Retroviruses*. 2011;27(2):123-130. doi:10.1089/aid.2010.0115
- 41
- 42 56. Henley C, Forgewei G, Welty T, et al. Scale-up and case-finding effectiveness of an HIV partner
- 43 services program in Cameroon: an innovative HIV prevention intervention for developing
- 44 countries. *Sex Transm Dis*. 2013;40(12):909-914. doi:10.1097/OLQ.0000000000000032
- 45
- 46 57. Centers for Disease Control and Prevention (CDC). Intimate Partner Violence and Sexual Violence
- 47 Victimization Assessment Instruments for Use in Healthcare Settings: (410572008-001). Published
- 48 online 2007. doi:10.1037/e410572008-001
- 49
- 50
- 51 58. Monroe-Wise A, Maingi Mutiti P, Kimani H, Moraa H, Bukusi DE, Farquhar C. Assisted partner
- 52 notification services for patients receiving HIV care and treatment in an HIV clinic in Nairobi,
- 53 Kenya: a qualitative assessment of barriers and opportunities for scale-up. *J Int AIDS Soc*.
- 54 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25315
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 59. Goyette MS, Mutiti PM, Bukusi D, et al. Hiv Assisted Partner Services Among Those with and  
4 Without A History of Intimate Partner Violence in Kenya. *J Acquir Immune Defic Syndr* 1999.  
5 Published online February 5, 2018. doi:10.1097/QAI.0000000000001638  
6  
7  
8 60. KELIN and the Kenya Key Populations Consortium. "Everyone Said No:" *Biometrics, HIV and Human*  
9 *Rights – A Kenya Case Study*. KELIN; 2018. Accessed April 10, 2020.  
10 <https://www.kelinkenya.org/everyonesaidno/>  
11  
12 61. Gathura G. Biometrics system for identifying people living with HIV ready. *The Standard*.  
13 [https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready)  
14 [living-with-hiv-ready](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready). Published November 17, 2019. Accessed April 10, 2020.  
15  
16 62. Anne N, Dunbar MD, Abuna F, et al. Feasibility and acceptability of an iris biometric system for  
17 unique patient identification in routine HIV services in Kenya. *Int J Med Inf*. 2020;133:104006.  
18 doi:10.1016/j.ijmedinf.2019.104006  
19  
20  
21  
22  
23  
24  
25  
26

27 **Table 1. Inclusion and Exclusion Criteria**

28  
29  
30  
31

<b><u>Group</u></b>	<b><u>Inclusion</u></b>	<b><u>Exclusion</u></b>
<b><i>Index</i></b>	<ul style="list-style-type: none"> <li>• 18 years of age or older</li> <li>• Recent intravenous drug use as defined by injecting at least once in the past year</li> <li>• HIV-positive</li> <li>• Willing and able to provide locator information for sexual and/or injecting partners</li> <li>• Willing and able to provide informed consent</li> </ul>	<ul style="list-style-type: none"> <li>• Classified as at high risk for IPV (described below)</li> </ul>
<b><i>Partner</i></b>	<ul style="list-style-type: none"> <li>• 18 years of age or older</li> <li>• identified by an index as either having injected with the index in the past 3 years or had sexual intercourse with the index in the past three years HIV-positive</li> <li>• Willing and able to provide informed consent</li> </ul>	None

32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Map of Study Sites




Figure 2. Study Flow Diagram

683x449mm (96 x 96 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 21 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ Included ___
Protocol version	3	Date and version identifier	___ 1 ___
Funding	4	Sources and types of financial, material, and other support	___ 23 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 23 ___
	5b	Name and contact information for the trial sponsor	_____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ N/A ___
5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ N/A ___	

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention \_\_\_ 5-7 \_\_\_

4

5

6 6b Explanation for choice of comparators \_\_\_ N/A \_\_\_

7

8 Objectives 7 Specific objectives or hypotheses \_\_\_ 6-7 \_\_\_

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) \_\_\_ 8 \_\_\_

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained \_\_\_ 8 \_\_\_

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) \_\_\_ 10-11 \_\_\_

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered \_\_\_ 11-14 \_\_\_

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) \_\_\_ N/A \_\_\_

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) \_\_\_ N/A \_\_\_

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial \_\_\_ 17 \_\_\_

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended \_\_\_ 18 \_\_\_

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) \_\_\_ 15 \_\_\_

41

42

43

44

45

46

1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including \_\_\_\_\_19\_\_\_\_\_

2 clinical and statistical assumptions supporting any sample size calculations

3

4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size \_\_\_\_\_11\_\_\_\_\_

5

6 **Methods: Assignment of interventions (for controlled trials)**

7 Allocation:

8

9

10 Sequence 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any \_\_\_\_\_N/A\_\_\_\_\_

11 generation factors for stratification. To reduce predictability of a random sequence, details of any planned restriction

12 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants

13 or assign interventions

14

15

16 Allocation 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, \_\_\_\_\_N/A\_\_\_\_\_

17 concealment opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

18 mechanism

19

20 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to \_\_\_\_\_N/A\_\_\_\_\_

21 interventions

22

23

24 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome \_\_\_\_\_N/A\_\_\_\_\_

25 assessors, data analysts), and how

26

27 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's \_\_\_\_\_N/A\_\_\_\_\_

28 allocated intervention during the trial

29

30

31 **Methods: Data collection, management, and analysis**

32

33 Data collection 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related \_\_\_\_\_12\_\_\_\_\_

34 methods processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of

35 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.

36 Reference to where data collection forms can be found, if not in the protocol

37

38

39 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be \_\_\_\_\_15\_\_\_\_\_

40 collected for participants who discontinue or deviate from intervention protocols

41

42

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___ 18 ___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___ 19-20 ___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___ N/A ___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___ N/A ___
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___ N/A ___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___ N/A ___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___ 21-22 ___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___ N/A ___
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___ 21 ___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___ 22 ___
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	__12-13__
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	__12-13__
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	__16-18__
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	__23__
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	__18__
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	__17-18__
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	__22-23__
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	__23__
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	__N/A__
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	__Attached__
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	__14-15, 20__
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 40  
 41  
 42

# BMJ Open

## Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041083.R2
Article Type:	Protocol
Date Submitted by the Author:	04-Jan-2021
Complete List of Authors:	<p>Monroe-Wise, Aliza; University of Washington, Mbogo, Loice; Kenyatta National Hospital  Guthrie, Brandon; University of Washington  Bukusi, David; Kenyatta National Hospital  Sambai, Betsy; Kenyatta National Hospital  Chohan, Bhavna; University of Washington; Kenya Medical Research Institute  Scott, John; University of Washington  Cherutich, Peter; Kenya Ministry of Health  Musyoki, Helgar; Kenya Ministry of Health  Bosire, Rose; Kenya Medical Research Institute; University of Washington  Dunbar, Matthew; University of Washington  Macharia, Paul; Kenya Ministry of Health  Masyuko, Sarah; Kenya Ministry of Health; University of Washington  Wilkinson, Eduan; University of KwaZulu-Natal  De Oliveira, Tulio; University of KwaZulu-Natal  Ludwig-Barron, Natasha; University of Washington  Sinkele, Bill; Support for Addiction Prevention and Treatment in Africa  Herbeck, Joshua; University of Washington School of Public Health,  Farquhar, Carey; University of Washington</p>
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Addiction, Epidemiology, Evidence based practice, Global health, Gastroenterology and hepatology
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Hepatology < INTERNAL MEDICINE, International health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Epidemiology < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, VIROLOGY



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and**  
4  
5 **HCV-positive people who inject drugs: a cohort study protocol**  
6  
7  
8  
9  
10  
11  
12  
13  
14

15 Aliza Monroe-Wise<sup>a</sup>, Loice Mbogo<sup>b</sup>, Brandon Guthrie<sup>a,c</sup>, David Bukusi<sup>b</sup>, Betsy Sambai<sup>b</sup>, Bhavna  
16 Chohan<sup>a,d</sup>, John Scott<sup>e</sup>, Peter Cherutich<sup>f</sup>, Helgar Musyoki<sup>f</sup>, Rose Bosire<sup>d</sup>, Matthew Dunbar<sup>g</sup>, Paul  
17 Macharia<sup>f</sup>, Sarah Masyuko<sup>a,f</sup>, Eduan Wilkinson<sup>h</sup>, Tulio de Oliveira<sup>h</sup>, Natasha Ludwig-Barron<sup>b</sup>,  
18  
19  
20 Bill Sinkele<sup>i</sup>, Joshua Herbeck<sup>a\*</sup>, Carey Farquhar<sup>a,b,e\*</sup>  
21  
22  
23  
24  
25  
26  
27  
28

29 <sup>a</sup>University of Washington Department of Global Health, <sup>b</sup>Kenyatta National Hospital,

30 <sup>c</sup>University of Washington Department of Epidemiology, <sup>d</sup>Kenya Medical Research Institute,

31 <sup>e</sup>University of Washington Department of Medicine, <sup>f</sup>Kenya's Ministry of Health, <sup>g</sup>Center for

32 <sup>h</sup>Studies in Demography and Ecology, University of Washington, <sup>h</sup>KwaZulu-Natal Research and

33 <sup>i</sup>Innovation Sequencing Platform, University of KwaZulu-Natal, <sup>i</sup>Support for Addiction

34 <sup>Prevention and Treatment in Africa</sup>

35  
36  
37  
38  
39  
40  
41  
42  
43  
44 Corresponding author: Aliza Monroe-Wise, MD, MSc. Email: alizamw@uw.edu

45  
46  
47 University of Washington, 325 Ninth Avenue, Box 359909, Seattle, WA 98104-2499

48  
49  
50 \*These authors share senior authorship.

51  
52  
53 V2.0 13/10/20  
54  
55  
56  
57  
58  
59  
60

## **Abstract**

### **Introduction**

Targeted, tailored interventions to test high-risk individuals for HIV and hepatitis C (HCV) are vital to achieving HIV control and HCV micro-elimination in Africa. Compared with the general population, people who inject drugs (PWID) are at increased risk of HIV and HCV and are less likely to be tested or successfully treated. Assisted partner services (APS) increases HIV testing among partners of people living with HIV and improves case-finding and linkage to care. We describe a study in Kenya examining whether APS can be adapted to find, test, and link to HIV care the partners of HIV-positive PWID using a network of community-embedded peer educators (PEs). Our study also identifies HCV-positive partners and uses phylogenetic analysis to determine risk factors for onward transmission of both viruses.

### **Methods**

This prospective cohort study leverages a network of PEs to identify 1,000 HIV-positive PWID for enrollment as index participants. Each index completes a questionnaire and provides names and contact information of all sexual and injecting partners during the previous 3 years. PEs then use a stepwise locator protocol to engage partners in the community and bring them to study sites for enrollment, questionnaire completion and rapid HIV and HCV testing. Outcomes include number and type of partners per index who are mentioned, enrolled, tested, diagnosed with HIV and HCV and linked to care.

### **Ethics and dissemination**

1  
2  
3 Potential index participants are screened for intimate partner violence (IPV) and those at high risk  
4 are not eligible to enroll. Those at medium risk are monitored for IPV following enrollment. A  
5  
6 community advisory board engages in feedback and discussion between the community and the  
7  
8 research team. A safety monitoring board discusses study progress and reviews data, including  
9  
10 IPV monitoring data. Dissemination plans include presentations at quarterly Ministry of Health  
11  
12 meetings, local and international conferences, and publications.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Strengths and limitations of this study**

- This cohort study investigates the use of assisted partner services (APS) to find, test for HIV and hepatitis C (HCV) and link to care the sexual and injecting partners of HIV-positive people who inject drugs (PWID) in Kenya; however, APS is not offered to HIV-negative, HCV-positive clients to identify those exposed to HCV but not HIV.
- Community embedded peer educators trained to provide harm reduction services conduct partner tracing, but there are limitations including logistical challenges and concerns for client confidentiality and safety of both the client and peer educator.
- An iris scanning biometric identification system ensures that each index participant enrolled is a unique individual and confirms that individual partner participants who enroll more than once in relation to different index participants are the same individual.
- Phylogenetic analysis of HIV and HCV viral sequences combined with APS will provide additional information about transmission dynamics within the cohort, including risk of onward transmission for different clusters and geographic regions.

### **Introduction**

Diagnosing 90% of those living with HIV has been among the most difficult of the UNAIDS 90-90-90 goals to achieve worldwide,<sup>1,2</sup> and strategies to reach individuals at high-risk for HIV who have never been tested is increasingly important.<sup>3</sup> In Kenya, despite success in achieving or

1  
2  
3 approaching the 2<sup>nd</sup> and 3<sup>rd</sup> UNAIDS goals, only 79.4% of people testing for HIV know their  
4 status.<sup>4</sup> Sharing needles and other drug paraphernalia is the most efficient mode of HIV  
5 transmission, and accounts for 13% of new infections globally.<sup>5,6</sup> In Kenya, prevalence of HIV  
6 among people who inject drugs (PWID) has been estimated at 15 – 50%<sup>6–10</sup>—significantly higher  
7 than the general population prevalence of 4.9%,<sup>11</sup> and up to 30% of PWID in Kenya have never  
8 tested for HIV.<sup>12,13</sup> Multiple studies have demonstrated low knowledge of HIV status and low  
9 engagement in care among Kenya's PWID.<sup>13,14</sup> Retention in care and adherence to ART are also  
10 both lower among PWID as compared with others worldwide.<sup>1</sup>

11  
12 In addition to HIV, PWID are at high risk for hepatitis C virus (HCV) globally and have the highest  
13 HCV prevalence of any group studied in Kenya at 13-40%<sup>10,15,16</sup>. This is especially high when  
14 compared to the general population HCV prevalence in Kenya of <1-4%.<sup>17,18</sup> However, multiple  
15 barriers exist at individual, provider and system levels resulting in low rates of testing, engagement  
16 in care, and completion of treatment courses for PWID.<sup>19–21</sup> Although less than 20% of PWID with  
17 chronic HCV worldwide have undergone antibody screening, the number who have completed  
18 PCR confirmatory testing is even lower.<sup>22</sup> Despite the introduction of highly effective direct acting  
19 antivirals (DAAs) into Kenya in 2016, only a small fraction of individuals living with HCV have  
20 been treated, prompting attention to micro-elimination strategies.<sup>23,24</sup>

21  
22 Assisted partner notification services (APS) for HIV is an evidence-based partner notification  
23 strategy in which providers elicit information about the sexual or injecting partners of an HIV-  
24 positive index client, and then contact, HIV test and link to care any partners found to be positive.<sup>25</sup>  
25 APS has been shown to significantly and safely increase the uptake of HIV testing services (HTS),  
26 case finding, and linkage to care for partners of HIV-positive people.<sup>25–27</sup> APS can also reduce  
27 barriers to disclosing HIV status<sup>28</sup> and is cost-effective.<sup>29</sup> APS has been successfully implemented

1  
2  
3 among HIV-positive patients from the general population in the USA,<sup>30</sup> Mozambique,<sup>31</sup>  
4 Malawi,<sup>32,33</sup> and Kenya,<sup>27</sup> and has recently been incorporated into the World Health Organization  
5 (WHO) guidelines for routine care for HIV-positive people worldwide.<sup>34</sup> While programs have  
6 introduced the practice of APS in high-risk key populations (KPs) such as female sex workers  
7 (FSW)<sup>35</sup> and men who have sex with men (MSM),<sup>36,37</sup> this intervention has not been well-studied  
8 among PWID,<sup>38</sup> an extremely high risk group.<sup>25,39</sup> Similar to FSW and MSM, PWID engage in  
9 behavior that is criminalized in many parts of the world<sup>40</sup> while experiencing high rates of  
10 marginalization and displacement,<sup>41</sup> making them difficult to study. These factors and others also  
11 contribute to significant barriers in the implementation of health programs targeting PWID.<sup>42–44</sup>

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Phylogenetic analysis is a method of identifying the role of specific risk groups and risk factors  
for onward transmission of HIV and HCV using the genetic sequence of each virus.<sup>45–47</sup> Viral  
phylogenetics can provide additional information on patterns of transmission,<sup>48–50</sup> epidemic  
growth,<sup>51,52</sup> risk groups,<sup>53–55</sup> and risk factors associated with onward transmission.<sup>47,56–58</sup>

Here we describe a prospective cohort study that seeks to determine whether and how APS can be  
implemented to find, test, and link to care the injection and sexual partners of HIV-positive PWID  
in Kenya. Simultaneously, our study will use phylogenetic analysis to study genetic sequences of  
HIV and HCV within our cohort to further understand transmission patterns and risk for onward  
transmission. All index and partner participants are tested for HCV in addition to HIV. While many  
partner contact methods for conducting APS have been used,<sup>25</sup> cellular telephones are the most  
common first-line communication modality for reaching partners in other populations.<sup>26,27,31,59</sup> In  
Kenya, however, the large majority of PWID do not have regular access to cellular telephones. As  
such, our APS model relies on the utilization of community-embedded peer educators (PEs) to  
locate and communicate with members of this difficult to reach population. We hypothesize that



1  
2  
3 we will be able to employ these customized APS procedures to reach a large number of injection  
4 and sexual partners, and that we will see differences between sexual and injection partners in  
5 uptake of HIV testing, HIV and HCV prevalence, and engagement in care. Additionally, we  
6 hypothesize that we will identify unique transmission patterns and risks for onward transmission  
7 in phylogenetic analysis, which may include behavioral, geographic, or other factors.  
8  
9  
10  
11  
12  
13  
14

## 15 **Methods and analysis**

### 16 *Approach*

17  
18  
19  
20  
21  
22 APS is a practice through which healthcare providers facilitate the notification, testing and linkage  
23 to care for partners who may have been exposed to HIV or other sexually transmitted infections  
24 by an individual known to be positive without revealing the identity of the person who may have  
25 exposed them. While there are many ways to provide partner services, APS in Kenya is often  
26 conducted by healthcare providers who elicit information about partners from an “index” patient  
27 and then call the partners over the telephone or physically trace them to alert them to their exposure  
28 and provide testing. We have designed customized procedures to ensure and improve the safety  
29 and efficacy of APS in the unique population of PWID in Kenya. Because PWID and their partners  
30 in Kenya rarely own cellular phones, we work with community-embedded peer educators (PEs) to  
31 find and engage with partners. Additionally, our protocol involves referrals to different facilities  
32 for injection partners and for sexual partners, as a precaution to ensure safety and confidentiality  
33 of index participants who may theoretically be at risk of negative outcomes if partners become  
34 aware of their HIV-positive status.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 *Study design*

1  
2  
3 Our study is a prospective cohort study with two groups: index and partner participants (“indexes”  
4 and “partners”). We use tailored APS procedures to identify, find, test and link to care the sexual  
5 and injection partners of HIV-positive PWID. All index participants, as well as partner participants  
6 and injection partners of HIV-positive PWID. All index participants, as well as partner participants  
7 who are diagnosed with HIV or HCV, complete a 6-month follow-up visit to assess linkage to and  
8 engagement in care.  
9

### 10 11 12 Study sites/setting 13

14  
15  
16 Study procedures take place in eight main sites including public health centers, medication-assisted  
17 treatment (MAT) centers, and needle and syringe programs (NSPs) in Nairobi, Kilifi, and  
18 Mombasa Counties in Kenya (Figure 1). Each site is staffed by at least one clinical officer (mid-  
19 level clinician) who works with researchers to ensure that only participants with documented HIV  
20 infection are enrolled as indexes, verifying HIV status through re-testing if documentation is not  
21 provided. In Nairobi County, the activities are centered at two NSP sites and one MAT center in  
22 the Mathare North area. The NSP sites, run by Support for Addiction Prevention and Treatment in  
23 Africa (SAPTA), offer routine HIV testing services. Referrals are made to local clinics providing  
24 care for those who test positive for HIV or HCV. We also recruit indexes from a government-run  
25 methadone clinic in Nairobi in the Ngara area. The Ngara Health Center MAT clinic offers HIV  
26 testing, care and treatment in addition to daily methadone administration, psychosocial services  
27 and treatment for other health conditions. In Kilifi county, participant recruitment and enrollment  
28 takes place at three needle and syringe program centers and one government hospital. The Omari  
29 Project is located in Malindi town and offers HIV counseling, testing, care and treatment in  
30 addition to harm reduction services. Malindi Sub-County Hospital’s MAT center is a recruitment  
31 site in Kilifi County within a mid-sized government hospital that offers a large range of medical  
32 and social services. Malindi Sub-County Hospital also has a large laboratory that houses the  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 study's samples collected in both Kilifi and Mombasa Counties. The Muslim Education and  
4 Welfare Association (MEWA) NSP sites in Kilifi and Mtwapa towns offer HIV counseling and  
5 testing, in addition to HIV care and treatment and harm reduction services. In Mombasa county,  
6 participants are recruited from the ReachOut Center, an NSP site in Mombasa city that offers a  
7 full range of harm reduction services in addition to HIV counseling, testing, care and treatment.  
8 All recruitment sites offer routine HCV testing when kits are available through specific donor-  
9 driven projects.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 Population

21  
22  
23 This study includes index participants and their sexual and/or drug-injecting partners . All indexes  
24 are HIV-positive PWID. Partners are either sexual partners or injecting partners of indexes.  
25  
26  
27  
28

29 Indexes are largely recruited from organizations and clinics that provide services to PWID  
30 populations, although they may also come from outreach efforts or informal referrals from other  
31 participants. Partners are identified and recruited through peer-mediated APS and may come from  
32 any geographic area or community.  
33  
34  
35  
36  
37  
38

### 39 Patient and Public Involvement

40  
41  
42 Members of the community of PWID being researched were consulted in the development of  
43 research questions and design of the study. The study is supported by a Community Advisory  
44 Board (CAB) composed of members of the community, peer educators and employees of  
45 organizations that provide services to the population. The CAB meets with the study team regularly  
46 and helps inform dissemination plans.  
47  
48  
49  
50  
51  
52  
53

### 54 Study procedures

## 1. Peer educator recruitment and training

PEs are recovering PWID with established relationships in the PWID communities that they serve. The majority are between the ages of 25 and 50, are enrolled in Kenya's methadone program and report having stopped injecting drugs. These men and women have been identified by the individual organizations at which they work as being key community members, and have undergone extensive training for their roles as PEs. Training is an intensive 5-day course with modules covering a broad spectrum of content including basics of drugs and drug-related harms, harm reduction efforts including NSP and MAT, abscess prevention and management, overdose prevention and management and behavior change communication. PEs have access to relatively hidden PWID community spaces, and provide health counseling, linkage to support organizations, information, and other services to this vulnerable population.

For this study, PEs who were actively carrying out basic duties were chosen by the leadership at each organization based on several factors including awareness and knowledge of HIV in the community and access to unique target populations (for instance, women who inject drugs may be more easily accessed by women PEs). Once identified, PEs underwent an intensive 1-day training to educate them on the practice and ethics of research, study procedures, and their role in the study. PEs are supervised by clinic managers, who are all collaborators in the study. PEs participate in regular health education and harm reduction training and engage in quarterly sessions with study leadership where they present barriers and lessons learned to the study team so that study-related issues can be addressed.

## 2. Inclusion & exclusion criteria

1  
2  
3 Inclusion and exclusion criteria are different for indexes and partners (Table 1). Any interested  
4  
5 individuals who are under the age of 18 are referred to the site clinicians for routine counseling  
6  
7 and harm reduction services.  
8  
9

### 10 11 3. Index recruitment and enrollment 12

13  
14 Enrollment began in March 2018. Clinicians at each site identify potential indexes using existing  
15  
16 clinical data on known HIV-positive clients. Additionally, any client who tests positive for HIV  
17  
18 during routine testing is invited to participate. Clinicians are employed by the sites, and are trained  
19  
20 clinical officers (COs), or mid-level providers. For this study, HIV rapid testing is performed by  
21  
22 non-study COs and takes place as part of standard clinic procedures. All potential indexes are re-  
23  
24 tested using HIV rapid tests (as per the national guidelines) to confirm HIV status prior to  
25  
26 enrollment. If HIV positive, either newly diagnosed or known to be positive, clinicians approach  
27  
28 potential indexes with one of two strategies. Either the clinicians discuss the study directly with  
29  
30 potential participants or engage PEs to find individuals and bring them to the study office if they  
31  
32 are not regular clients at the site. Importantly, PEs are not told whether participants are being traced  
33  
34 as an index or a partner, protecting the confidentiality of indexes' HIV status.  
35  
36  
37  
38  
39

40  
41 Study staff health advisors (HAs) are the individuals responsible for conducting study procedures  
42  
43 including notification of exposure, data collection, HIV and HCV testing, and the coordination of  
44  
45 APS efforts (Figure 2). All HAs were trained and experienced in HIV testing services prior to  
46  
47 working for the study, and many had previous experience working with PWID. All HAs underwent  
48  
49 a week-long training course at the beginning of the study in which they learned the basics and  
50  
51 purpose of research, research ethics, study procedures, unique ethical and logistical issues to  
52  
53 consider when working with PWID, and other topics. All HAs also completed the Collaborative  
54  
55  
56  
57

1  
2  
3 Institutional Training Initiative (CITI) course on Human Subjects Research and the Responsible  
4 Conduct of Research. HAs explain the benefits and rationale for providing APS, discuss the  
5 importance of learning more about HIV and HCV, and describe the process of notifying partners  
6 without revealing the identity of the index. They ask participants to provide written informed  
7 consent for study participation, APS, and future use of biological specimens and future contact for  
8 additional studies, using an iris-scanning biometric device to record a unique identifier for each  
9 participant, thus enabling the study team to confirm that a person does not enroll into the program  
10 as an index more than once.  
11  
12

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23 Indexes undergo a structured questionnaire administered by the HA using open data kit (ODK)  
24 software on tablet devices (ODK, 2017, Seattle, WA, USA). Questionnaires cover a variety of  
25 topics including demographics, sexual and injecting behaviors, drug use history, and HIV testing  
26 and history of engagement in HIV care. Participants are then asked to recall all of their sexual and  
27 injecting partners over the three years prior to enrollment, naming these partners one by one and  
28 assigning each partner a letter (“A,” “B,” etc). Sexual intercourse is defined as vaginal, oral, or  
29 anal sex and drug injecting partner is defined as a friend that you inject with frequently. Indexes  
30 are asked to give as much locator information as possible for each partner, including names (which  
31 may be nicknames), phone numbers, and location of employment or residence. Locator  
32 information is written on a paper form for each partner. Indexes then complete a short ODK  
33 questionnaire about each partner mentioned, which includes information about the relationship  
34 between the index and the partner. Indexes who wish to notify partners themselves are given a 2-  
35 week window in which to do so, after which partners are contacted by study staff. Partners notified  
36 by indexes through passive referral are told to present to the study site for enrollment in the study,  
37 and mode of referral is recorded for each partner in the study.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Indexes then undergo rapid HCV antibody testing as part of routine study procedures. HAs conduct  
4 pre- and post- test counseling and ensure individuals who test positive are available for follow-up  
5 visits to discuss confirmatory HCV PCR testing and enrolling in a treatment program administered  
6 by the Ministry of Health. All indexes then undergo phlebotomy with a sample of 10mL of blood  
7 drawn for further testing (see section 6 below). Indexes receive 400 Kenya Shillings (KES,  
8 equivalent to about \$4) as compensation for travel and time spent in the study procedures.  
9

#### 18 4. Peer-educator mediated assisted partner services and partner recruitment

21 For those partners who have phone numbers listed, HAs attempt phone communication first.  
22 However, the vast majority of partners mentioned by indexes do not have working cellular phones;  
23 therefore, with few exceptions, PEs locate and conduct the study's first interaction in person with  
24 identified partners. PEs are given paper forms containing names and locator information for  
25 identified partners, and they verify that the names and locations provided on the locator form  
26 matches those of the person they have contacted. They are never told which index referred the  
27 team to each partner, and that information is not listed on locator forms or any other accessible  
28 file. PEs then locate and approach potential participants in the community and inform them that  
29 they have been identified as an individual who might need to be seen in a clinic due to a health  
30 concern. When approaching a partner, PEs alert partners that the PEs are working with a research  
31 study, and that the partner may have a health issue that should be addressed. The PEs then urge  
32 the partner to accompany them to a health facility for testing and possible enrollment in the study.  
33 Although PEs are trained using a standardized script, they are encouraged to allow the conversation  
34 to progress naturally, responding to questions and concerns that may arise and urging partners to  
35 come to the site for further information. PEs do not notify partners of their exposure during initial  
36 contact for several reasons: 1) to protect the HIV status of indexes, PEs are not told whether they  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 are recruiting an index or a partner, and 2) PEs have not felt comfortable discussing HIV or HCV  
4 exposure with potential participants. Once PEs have notified potential participants of their possible  
5 eligibility, they then accompany interested individuals to the nearest research office, where the  
6 study's HAs inform partners of their potential exposure to HIV and/or HCV, and conduct informed  
7 consent. Informed consent includes consent to future use of biological specimens and future  
8 contact for additional studies. In the rare event that a potential participant does not agree to come  
9 to the study office, an HA returns to the site with the PE and notifies the individual of the exposure,  
10 and in the rare event that a potential participant agrees to come to the study office but does not  
11 want to enroll in the study, the health advisor notifies the individual of the exposure and encourages  
12 the individual to undergo testing for HIV and HCV outside of study procedures.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

### 27 5. Partner enrollment

28  
29  
30 After informed consent and biometric identification, partners complete a structured questionnaire  
31 similar to that of indexes, administered by HAs on a handheld device using ODK software.  
32 Following the questionnaire, all partners undergo rapid antibody testing for both HIV and HCV.  
33 HIV testing services are provided in accordance with national HIV testing guidelines. Any partner  
34 found to be positive for either HIV or HCV antibodies undergoes a 20mL blood draw. Those  
35 partners who test negative for both HIV and HCV are finished with study procedures at this time  
36 and are counseled on risk reduction measures and provided information about HIV and HCV  
37 prevention services before leaving the study site. All partners receive 400 Kenya Shillings (KES,  
38 equivalent to about \$4) as compensation for travel and time spent in the study procedures.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 HIV-positive partners are invited to undergo screening as an index once data collection procedures  
53 for their partner enrollment are complete. If they meet eligibility criteria as an index, they may  
54  
55  
56  
57



1  
2  
3 enroll as an index. Study procedures are slightly amended for indexes that have previously enrolled  
4 as partners. After undergoing informed consent and completing a short questionnaire that only  
5 includes questions that were not a part of the partner enrollment questionnaire, they complete the  
6 identification and data collection on each of their sexual and injection partners, identical to partner  
7 identification procedures for indexes described above.  
8  
9  
10  
11  
12  
13

## 14 15 16 6. Laboratory Procedures

17  
18  
19 Blood samples from both index and partner enrollment visits are collected in EDTA vacutainer  
20 tubes. Blood is mixed with the anticoagulant by inversion and the anticoagulated blood is stored  
21 at room temperature at the sites for less than 4 hours. A motorcycle courier picks samples from  
22 each site daily and brings them to the University of Nairobi Pediatric Research Laboratory in  
23 Nairobi or the Malindi Sub-County Hospital Laboratory for coast sites. At each laboratory,  
24 samples are first used to prepare two Whatman 903 Protein Saver dried blood spot (DBS) cards  
25 with 50ul of whole blood on each spot. Blood samples are then centrifuged and used to prepare 2  
26 to 3 aliquots of 1ml of plasma in labeled serum vials. Plasma aliquots and air-dried DBS cards  
27 (with desiccant in sealed Ziploc bags) are then stored at -80° Celsius and shipped on dry ice to the  
28 University of KwaZulu-Natal laboratory. There, samples undergo HIV and HCV viral load testing  
29 and amplification for sequencing.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

## 45 7. Participant follow-up

46  
47  
48 All indexes and any partners who were positive for HIV or HCV complete a six-month follow-up  
49 visit. HAs identify which participants are due for follow-up visits on a weekly basis and give PEs  
50 as list of these names. PEs then trace participants and bring them back to clinics where data  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 collection procedures are conducted. PEs make several attempts to find participants in the  
4  
5 community before considering them lost to follow-up.  
6  
7

8  
9 Six-month visits involve a brief questionnaire covering questions on testing for HIV or HCV (if  
10  
11 not infected with both on enrollment), enrollment in care and treatment, engagement in care, and  
12  
13 follow-up testing. The purpose of this visit is to assess whether engagement in care has changed  
14  
15 following APS procedures, for both indexes and partners. We do not collect additional data from  
16  
17 those lost to follow up.  
18  
19

## 20 21 8. Intimate partner violence (IPV) monitoring

22

23  
24 Given historical concerns that APS may increase one's risk of experiencing intimate partner  
25  
26 violence, all potential participants undergo screening for IPV before enrollment. IPV is defined as  
27  
28 any physical, sexual or psychological harm inflicted on a person by a current or former sexual  
29  
30 partner. After answering a standardized set of six questions about physical, emotional and sexual  
31  
32 IPV and the timing of any previous experience of IPV based on published screening tools reviewed  
33  
34 by the Centers for Disease Control and Prevention,<sup>60</sup> potential participants are classified as low,  
35  
36 medium or high risk for IPV. Individuals are classified as at high risk for IPV if they report IPV  
37  
38 within the last month. Any potential index who is classified as high IPV risk is excluded from  
39  
40 study participation and provided with IPV counseling and resources. Any potential partner  
41  
42 participant who is classified as high IPV risk is allowed to enroll, but then receives special  
43  
44 monitoring for IPV following enrollment.  
45  
46  
47  
48  
49

50  
51 Potential participants are classified as at moderate risk for IPV if they report 1) IPV during their  
52  
53 lifetime either from a current or past partner; and/or 2) fear of IPV if they participate in the study.  
54  
55  
56  
57

1  
2  
3 All index or partner participants classified as moderate IPV risk receive special monitoring for  
4  
5 IPV following their enrollment in the study.  
6  
7

8  
9 Potential participants are classified as at low risk for IPV if they report 1) no IPV during their  
10  
11 lifetime ; and 2) no fear of IPV if they participate in the study. These individuals undergo standard  
12  
13 study procedures which include completing the baseline IPV case report form and a follow-up IPV  
14  
15 case report to capture reports of any interim IPV.  
16  
17

### 18 19 9. Confidentiality and safety 20 21

22 *Participants:* All study procedures take place in private rooms at each study facility. To ensure the  
23  
24 safety and confidentiality of indexes, PEs who are tasked with finding partners are blinded to the  
25  
26 identity of the linked index through the use of partner locator forms that do not contain identifying  
27  
28 information about the index participant. Locator forms do contain a printed barcode label that are  
29  
30 then used by study staff to link the partner with the index who referred the partner.  
31  
32  
33

34  
35 Sexual partners are brought to independent facilities for enrollment rather than to centers that serve  
36  
37 PWID, in order to further protect the identity of the index participant who referred them. The  
38  
39 independent facilities are local healthcare clinics that serve the general population.  
40  
41

42  
43 *Peer educators:* PEs have frequent interactions with police, and can be victims of harassment or  
44  
45 violence, both by police and by PWID. To reduce the risk of law enforcement troubles, PEs carry  
46  
47 identification showing that they are working on a study being conducted by the Ministry of Health.  
48  
49 Local law enforcement officials have also attended ongoing sensitization trainings by the Ministry  
50  
51 of Health and by organizations working with PWID.  
52  
53

### 54 55 10. Referrals to care 56 57

1  
2  
3 *HIV Counseling and Care:* Participants are provided with their HIV test results in the context of  
4 post-test counseling, and are then referred to available medical and psychosocial care and support  
5 facilities either within the research site or in close proximity to the research site or the participant's  
6 home. Additionally, HIV-positive individuals are offered individual or group support sessions as  
7 available within each site.  
8  
9

10  
11  
12  
13  
14  
15 *HCV Counseling and Care:* Participants who test positive for HCV antibodies using rapid testing  
16 are provided with their HCV antibody test results in the context of pre- and post-test counseling.  
17 They are informed that they may have active HCV infection; however, further confirmatory testing  
18 must be done prior to establishing the diagnosis. Confirmatory polymerase chain reaction (PCR)  
19 testing is done in batches of samples at our partnering laboratory at the University of KwaZulu-  
20 Natal, South Africa, and participants with active infection are later contacted for results and  
21 counseling. Turnaround time from enrollment to PCR result notification varies, but is typically  
22 between 1 and 4 months. Once notified of their PCR results, those with active infection are paired  
23 with a PE at their site to ensure close contact is maintained. Study participants with active HCV  
24 infections will be eligible to receive free treatment with direct acting antivirals, which the Kenyan  
25 MoH has procured.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

#### 42 Data management

43  
44

45 After each study visit, HAs review their work for omissions or errors and all data are uploaded  
46 into the study database. Electronic data are stored securely in an encrypted database on servers  
47 using Open Data Kit Aggregate, within Kenya's Ministry of Health (MoH). All errors or omissions  
48 identified at any step in the quality assurance/quality control process are revised by the staff  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 member who originally completed the document. All additions and corrections are initialed and  
4  
5 dated by the staff member who records the entry.  
6  
7

8  
9 A link-log is separately encrypted to further ensure that data remains secure. Any data transferred  
10  
11 to investigators or MoH are de-identified and encrypted during the process of transfer from the  
12  
13 server. Each investigator maintains and stores secure, complete, accurate and current study records  
14  
15 throughout the study. A database manager performs regular data cleaning and resolves any  
16  
17 discrepancies that occur. Study sites also conduct quality control and quality assurance procedures.  
18  
19 All co-investigators have access to the final dataset and this is not limited by contractual  
20  
21 agreements. Study data will be available upon request at the completion of the study.  
22  
23  
24  
25

### 26 Outcome measures

27  
28  
29 The primary outcomes of interest to assess the success of the APS intervention are: a) number of  
30  
31 sexual and injection partners tested for HIV and HCV through APS, identified by each index  
32  
33 participant over the course of the study period; b) number of sexual and injection partners newly  
34  
35 testing positive for HIV and HCV, per index participant; c) number of known HIV or HCV cases  
36  
37 identified through APS who are not engaged in care; d) number of index and partner participants  
38  
39 with HIV and/or HCV infection who are linked to care; e) number of index and partners with HIV  
40  
41 and/or HCV infection who remain in care and are receiving appropriate treatment at 6 months after  
42  
43 testing positive. Secondary outcomes are linked to inclusion in phylogenetic clusters identified as  
44  
45 high risk for onward transmission of HIV and HCV.  
46  
47  
48  
49

### 50 Sample size

1  
2  
3 We are enrolling 1000 HIV-positive indexes and their sexual and injecting partners. Based on  
4 HCV data from MoH and our preliminary results, we estimate that 20% of PWID with HIV will  
5 be co-infected with HCV and that each index will identify on average two partners who will accept  
6 HIV and HCV testing, 20% of whom will be HIV-positive, and 20% of whom will be HCV-  
7 infected. Thus, with provision of APS to 1,000 HIV-positive indexes and testing of 2,000 partners,  
8 we will identify an estimated 600 indexes and partners infected with HCV and 400 HIV-positive  
9 partners. This study was designed to have high precision in estimating the prevalence of HIV and  
10 HCV infection among partners, providing valuable input for modeling the impact of APS in the  
11 population. For an observed HIV or HCV prevalence of 10% among partners, precision is  
12 estimated at 1.9%; with an observed HIV or HCV prevalence of 30% among partners, precision is  
13 estimated at 2.9%. *Statistical methods and analysis*

14  
15 To determine efficacy of the APS intervention, we will use generalized estimating equations  
16 (GEE) models with a Poisson link using the following variables and offsets: 1) rate of HIV and  
17 HCV testing of partners: number of individuals tested for HIV or HCV, offset by the number of  
18 partners located with locator information provided by the index participant; 2) prevalence of HIV  
19 and HCV infection: number of individuals identified as HIV or HCV-positive, offset by the  
20 number of individuals who were HIV tested; and 3) rate of linkage to HIV and HCV care:  
21 individuals who test HIV or HCV-positive and link to care, offset by the total number of  
22 individuals who test HIV or HCV-positive.

23  
24 Additionally, using both GEE and phylogenetic analysis, we will determine the following: 1)  
25 identifiable and individual risk factors linked to high rates of HIV and HCV transmission, 2) risk  
26 factors linked to both needle-sharing and sexual transmission, and 3) identification of transmission  
27 clusters among PWID for both HIV and HCV.

### Phylogenetic analysis

HIV and HCV gene sequencing are attempted for all study participants who test positive for either virus. Sequencing will be performed at the KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP) at the University of KwaZulu-Natal in Durban, South Africa. For HIV we will subsequently combine our data with additional, publicly available, HIV sequences from Kenya and perform phylogenetic and phylodynamic analyses to describe patterns and rates of viral transmission among key populations in Kenya and identify traits associated with relative infectiousness. For HCV we will use phylogenetic methods to characterize the modes and risk factors for onward transmission among PWID.

### **Ethics and Dissemination**

#### General ethical considerations

This study is registered at clinicaltrials.gov (NCT03447210) and has ethical approval from both the University of Washington Human Subjects Division and the Kenyatta National Hospital Ethics and Research Committee. It also has approval from Kenya's National Commission for Science, Technology and Innovation.

There are a number of potential risks to participants. Risks of conducting APS include psychological distress, social or economic hardship, criminal penalties, and loss of privacy and/or confidentiality. Study procedures, including confidentiality and counseling procedures, are specifically designed to minimize these risks to participants. While IPV has the potential to cause harm, it has not increased in other US or African studies when this intervention has been implemented in the general population.<sup>25,61,62</sup> We recognize that risks may be different when

1  
2  
3 implementing APS among key populations and study staff are highly trained in counseling about  
4 risk behaviors, implications of testing HIV-positive, and protecting confidentiality to avoid  
5 potential social harms. In addition, staff have undergone extensive training on IPV counseling and  
6 ensure that resources have been identified in all sites so we can safely refer participants who report  
7 abuse or are concerned for their safety. Participants reporting moderate IPV are monitored as  
8 described in Section 8; they are counseled and referred for services if IPV is reported at any of  
9 these follow-up visits.

10  
11 A safety monitoring board composed of researchers and policy makers in both Kenya and the US  
12 reviews study safety data twice per year. The board monitors enrollments, deaths, loss to follow  
13 up, adverse events, including social harms, and IPV monitoring data and makes recommendations  
14 regarding study procedures.

15  
16 Ethical considerations surrounding the use of biometric identification systems among key  
17 populations in Kenya have been discussed extensively.<sup>63</sup> Despite early opposition from the Key  
18 Populations Consortium and other organizations to the government's use of fingerprint-based  
19 biometric data collection, the organizations and individuals working with PWID communities  
20 continued to report no opposition to iris scanning for research purposes among PWID. In  
21 November 2019, Kenya passed the Data Protection Bill, rendering it legal to collect biometric data  
22 as long as the use of such data does not violate the subjects' rights.<sup>64</sup> The use of biometrics is now  
23 standard practice in many research and clinical settings, and has been found to be acceptable to  
24 participants.<sup>65</sup> Our participants have not reported any concerns, fears, or hesitations regarding the  
25 use of an iris scanning biometric identification system.

### 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 *Dissemination plan*



1  
2  
3 Results from the study and changes to the study are presented on an ongoing basis at Kenya's  
4 quarterly MoH harm reduction and key population technical working group meetings, and  
5 discussed at biannual meetings by the Community Advisory Board that was established for this  
6 study. Our study team includes several collaborators from the MoH. Ongoing study analyses are  
7 also presented at national conferences annually. Additionally, study results are presented in at least  
8 one international conference per year. Finally, the study team reviews data on a weekly basis and  
9 any changes in data trends or other concerns are discussed directly with the organizations through  
10 which study procedures take place.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### **Authors' contributions**

22  
23  
24  
25  
26 CF and JH conceived of the study; AMW, BG, BC, MD, PM, BSi, JH and CF contributed to the  
27 study design and data collection structure; AMW, LM, DB, BSa, BC, JS, PC, HM, RB, PM, SM,  
28 EW, TDO, BSi, JH and CF contributed to data collection; AMW, LM, BG, DB, BSa, PC, HM,  
29 RB, SM, EW, TDO, NLB, JH and CF contributed to data analysis and dissemination; AMW, BG,  
30 JH and CF wrote the manuscript; all authors reviewed the manuscript for content.  
31  
32  
33  
34  
35  
36  
37

### **Funding**

38  
39  
40  
41 This work was supported by the Division of AIDS, National Institute of Drug Abuse, grant number  
42 R01 DA043409. 301 North Stonestreet Ave, Bethesda, MD 20892. +1 301-443-1124.  
43  
44  
45  
46

### **Competing interests**

47  
48  
49  
50 All authors state that they have no competing interests.  
51  
52

53  
54 Figure 1. Map of Study Sites  
55  
56  
57

Figure 2. Study Flow Diagram

## References

1. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. *BMJ Glob Health*. 2016;1(2):e000010. doi:10.1136/bmjgh-2015-000010
2. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Published October 2014. Accessed March 7, 2018. [http://www.unaids.org/sites/default/files/media\\_asset/90-90-90\\_en.pdf](http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf)
3. Staveteig S, Croft TN, Kampa KT, Head SK. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries. *PLOS ONE*. 2017;12(10):e0186316. doi:10.1371/journal.pone.0186316
4. National AIDS and STI Control Programme (NASCOP). *Preliminary KENPHIA 2018 Report*.; 2020. Accessed December 16, 2020. [https://phia.icap.columbia.edu/wp-content/uploads/2020/04/KENPHIA-2018\\_Preliminary-Report\\_final-web.pdf](https://phia.icap.columbia.edu/wp-content/uploads/2020/04/KENPHIA-2018_Preliminary-Report_final-web.pdf)
5. Brodish P, Singh K, Rinyuri A, et al. Evidence of high-risk sexual behaviors among injection drug users in the Kenya PLACE study. *Drug Alcohol Depend*. 2011;119(1-2):138-141. doi:10.1016/j.drugalcdep.2011.05.030
6. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet Lond Engl*. 2008;372(9651):1733-1745. doi:10.1016/S0140-6736(08)61311-2
7. National AIDS Control Council NS and ACP. Kenya HIV Prevention Revolution Road Map: Count Down to 2030. Published online June 2014.
8. Kurth AE, Cleland CM, Des Jarlais DC, et al. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya. *J Acquir Immune Defic Syndr* 1999. 2015;70(4):420-427. doi:10.1097/QAI.0000000000000769
9. Ndetei, David M. A study on the linkages between drug abuse, injecting drug use and HIV/AIDS in Kenya: a rapid situation assessment. *U N Off Drugs Crime*.:45.
10. Odek-Ogunde M, Okoth, F, Lore, W, Owiti, F.R. Seroprevalence of HIV, HBC and HCV in Injecting Drug Users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II Findings. In: ; 2004.
11. National AIDS Control Council. *Kenya HIV Estimates Report 2018*. Accessed February 21, 2019. <https://nacc.or.ke/wp-content/uploads/2018/11/HIV-estimates-report-Kenya-20182.pdf>

12. Tun W, Sheehy M, Broz D, et al. HIV and STI Prevalence and Injection Behaviors Among People Who Inject Drugs in Nairobi: Results from a 2011 Bio-behavioral Study Using Respondent-Driven Sampling. *AIDS Behav.* 2015;19(Suppl 1):24-35. doi:10.1007/s10461-014-0936-3
13. Lizcano, J. Testing and Linkage to Care for Injecting Drug Users. In: ; 2016.
14. Githuka G, Hladik W, Mwalili S, et al. Populations at Increased Risk for HIV Infection in Kenya: Results From a National Population-Based Household Survey, 2012. *J Acquir Immune Defic Syndr* 1999. 2014;66(Suppl 1):S46-S56. doi:10.1097/QAI.0000000000000137
15. Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. *Lancet Infect Dis.* 2019;19(11):1255-1263. doi:10.1016/S1473-3099(19)30264-6
16. Muasya T, Lore W, Yano K, et al. Prevalence of Hepatitis C Virus and its genotypes among a cohort of drug users in Kenya. *East Afr Med J.* 2008;85(7). doi:10.4314/eamj.v85i7.9649
17. Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. *Pan Afr Med J.* 2019;34. doi:10.11604/pamj.2019.34.31.17885
18. Loarec A, Carnimeo V, Molino L, et al. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. *AIDS Lond Engl.* 2019;33(2):353-355. doi:10.1097/QAD.0000000000002070
19. Litwin AH, Jost J, Wagner K, et al. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. *Contemp Clin Trials.* 2019;87:105859. doi:10.1016/j.cct.2019.105859
20. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. *Drug Alcohol Rev.* 2012;31(7):918-924. doi:10.1111/j.1465-3362.2012.00468.x
21. Enkelmann J, Gassowski M, Nielsen S, et al. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing. *Harm Reduct J.* 2020;17(1):7. doi:10.1186/s12954-019-0338-y
22. Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. *Liver Int Off J Int Assoc Study Liver.* 2019;39(1):20-30. doi:10.1111/liv.13949
23. Medecins du Monde. Our Activities in Kenya. Accessed November 24, 2020. <https://www.medecinsdumonde.org/en/countries/africa/kenya>
24. Cherutich P, Kurth A, Lizcano JA, Akiyama MJ. Integration of Hepatitis C treatment services with harm reduction service centers for people who inject drugs in Kenya: experience from test and link to care for injecting drug users study. In: *Reviews in Antiviral Therapy & Infectious Diseases.* ; 2019.

- 1
- 2
- 3 25. Dalal S, Johnson C, Fonner V, et al. Improving HIV test uptake and case finding with assisted
- 4 partner notification services. *AIDS Lond Engl*. 2017;31(13):1867-1876.
- 5 doi:10.1097/QAD.0000000000001555
- 6
- 7 26. Kahabuka C, Plotkin M, Christensen A, et al. Addressing the First 90: A Highly Effective Partner
- 8 Notification Approach Reaches Previously Undiagnosed Sexual Partners in Tanzania. *AIDS Behav*.
- 9 2017;21(8):2551-2560. doi:10.1007/s10461-017-1750-5
- 10
- 11 27. Cherutich P, Golden MR, Wamuti B, et al. Assisted partner services for HIV in Kenya: a cluster
- 12 randomised controlled trial. *Lancet HIV*. 2017;4(2):e74-e82. doi:10.1016/S2352-3018(16)30214-4
- 13
- 14 28. Plotkin M, Kahabuka C, Christensen A, et al. Outcomes and Experiences of Men and Women with
- 15 Partner Notification for HIV Testing in Tanzania: Results from a Mixed Method Study. *AIDS Behav*.
- 16 2018;22(1):102. doi:10.1007/s10461-017-1936-x
- 17
- 18 29. Sharma M, Smith JA, Farquhar C, et al. Assisted partner notification services are cost-effective for
- 19 decreasing HIV burden in western Kenya. *AIDS Lond Engl*. 2018;32(2):233-241.
- 20 doi:10.1097/QAD.0000000000001697
- 21
- 22 30. Landis SE, Schoenbach VJ, Weber DJ, et al. Results of a randomized trial of partner notification in
- 23 cases of HIV infection in North Carolina. *N Engl J Med*. 1992;326(2):101-106.
- 24 doi:10.1056/NEJM199201093260205
- 25
- 26 31. Myers RS, Feldacker C, Cesár F, et al. Acceptability and Effectiveness of Assisted Human
- 27 Immunodeficiency Virus Partner Services in Mozambique: Results From a Pilot Program in a Public,
- 28 Urban Clinic. *Sex Transm Dis*. 2016;43(11):690-695. doi:10.1097/OLQ.0000000000000529
- 29
- 30 32. Brown LB, Miller WC, Kamanga G, et al. HIV partner notification is effective and feasible in sub-
- 31 Saharan Africa: opportunities for HIV treatment and prevention. *J Acquir Immune Defic Syndr*
- 32 1999. 2011;56(5):437-442.
- 33
- 34 33. Brown LB, Miller WC, Kamanga G, et al. Predicting partner HIV testing and counseling following a
- 35 partner notification intervention. *AIDS Behav*. 2012;16(5):1148-1155. doi:10.1007/s10461-011-
- 36 0094-9
- 37
- 38 34. World Health Organization. WHO | WHO recommends assistance for people with HIV to notify
- 39 their partners. WHO. Accessed February 22, 2019. [http://www.who.int/hiv/pub/vct/who-partner-](http://www.who.int/hiv/pub/vct/who-partner-notification-policy/en/)
- 40 notification-policy/en/
- 41
- 42 35. Quinn C, Nakyanjo N, Ddaaki W, et al. HIV partner notification values and preferences among sex
- 43 workers, fishermen, and mainland community members in Rakai, Uganda: a qualitative study. *AIDS*
- 44 *Behav*. 2018;22(10):3407-3416. doi:10.1007/s10461-018-2035-3
- 45
- 46 36. Rane V, Tomnay J, Fairley C, et al. Opt-Out Referral of Men Who Have Sex With Men Newly
- 47 Diagnosed With HIV to Partner Notification Officers: Results and Yield of Sexual Partners Being
- 48 Contacted. *Sex Transm Dis*. 2016;43(6):341-345. doi:10.1097/OLQ.0000000000000449
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 37. Halkitis PN, Kupprat SA, McCree DH, et al. Evaluation of the relative effectiveness of three HIV
- 5 testing strategies targeting African American men who have sex with men (MSM) in New York City.
- 6 *Ann Behav Med Publ Soc Behav Med.* 2011;42(3):361-369. doi:10.1007/s12160-011-9299-4
- 7
- 8 38. Levy JA, Fox SE. The outreach-assisted model of partner notification with IDUs. *Public Health Rep*
- 9 *Wash DC 1974.* 1998;113 Suppl 1:160-169.
- 10
- 11 39. Malik M, Jamil MS, Johnson CC, Pasha MS, Hermez J, Qureshi S ul H. Integrating assisted partner
- 12 notification within HIV prevention service package for people who inject drugs in Pakistan. *J Int*
- 13 *AIDS Soc.* 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25317
- 14
- 15 40. DeBeck K, Cheng T, Montaner JS, et al. HIV and the criminalisation of drug use among people who
- 16 inject drugs: a systematic review. *Lancet HIV.* 2017;4(8):e357-e374. doi:10.1016/S2352-
- 17 3018(17)30073-5
- 18
- 19 41. United Nations, Office on Drugs and Crime. *World Drug Report 2016.*; 2016.
- 20
- 21 42. Molinaro S, Resce G, Alberti A, et al. Barriers to effective management of hepatitis C virus in
- 22 people who inject drugs: Evidence from outpatient clinics. *Drug Alcohol Rev.* 2019;38(6):644-655.
- 23 doi:10.1111/dar.12978
- 24
- 25 43. Phillips KT. Barriers to practicing risk reduction strategies among people who inject drugs. *Addict*
- 26 *Res Theory.* 2016;24(1):62-68. doi:10.3109/16066359.2015.1068301
- 27
- 28 44. Heath AJ, Kerr T, Ti L, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand.
- 29 *J Public Health Oxf Engl.* 2016;38(3):e301-e308. doi:10.1093/pubmed/fdv143
- 30
- 31 45. Frost SDW, Pillay D. Understanding Drivers of Phylogenetic Clustering in Molecular Epidemiological
- 32 Studies of HIV. *J Infect Dis.* 2015;211(6):856-858. doi:10.1093/infdis/jiu563
- 33
- 34 46. Brenner BG, Wainberg MA. Future of phylogeny in HIV prevention. *J Acquir Immune Defic Syndr*
- 35 *1999.* 2013;63 Suppl 2:S248-254. doi:10.1097/QAI.0b013e3182986f96
- 36
- 37 47. Jacka B, Applegate T, Kraiden M, et al. Phylogenetic clustering of hepatitis C virus among people
- 38 who inject drugs in Vancouver, Canada. *Hepatology Baltim Md.* 2014;60(5):1571-1580.
- 39 doi:10.1002/hep.27310
- 40
- 41 48. Grabowski MK, Lessler J, Redd AD, et al. The Role of Viral Introductions in Sustaining Community-
- 42 Based HIV Epidemics in Rural Uganda: Evidence from Spatial Clustering, Phylogenetics, and
- 43 Egocentric Transmission Models. Hallett T, ed. *PLoS Med.* 2014;11(3):e1001610.
- 44 doi:10.1371/journal.pmed.1001610
- 45
- 46 49. Worobey M, Gemmel M, Teuwen DE, et al. Direct Evidence of Extensive Diversity of HIV-1 in
- 47 Kinshasa by 1960. *Nature.* 2008;455(7213):661-664. doi:10.1038/nature07390
- 48
- 49 50. de Oliveira T, Pillay D, Gifford RJ. The HIV-1 Subtype C Epidemic in South America Is Linked to the
- 50 United Kingdom. *PLoS ONE.* 2010;5(2). doi:10.1371/journal.pone.0009311
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 51. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ. Molecular Phylodynamics of  
4 the Heterosexual HIV Epidemic in the United Kingdom. *PLoS Pathog.* 2009;5(9).  
5 doi:10.1371/journal.ppat.1000590  
6
- 7 52. Hué S, Clewley JP, Cane PA, Pillay D. Investigation of HIV-1 transmission events by phylogenetic  
8 methods: requirement for scientific rigour. *AIDS Lond Engl.* 2005;19(4):449-450.  
9 doi:10.1097/01.aids.0000161778.15568.a1  
10
- 11 53. Dennis AM, Hué S, Hurt CB, et al. Phylogenetic insights into regional HIV transmission. *AIDS Lond*  
12 *Engl.* 2012;26(14):1813-1822. doi:10.1097/QAD.0b013e3283573244  
13  
14
- 15 54. Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the  
16 molecular epidemiology of newly diagnosed HIV infections. *AIDS Lond Engl.* 2012;26(16):2079-  
17 2086. doi:10.1097/QAD.0b013e32835805b6  
18
- 19 55. Kouyos RD, Rauch A, Böni J, et al. Clustering of HCV coinfections on HIV phylogeny indicates  
20 domestic and sexual transmission of HCV. *Int J Epidemiol.* 2014;43(3):887-896.  
21 doi:10.1093/ije/dyt276  
22
- 23 56. Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with  
24 men: a combined clinical, epidemiological and phylogenetic approach. *AIDS.* 2010;24(11):1739-  
25 1747. doi:10.1097/QAD.0b013e32833ac9e6  
26  
27
- 28 57. Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early  
29 HIV-1 infection. *J Infect Dis.* 2007;195(7):951-959. doi:10.1086/512088  
30
- 31 58. Kramer MA, Cornelissen M, Paraskevis D, et al. HIV transmission patterns among The Netherlands,  
32 Suriname, and The Netherlands Antilles: a molecular epidemiological study. *AIDS Res Hum*  
33 *Retroviruses.* 2011;27(2):123-130. doi:10.1089/aid.2010.0115  
34
- 35 59. Henley C, Forgewei G, Welty T, et al. Scale-up and case-finding effectiveness of an HIV partner  
36 services program in Cameroon: an innovative HIV prevention intervention for developing  
37 countries. *Sex Transm Dis.* 2013;40(12):909-914. doi:10.1097/OLQ.0000000000000032  
38  
39
- 40 60. Centers for Disease Control and Prevention (CDC). Intimate Partner Violence and Sexual Violence  
41 Victimization Assessment Instruments for Use in Healthcare Settings: (410572008-001). Published  
42 online 2007. doi:10.1037/e410572008-001  
43
- 44 61. Monroe-Wise A, Maingi Mutiti P, Kimani H, Moraa H, Bukusi DE, Farquhar C. Assisted partner  
45 notification services for patients receiving HIV care and treatment in an HIV clinic in Nairobi,  
46 Kenya: a qualitative assessment of barriers and opportunities for scale-up. *J Int AIDS Soc.*  
47 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25315  
48
- 49 62. Goyette MS, Mutiti PM, Bukusi D, et al. Hiv Assisted Partner Services Among Those with and  
50 Without A History of Intimate Partner Violence in Kenya. *J Acquir Immune Defic Syndr* 1999.  
51 Published online February 5, 2018. doi:10.1097/QAI.0000000000001638  
52  
53  
54  
55  
56  
57

- 1  
2  
3 63. KELIN and the Kenya Key Populations Consortium. "Everyone Said No:" *Biometrics, HIV and Human Rights – A Kenya Case Study*. KELIN; 2018. Accessed April 10, 2020.  
4 <https://www.kelinkenya.org/everyonesaidno/>  
5  
6  
7  
8 64. Gathura G. Biometrics system for identifying people living with HIV ready. *The Standard*.  
9 [https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready)  
10 [living-with-hiv-ready](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready). Published November 17, 2019. Accessed April 10, 2020.  
11  
12 65. Anne N, Dunbar MD, Abuna F, et al. Feasibility and acceptability of an iris biometric system for  
13 unique patient identification in routine HIV services in Kenya. *Int J Med Inf*. 2020;133:104006.  
14 doi:10.1016/j.ijmedinf.2019.104006  
15  
16  
17  
18  
19  
20  
21

22 **Table 1. Inclusion and Exclusion Criteria**  
23  
24

<u>Group</u>	<u>Inclusion</u>	<u>Exclusion</u>
<i>Index</i>	<ul style="list-style-type: none"> <li>• 18 years of age or older</li> <li>• Recent intravenous drug use as defined by injecting at least once in the past year</li> <li>• HIV-positive</li> <li>• Willing and able to provide locator information for sexual and/or injecting partners</li> <li>• Willing and able to provide informed consent</li> </ul>	<ul style="list-style-type: none"> <li>• Classified as at high risk for IPV (described below)</li> </ul>
<i>Partner</i>	<ul style="list-style-type: none"> <li>• 18 years of age or older</li> <li>• identified by an index as either having injected with the index in the past 3 years or had sexual intercourse with the index in the past three years</li> <li>• Willing and able to provide informed consent</li> </ul>	None




Figure 1. Map of Study Sites



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Study Flow Diagram

683x449mm (96 x 96 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 21 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ Included ___
Protocol version	3	Date and version identifier	___ 1 ___
Funding	4	Sources and types of financial, material, and other support	___ 23 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 23 ___
	5b	Name and contact information for the trial sponsor	_____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ N/A ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ N/A ___

1 **Introduction**

2

3 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant \_\_\_ 5-7 \_\_\_

4 rationale studies (published and unpublished) examining benefits and harms for each intervention

5

6 6b Explanation for choice of comparators \_\_\_ N/A \_\_\_

7

8 Objectives 7 Specific objectives or hypotheses \_\_\_ 6-7 \_\_\_

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),

11 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) \_\_\_ 8 \_\_\_

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will \_\_\_ 8 \_\_\_

17 be collected. Reference to where list of study sites can be obtained

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and \_\_\_ 10-11 \_\_\_

20 individuals who will perform the interventions (eg, surgeons, psychotherapists)

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be \_\_\_ 11-14 \_\_\_

23 administered

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose \_\_\_ N/A \_\_\_

26 change in response to harms, participant request, or improving/worsening disease)

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence \_\_\_ N/A \_\_\_

29 (eg, drug tablet return, laboratory tests)

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial \_\_\_ 17 \_\_\_

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood \_\_\_ 18 \_\_\_

35 pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen

36 efficacy and harm outcomes is strongly recommended

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for \_\_\_ 15 \_\_\_

41 participants. A schematic diagram is highly recommended (see Figure)

42

43

44

45

46

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	___ 19 ___
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	___ 11 ___
5				

### 6 **Methods: Assignment of interventions (for controlled trials)**

#### 7 Allocation:

8				
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	___ N/A ___
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	___ N/A ___
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	___ N/A ___
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	___ N/A ___
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	___ N/A ___
28				
29				
30				

### 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	___ 12 ___
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	___ 15 ___
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___ 18 ___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___ 19-20 ___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___ N/A ___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___ N/A ___
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___ N/A ___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___ N/A ___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___ 21-22 ___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___ N/A ___
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___ 21 ___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___ 22 ___
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_12-13_____
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_12-13_____
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_16-18_____
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_23_____
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_18_____
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_17-18_____
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_22-23_____
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	_23_____
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_N/A_____
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_Attached_
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_14-15, 20_____
35				
36				

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

# BMJ Open

## Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and HCV-positive people who inject drugs: a cohort study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041083.R3
Article Type:	Protocol
Date Submitted by the Author:	15-Feb-2021
Complete List of Authors:	<p>Monroe-Wise, Aliza; University of Washington, Mbogo, Loice; Kenyatta National Hospital Guthrie, Brandon; University of Washington Bukusi, David; Kenyatta National Hospital Sambai, Betsy; Kenyatta National Hospital Chohan, Bhavna; University of Washington; Kenya Medical Research Institute</p> <p>Scott, John; University of Washington Cherutich, Peter; Kenya Ministry of Health Musyoki, Helgar; Kenya Ministry of Health Bosire, Rose; Kenya Medical Research Institute; University of Washington</p> <p>Dunbar, Matthew; University of Washington Macharia, Paul; Kenya Ministry of Health Masyuko, Sarah; Kenya Ministry of Health; University of Washington Wilkinson, Eduan; University of KwaZulu-Natal De Oliveira, Tulio; University of KwaZulu-Natal Ludwig-Barron, Natasha; University of Washington Sinkele, Bill; Support for Addiction Prevention and Treatment in Africa Herbeck, Joshua; University of Washington School of Public Health, Farquhar, Carey; University of Washington</p>
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Addiction, Epidemiology, Evidence based practice, Global health, Gastroenterology and hepatology
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Hepatology < INTERNAL MEDICINE, International health services < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Epidemiology < INFECTIOUS DISEASES, Molecular diagnostics < INFECTIOUS DISEASES, VIROLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Peer-mediated HIV assisted partner services to identify and link to care HIV-positive and**  
4  
5 **HCV-positive people who inject drugs: a cohort study protocol**  
6  
7  
8  
9

10  
11  
12  
13  
14  
15 Aliza Monroe-Wise<sup>a</sup>, Loice Mbogo<sup>b</sup>, Brandon Guthrie<sup>a,c</sup>, David Bukusi<sup>b</sup>, Betsy Sambai<sup>b</sup>, Bhavna  
16 Chohan<sup>a,d</sup>, John Scott<sup>e</sup>, Peter Cherutich<sup>f</sup>, Helgar Musyoki<sup>f</sup>, Rose Bosire<sup>d</sup>, Matthew Dunbar<sup>g</sup>, Paul  
17 Macharia<sup>f</sup>, Sarah Masyuko<sup>a,f</sup>, Eduan Wilkinson<sup>h</sup>, Tulio de Oliveira<sup>h</sup>, Natasha Ludwig-Barron<sup>b</sup>,  
18  
19  
20 Bill Sinkele<sup>i</sup>, Joshua Herbeck<sup>a\*</sup>, Carey Farquhar<sup>a,b,e\*</sup>  
21  
22  
23  
24  
25  
26  
27  
28

29 <sup>a</sup>University of Washington Department of Global Health, <sup>b</sup>Kenyatta National Hospital,

30 <sup>c</sup>University of Washington Department of Epidemiology, <sup>d</sup>Kenya Medical Research Institute,

31 <sup>e</sup>University of Washington Department of Medicine, <sup>f</sup>Kenya's Ministry of Health, <sup>g</sup>Center for

32 <sup>h</sup>Studies in Demography and Ecology, University of Washington, <sup>h</sup>KwaZulu-Natal Research and

33 <sup>i</sup>Innovation Sequencing Platform, University of KwaZulu-Natal, <sup>i</sup>Support for Addiction

34 <sup>Prevention and Treatment in Africa</sup>

35  
36  
37  
38  
39  
40  
41  
42  
43  
44 Corresponding author: Aliza Monroe-Wise, MD, MSc. Email: alizamw@uw.edu

45  
46  
47 University of Washington, 325 Ninth Avenue, Box 359909, Seattle, WA 98104-2499

48  
49  
50 \*These authors share senior authorship.

51  
52  
53 V2.0 13/10/20

## **Abstract**

### **Introduction**

Targeted, tailored interventions to test high-risk individuals for HIV and hepatitis C (HCV) are vital to achieving HIV control and HCV micro-elimination in Africa. Compared with the general population, people who inject drugs (PWID) are at increased risk of HIV and HCV and are less likely to be tested or successfully treated. Assisted partner services (APS) increases HIV testing among partners of people living with HIV and improves case-finding and linkage to care. We describe a study in Kenya examining whether APS can be adapted to find, test, and link to HIV care the partners of HIV-positive PWID using a network of community-embedded peer educators (PEs). Our study also identifies HCV-positive partners and uses phylogenetic analysis to determine risk factors for onward transmission of both viruses.

### **Methods**

This prospective cohort study leverages a network of PEs to identify 1,000 HIV-positive PWID for enrollment as index participants. Each index completes a questionnaire and provides names and contact information of all sexual and injecting partners during the previous 3 years. PEs then use a stepwise locator protocol to engage partners in the community and bring them to study sites for enrollment, questionnaire completion and rapid HIV and HCV testing. Outcomes include number and type of partners per index who are mentioned, enrolled, tested, diagnosed with HIV and HCV and linked to care.

### **Ethics and dissemination**

1  
2  
3 Potential index participants are screened for intimate partner violence (IPV) and those at high risk  
4 are not eligible to enroll. Those at medium risk are monitored for IPV following enrollment. A  
5  
6 community advisory board engages in feedback and discussion between the community and the  
7  
8 research team. A safety monitoring board discusses study progress and reviews data, including  
9  
10 IPV monitoring data. Dissemination plans include presentations at quarterly Ministry of Health  
11  
12 meetings, local and international conferences, and publications.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Strengths and limitations of this study**

- This cohort study investigates the use of assisted partner services (APS) to find, test for HIV and hepatitis C (HCV) and link to care the sexual and injecting partners of HIV-positive people who inject drugs (PWID) in Kenya; however, APS is not offered to HIV-negative, HCV-positive clients to identify those exposed to HCV but not HIV.
- Community embedded peer educators trained to provide harm reduction services conduct partner tracing, but there are limitations including logistical challenges and concerns for client confidentiality and safety of both the client and peer educator.
- An iris scanning biometric identification system ensures that each index participant enrolled is a unique individual and confirms that individual partner participants who enroll more than once in relation to different index participants are the same individual.
- Phylogenetic analysis of HIV and HCV viral sequences combined with APS will provide additional information about transmission dynamics within the cohort, including risk of onward transmission for different clusters and geographic regions.

### **Introduction**

Diagnosing 90% of those living with HIV has been among the most difficult of the UNAIDS 90-90-90 goals to achieve worldwide,<sup>1,2</sup> and strategies to reach individuals at high-risk for HIV who have never been tested is increasingly important.<sup>3</sup> In Kenya, despite success in achieving or

1  
2  
3 approaching the 2<sup>nd</sup> and 3<sup>rd</sup> UNAIDS goals, only 79.4% of people testing for HIV know their  
4 status.<sup>4</sup> Sharing needles and other drug paraphernalia is the most efficient mode of HIV  
5 transmission, and accounts for 13% of new infections globally.<sup>5,6</sup> In Kenya, prevalence of HIV  
6 among people who inject drugs (PWID) has been estimated at 15 – 50%<sup>6–10</sup>—significantly higher  
7 than the general population prevalence of 4.9%,<sup>11</sup> and up to 30% of PWID in Kenya have never  
8 tested for HIV.<sup>12,13</sup> Multiple studies have demonstrated low knowledge of HIV status and low  
9 engagement in care among Kenya's PWID.<sup>13,14</sup> Retention in care and adherence to ART are also  
10 both lower among PWID as compared with others worldwide.<sup>1</sup>

11  
12 In addition to HIV, PWID are at high risk for hepatitis C virus (HCV) globally and have the highest  
13 HCV prevalence of any group studied in Kenya at 13-40%<sup>10,15,16</sup>. This is especially high when  
14 compared to the general population HCV prevalence in Kenya of <1-4%.<sup>17,18</sup> However, multiple  
15 barriers exist at individual, provider and system levels resulting in low rates of testing, engagement  
16 in care, and completion of treatment courses for PWID.<sup>19–21</sup> Although less than 20% of PWID with  
17 chronic HCV worldwide have undergone antibody screening, the number who have completed  
18 PCR confirmatory testing is even lower.<sup>22</sup> Despite the introduction of highly effective direct acting  
19 antivirals (DAAs) into Kenya in 2016, only a small fraction of individuals living with HCV have  
20 been treated, prompting attention to micro-elimination strategies.<sup>23,24</sup>

21  
22 Assisted partner notification services (APS) for HIV is an evidence-based partner notification  
23 strategy in which providers elicit information about the sexual or injecting partners of an HIV-  
24 positive index client, and then contact, HIV test and link to care any partners found to be positive.<sup>25</sup>  
25 APS has been shown to significantly and safely increase the uptake of HIV testing services (HTS),  
26 case finding, and linkage to care for partners of HIV-positive people.<sup>25–27</sup> APS can also reduce  
27 barriers to disclosing HIV status<sup>28</sup> and is cost-effective.<sup>29</sup> APS has been successfully implemented

1  
2  
3 among HIV-positive patients from the general population in the USA,<sup>30</sup> Mozambique,<sup>31</sup>  
4 Malawi,<sup>32,33</sup> and Kenya,<sup>27</sup> and has recently been incorporated into the World Health Organization  
5 (WHO) guidelines for routine care for HIV-positive people worldwide.<sup>34</sup> While programs have  
6 introduced the practice of APS in high-risk key populations (KPs) such as female sex workers  
7 (FSW)<sup>35</sup> and men who have sex with men (MSM),<sup>36,37</sup> this intervention has not been well-studied  
8 among PWID,<sup>38</sup> an extremely high risk group.<sup>25,39</sup> Similar to FSW and MSM, PWID engage in  
9 behavior that is criminalized in many parts of the world<sup>40</sup> while experiencing high rates of  
10 marginalization and displacement,<sup>41</sup> making them difficult to study. These factors and others also  
11 contribute to significant barriers in the implementation of health programs targeting PWID.<sup>42–44</sup>

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Phylogenetic analysis is a method of identifying the role of specific risk groups and risk factors  
for onward transmission of HIV and HCV using the genetic sequence of each virus.<sup>45–47</sup> Viral  
phylogenetics can provide additional information on patterns of transmission,<sup>48–50</sup> epidemic  
growth,<sup>51,52</sup> risk groups,<sup>53–55</sup> and risk factors associated with onward transmission.<sup>47,56–58</sup>

Here we describe a prospective cohort study that seeks to determine whether and how APS can be  
implemented to find, test, and link to care the injection and sexual partners of HIV-positive PWID  
in Kenya. Simultaneously, our study will use phylogenetic analysis to study genetic sequences of  
HIV and HCV within our cohort to further understand transmission patterns and risk for onward  
transmission. All index and partner participants are tested for HCV in addition to HIV. While many  
partner contact methods for conducting APS have been used,<sup>25</sup> cellular telephones are the most  
common first-line communication modality for reaching partners in other populations.<sup>26,27,31,59</sup> In  
Kenya, however, the large majority of PWID do not have regular access to cellular telephones. As  
such, our APS model relies on the utilization of community-embedded peer educators (PEs) to  
locate and communicate with members of this difficult to reach population. We hypothesize that

1  
2  
3 we will be able to employ these customized APS procedures to reach a large number of injection  
4 and sexual partners, and that we will see differences between sexual and injection partners in  
5 uptake of HIV testing, HIV and HCV prevalence, and engagement in care. Additionally, we  
6 hypothesize that we will identify unique transmission patterns and risks for onward transmission  
7 in phylogenetic analysis, which may include behavioral, geographic, or other factors.  
8  
9  
10  
11  
12  
13

## 14 **Methods and analysis**

### 15 *Approach*

16  
17  
18  
19  
20  
21  
22 APS is a practice through which healthcare providers facilitate the notification, testing and linkage  
23 to care for partners who may have been exposed to HIV or other sexually transmitted infections  
24 by an individual known to be positive without revealing the identity of the person who may have  
25 exposed them. While there are many ways to provide partner services, APS in Kenya is often  
26 conducted by healthcare providers who elicit information about partners from an “index” patient  
27 and then call the partners over the telephone or physically trace them to alert them to their exposure  
28 and provide testing. We have designed customized procedures to ensure and improve the safety  
29 and efficacy of APS in the unique population of PWID in Kenya. Because PWID and their partners  
30 in Kenya rarely own cellular phones, we work with community-embedded peer educators (PEs) to  
31 find and engage with partners. Additionally, our protocol involves referrals to different facilities  
32 for injection partners and for sexual partners, as a precaution to ensure safety and confidentiality  
33 of index participants who may theoretically be at risk of negative outcomes if partners become  
34 aware of their HIV-positive status.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 *Study design*



1  
2  
3 Our study is a prospective cohort study with two groups: index and partner participants (“indexes”  
4 and “partners”). We use tailored APS procedures to identify, find, test and link to care the sexual  
5 and injection partners of HIV-positive PWID. All index participants, as well as partner participants  
6 and injection partners of HIV-positive PWID. All index participants, as well as partner participants  
7 who are diagnosed with HIV or HCV, complete a 6-month follow-up visit to assess linkage to and  
8 engagement in care.  
9

### 10 11 12 Study sites/setting 13

14  
15  
16 Study procedures take place in eight main sites including public health centers, medication-assisted  
17 treatment (MAT) centers, and needle and syringe programs (NSPs) in Nairobi, Kilifi, and  
18 Mombasa Counties in Kenya (Figure 1). Each site is staffed by at least one clinical officer (mid-  
19 level clinician) who works with researchers to ensure that only participants with documented HIV  
20 infection are enrolled as indexes, verifying HIV status through re-testing if documentation is not  
21 provided. In Nairobi County, the activities are centered at two NSP sites and one MAT center in  
22 the Mathare North area. The NSP sites, run by Support for Addiction Prevention and Treatment in  
23 Africa (SAPTA), offer routine HIV testing services. Referrals are made to local clinics providing  
24 care for those who test positive for HIV or HCV. We also recruit indexes from a government-run  
25 methadone clinic in Nairobi in the Ngara area. The Ngara Health Center MAT clinic offers HIV  
26 testing, care and treatment in addition to daily methadone administration, psychosocial services  
27 and treatment for other health conditions. In Kilifi county, participant recruitment and enrollment  
28 takes place at three needle and syringe program centers and one government hospital. The Omari  
29 Project is located in Malindi town and offers HIV counseling, testing, care and treatment in  
30 addition to harm reduction services. Malindi Sub-County Hospital’s MAT center is a recruitment  
31 site in Kilifi County within a mid-sized government hospital that offers a large range of medical  
32 and social services. Malindi Sub-County Hospital also has a large laboratory that houses the  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 study's samples collected in both Kilifi and Mombasa Counties. The Muslim Education and  
4 Welfare Association (MEWA) NSP sites in Kilifi and Mtwapa towns offer HIV counseling and  
5 testing, in addition to HIV care and treatment and harm reduction services. In Mombasa county,  
6 participants are recruited from the ReachOut Center, an NSP site in Mombasa city that offers a  
7 full range of harm reduction services in addition to HIV counseling, testing, care and treatment.  
8 All recruitment sites offer routine HCV testing when kits are available through specific donor-  
9 driven projects.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

### 20 Population

21  
22  
23 This study includes index participants and their sexual and/or drug-injecting partners . All indexes  
24 are HIV-positive PWID. Partners are either sexual partners or injecting partners of indexes.  
25  
26  
27  
28

29 Indexes are largely recruited from organizations and clinics that provide services to PWID  
30 populations, although they may also come from outreach efforts or informal referrals from other  
31 participants. Partners are identified and recruited through peer-mediated APS and may come from  
32 any geographic area or community.  
33  
34  
35  
36  
37  
38

### 39 Patient and Public Involvement

40  
41  
42 Members of the community of PWID being researched were consulted in the development of  
43 research questions and design of the study. The study is supported by a Community Advisory  
44 Board (CAB) composed of members of the community, peer educators and employees of  
45 organizations that provide services to the population. The CAB meets with the study team regularly  
46 and helps inform dissemination plans.  
47  
48  
49  
50  
51  
52  
53

### 54 Study procedures

## 1. Peer educator recruitment and training

PEs are recovering PWID with established relationships in the PWID communities that they serve. The majority are between the ages of 25 and 50, are enrolled in Kenya's methadone program and report having stopped injecting drugs. These men and women have been identified by the individual organizations at which they work as being key community members, and have undergone extensive training for their roles as PEs. Training is an intensive 5-day course with modules covering a broad spectrum of content including basics of drugs and drug-related harms, harm reduction efforts including NSP and MAT, abscess prevention and management, overdose prevention and management and behavior change communication. PEs have access to relatively hidden PWID community spaces, and provide health counseling, linkage to support organizations, information, and other services to this vulnerable population.

For this study, PEs who were actively carrying out basic duties were chosen by the leadership at each organization based on several factors including awareness and knowledge of HIV in the community and access to unique target populations (for instance, women who inject drugs may be more easily accessed by women PEs). Once identified, PEs underwent an intensive 1-day training to educate them on the practice and ethics of research, study procedures, and their role in the study. PEs are supervised by clinic managers, who are all collaborators in the study. PEs participate in regular health education and harm reduction training and engage in quarterly sessions with study leadership where they present barriers and lessons learned to the study team so that study-related issues can be addressed.

## 2. Inclusion & exclusion criteria

1  
2  
3 Inclusion and exclusion criteria are different for indexes and partners (Table 1). Any interested  
4  
5 individuals who are under the age of 18 are referred to the site clinicians for routine counseling  
6  
7 and harm reduction services.  
8  
9

### 10 11 3. Index recruitment and enrollment 12

13  
14 Enrollment began in March 2018. Clinicians at each site identify potential indexes using existing  
15  
16 clinical data on known HIV-positive clients. Additionally, any client who tests positive for HIV  
17  
18 during routine testing is invited to participate. Clinicians are employed by the sites, and are trained  
19  
20 clinical officers (COs), or mid-level providers. For this study, HIV rapid testing is performed by  
21  
22 non-study COs and takes place as part of standard clinic procedures. All potential indexes are re-  
23  
24 tested using HIV rapid tests (as per the national guidelines) to confirm HIV status prior to  
25  
26 enrollment. If HIV positive, either newly diagnosed or known to be positive, clinicians approach  
27  
28 potential indexes with one of two strategies. Either the clinicians discuss the study directly with  
29  
30 potential participants or engage PEs to find individuals and bring them to the study office if they  
31  
32 are not regular clients at the site. Importantly, PEs are not told whether participants are being traced  
33  
34 as an index or a partner, protecting the confidentiality of indexes' HIV status.  
35  
36  
37  
38  
39

40  
41 Study staff health advisors (HAs) are the individuals responsible for conducting study procedures  
42  
43 including notification of exposure, data collection, HIV and HCV testing, and the coordination of  
44  
45 APS efforts (Figure 2). All HAs were trained and experienced in HIV testing services prior to  
46  
47 working for the study, and many had previous experience working with PWID. All HAs underwent  
48  
49 a week-long training course at the beginning of the study in which they learned the basics and  
50  
51 purpose of research, research ethics, study procedures, unique ethical and logistical issues to  
52  
53 consider when working with PWID, and other topics. All HAs also completed the Collaborative  
54  
55  
56  
57

1  
2  
3 Institutional Training Initiative (CITI) course on Human Subjects Research and the Responsible  
4 Conduct of Research. HAs explain the benefits and rationale for providing APS, discuss the  
5 importance of learning more about HIV and HCV, and describe the process of notifying partners  
6 without revealing the identity of the index. They ask participants to provide written informed  
7 consent for study participation, APS, and future use of biological specimens and future contact for  
8 additional studies, using an iris-scanning biometric device to record a unique identifier for each  
9 participant, thus enabling the study team to confirm that a person does not enroll into the program  
10 as an index more than once.  
11  
12

13  
14  
15  
16  
17  
18  
19  
20  
21  
22 Indexes undergo a structured questionnaire administered by the HA using open data kit (ODK)  
23 software on tablet devices (ODK, 2017, Seattle, WA, USA). Questionnaires cover a variety of  
24 topics including demographics, sexual and injecting behaviors, drug use history, and HIV testing  
25 and history of engagement in HIV care. Participants are then asked to recall all of their sexual and  
26 injecting partners over the three years prior to enrollment, naming these partners one by one and  
27 assigning each partner a letter (“A,” “B,” etc). Sexual intercourse is defined as vaginal, oral, or  
28 anal sex and drug injecting partner is defined as a friend that you inject with frequently. Indexes  
29 are asked to give as much locator information as possible for each partner, including names (which  
30 may be nicknames), phone numbers, and location of employment or residence. Locator  
31 information is written on a paper form for each partner. Indexes then complete a short ODK  
32 questionnaire about each partner mentioned, which includes information about the relationship  
33 between the index and the partner. Indexes who wish to notify partners themselves are given a 2-  
34 week window in which to do so, after which partners are contacted by study staff. Partners notified  
35 by indexes through passive referral are told to present to the study site for enrollment in the study,  
36 and mode of referral is recorded for each partner in the study.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Indexes then undergo rapid HCV antibody testing as part of routine study procedures. HAs conduct  
4 pre- and post- test counseling and ensure individuals who test positive are available for follow-up  
5 visits to discuss confirmatory HCV PCR testing and enrolling in a treatment program administered  
6 by the Ministry of Health. All indexes then undergo phlebotomy with a sample of 10mL of blood  
7 drawn for further testing (see section 6 below). Indexes receive 400 Kenya Shillings (KES,  
8 equivalent to about \$4) as compensation for travel and time spent in the study procedures.  
9

#### 18 4. Peer-educator mediated assisted partner services and partner recruitment

21 For those partners who have phone numbers listed, HAs attempt phone communication first.  
22 However, the vast majority of partners mentioned by indexes do not have working cellular phones;  
23 therefore, with few exceptions, PEs locate and conduct the study's first interaction in person with  
24 identified partners. PEs are given paper forms containing names and locator information for  
25 identified partners, and they verify that the names and locations provided on the locator form  
26 matches those of the person they have contacted. They are never told which index referred the  
27 team to each partner, and that information is not listed on locator forms or any other accessible  
28 file. PEs then locate and approach potential participants in the community and inform them that  
29 they have been identified as an individual who might need to be seen in a clinic due to a health  
30 concern. When approaching a partner, PEs alert partners that the PEs are working with a research  
31 study, and that the partner may have a health issue that should be addressed. The PEs then urge  
32 the partner to accompany them to a health facility for testing and possible enrollment in the study.  
33 Although PEs are trained using a standardized script (Appendix A), they are encouraged to allow  
34 the conversation to progress naturally, responding to questions and concerns that may arise and  
35 urging partners to come to the site for further information. PEs do not notify partners of their  
36 exposure during initial contact for several reasons: 1) to protect the HIV status of indexes, PEs are  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 not told whether they are recruiting an index or a partner, and 2) PEs have not felt comfortable  
4 discussing HIV or HCV exposure with potential participants. Once PEs have notified potential  
5 participants of their possible eligibility, they then accompany interested individuals to the nearest  
6 research office, where the study's HAs inform partners of their potential exposure to HIV and/or  
7 HCV (Appendix B), and conduct informed consent. Informed consent includes consent to future  
8 use of biological specimens and future contact for additional studies. In the rare event that a  
9 potential participant does not agree to come to the study office, an HA returns to the site with the  
10 PE and notifies the individual of the exposure, and in the rare event that a potential participant  
11 agrees to come to the study office but does not want to enroll in the study, the health advisor  
12 notifies the individual of the exposure and encourages the individual to undergo testing for HIV  
13 and HCV outside of study procedures.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 5. Partner enrollment

30  
31  
32 After informed consent and biometric identification, partners complete a structured questionnaire  
33 similar to that of indexes, administered by HAs on a handheld device using ODK software.  
34 Following the questionnaire, all partners undergo rapid antibody testing for both HIV and HCV.  
35 HIV testingservices are provided in accordance with national HIV testing guidelines. Any partner  
36 found to be positive for either HIV or HCV antibodies undergoes a 20mL blood draw. Those  
37 partners who test negative for both HIV and HCV are finished with study procedures at this time  
38 and are counseled on risk reduction measures and provided information about HIV and HCV  
39 prevention services before leaving the study site. All partners receive 400 Kenya Shillings (KES,  
40 equivalent to about \$4) as compensation for travel and time spent in the study procedures.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 HIV-positive partners are invited to undergo screening as an index once data collection procedures  
4 for their partner enrollment are complete. If they meet eligibility criteria as an index, they may  
5 enroll as an index. Study procedures are slightly amended for indexes that have previously enrolled  
6 as partners. After undergoing informed consent and completing a short questionnaire that only  
7 includes questions that were not a part of the partner enrollment questionnaire, they complete the  
8 identification and data collection on each of their sexual and injection partners, identical to partner  
9 identification procedures for indexes described above.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

## 20 6. Laboratory Procedures

21  
22  
23 Blood samples from both index and partner enrollment visits are collected in EDTA vacutainer  
24 tubes. Blood is mixed with the anticoagulant by inversion and the anticoagulated blood is stored  
25 at room temperature at the sites for less than 4 hours. A motorcycle courier picks samples from  
26 each site daily and brings them to the University of Nairobi Pediatric Research Laboratory in  
27 Nairobi or the Malindi Sub-County Hospital Laboratory for coast sites. At each laboratory,  
28 samples are first used to prepare two Whatman 903 Protein Saver dried blood spot (DBS) cards  
29 with 50ul of whole blood on each spot. Blood samples are then centrifuged and used to prepare 2  
30 to 3 aliquots of 1ml of plasma in labeled serum vials. Plasma aliquots and air-dried DBS cards  
31 (with desiccant in sealed Ziploc bags) are then stored at -80° Celsius and shipped on dry ice to the  
32 University of KwaZulu-Natal laboratory. There, samples undergo HIV and HCV viral load testing  
33 and amplification for sequencing.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 7. Participant follow-up

51  
52  
53 All indexes and any partners who were positive for HIV or HCV complete a six-month follow-up  
54 visit. HAs identify which participants are due for follow-up visits on a weekly basis and give PEs  
55  
56  
57



1  
2  
3 as list of these names. PEs then trace participants and bring them back to clinics where data  
4 collection procedures are conducted. PEs make several attempts to find participants in the  
5 community before considering them lost to follow-up.  
6  
7  
8  
9

10  
11 Six-month visits involve a brief questionnaire covering questions on testing for HIV or HCV (if  
12 not infected with both on enrollment), enrollment in care and treatment, engagement in care, and  
13 follow-up testing. The purpose of this visit is to assess whether engagement in care has changed  
14 following APS procedures, for both indexes and partners. We do not collect additional data from  
15 those lost to follow up.  
16  
17  
18  
19  
20  
21  
22

### 23 8. Intimate partner violence (IPV) monitoring

24  
25  
26  
27 Given historical concerns that APS may increase one's risk of experiencing intimate partner  
28 violence, all potential participants undergo screening for IPV before enrollment. IPV is defined as  
29 any physical, sexual or psychological harm inflicted on a person by a current or former sexual  
30 partner. After answering a standardized set of six questions about physical, emotional and sexual  
31 IPV and the timing of any previous experience of IPV based on published screening tools reviewed  
32 by the Centers for Disease Control and Prevention,<sup>60</sup> potential participants are classified as low,  
33 medium or high risk for IPV. Individuals are classified as at high risk for IPV if they report IPV  
34 within the last month. Any potential index who is classified as high IPV risk is excluded from  
35 study participation and provided with IPV counseling and resources. Any potential partner  
36 participant who is classified as high IPV risk is allowed to enroll, but then receives special  
37 monitoring for IPV following enrollment.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52  
53 Potential participants are classified as at moderate risk for IPV if they report 1) IPV during their  
54 lifetime either from a current or past partner; and/or 2) fear of IPV if they participate in the study.  
55  
56  
57

1  
2  
3 All index or partner participants classified as moderate IPV risk receive special monitoring for  
4  
5 IPV following their enrollment in the study.  
6  
7

8  
9 Potential participants are classified as at low risk for IPV if they report 1) no IPV during their  
10  
11 lifetime ; and 2) no fear of IPV if they participate in the study. These individuals undergo standard  
12  
13 study procedures which include completing the baseline IPV case report form and a follow-up IPV  
14  
15 case report to capture reports of any interim IPV.  
16  
17

### 18 19 9. Confidentiality and safety 20 21

22 *Participants:* All study procedures take place in private rooms at each study facility. To ensure the  
23  
24 safety and confidentiality of indexes, PEs who are tasked with finding partners are blinded to the  
25  
26 identity of the linked index through the use of partner locator forms that do not contain identifying  
27  
28 information about the index participant. Locator forms do contain a printed barcode label that are  
29  
30 then used by study staff to link the partner with the index who referred the partner.  
31  
32  
33

34  
35 Sexual partners are brought to independent facilities for enrollment rather than to centers that serve  
36  
37 PWID, in order to further protect the identity of the index participant who referred them. The  
38  
39 independent facilities are local healthcare clinics that serve the general population.  
40  
41

42  
43 *Peer educators:* PEs have frequent interactions with police, and can be victims of harassment or  
44  
45 violence, both by police and by PWID. To reduce the risk of law enforcement troubles, PEs carry  
46  
47 identification showing that they are working on a study being conducted by the Ministry of Health.  
48  
49 Local law enforcement officials have also attended ongoing sensitization trainings by the Ministry  
50  
51 of Health and by organizations working with PWID.  
52  
53

### 54 55 10. Referrals to care 56 57

1  
2  
3 *HIV Counseling and Care:* Participants are provided with their HIV test results in the context of  
4 post-test counseling, and are then referred to available medical and psychosocial care and support  
5 facilities either within the research site or in close proximity to the research site or the participant's  
6 home. Additionally, HIV-positive individuals are offered individual or group support sessions as  
7 available within each site.  
8  
9

10  
11  
12  
13  
14  
15 *HCV Counseling and Care:* Participants who test positive for HCV antibodies using rapid testing  
16 are provided with their HCV antibody test results in the context of pre- and post-test counseling.  
17 They are informed that they may have active HCV infection; however, further confirmatory testing  
18 must be done prior to establishing the diagnosis. Confirmatory polymerase chain reaction (PCR)  
19 testing is done in batches of samples at our partnering laboratory at the University of KwaZulu-  
20 Natal, South Africa, and participants with active infection are later contacted for results and  
21 counseling. Turnaround time from enrollment to PCR result notification varies, but is typically  
22 between 1 and 4 months. Once notified of their PCR results, those with active infection are paired  
23 with a PE at their site to ensure close contact is maintained. Study participants with active HCV  
24 infections will be eligible to receive free treatment with direct acting antivirals, which the Kenyan  
25 MoH has procured.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

#### 42 Data management

43  
44

45 After each study visit, HAs review their work for omissions or errors and all data are uploaded  
46 into the study database. Electronic data are stored securely in an encrypted database on servers  
47 using Open Data Kit Aggregate, within Kenya's Ministry of Health (MoH). All errors or omissions  
48 identified at any step in the quality assurance/quality control process are revised by the staff  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 member who originally completed the document. All additions and corrections are initialed and  
4  
5 dated by the staff member who records the entry.  
6  
7

8  
9 A link-log is separately encrypted to further ensure that data remains secure. Any data transferred  
10  
11 to investigators or MoH are de-identified and encrypted during the process of transfer from the  
12  
13 server. Each investigator maintains and stores secure, complete, accurate and current study records  
14  
15 throughout the study. A database manager performs regular data cleaning and resolves any  
16  
17 discrepancies that occur. Study sites also conduct quality control and quality assurance procedures.  
18  
19 All co-investigators have access to the final dataset and this is not limited by contractual  
20  
21 agreements. Study data will be available upon request at the completion of the study.  
22  
23  
24  
25

### 26 Outcome measures

27  
28  
29 The primary outcomes of interest to assess the success of the APS intervention are: a) number of  
30  
31 sexual and injection partners tested for HIV and HCV through APS, identified by each index  
32  
33 participant over the course of the study period; b) number of sexual and injection partners newly  
34  
35 testing positive for HIV and HCV, per index participant; c) number of known HIV or HCV cases  
36  
37 identified through APS who are not engaged in care; d) number of index and partner participants  
38  
39 with HIV and/or HCV infection who are linked to care; e) number of index and partners with HIV  
40  
41 and/or HCV infection who remain in care and are receiving appropriate treatment at 6 months after  
42  
43 testing positive. Secondary outcomes are linked to inclusion in phylogenetic clusters identified as  
44  
45 high risk for onward transmission of HIV and HCV.  
46  
47  
48  
49

### 50 Sample size

1  
2  
3 We are enrolling 1000 HIV-positive indexes and their sexual and injecting partners. Based on  
4 HCV data from MoH and our preliminary results, we estimate that 20% of PWID with HIV will  
5 be co-infected with HCV and that each index will identify on average two partners who will accept  
6 HIV and HCV testing, 20% of whom will be HIV-positive, and 20% of whom will be HCV-  
7 infected. Thus, with provision of APS to 1,000 HIV-positive indexes and testing of 2,000 partners,  
8 we will identify an estimated 600 indexes and partners infected with HCV and 400 HIV-positive  
9 partners. This study was designed to have high precision in estimating the prevalence of HIV and  
10 HCV infection among partners, providing valuable input for modeling the impact of APS in the  
11 population. For an observed HIV or HCV prevalence of 10% among partners, precision is  
12 estimated at 1.9%; with an observed HIV or HCV prevalence of 30% among partners, precision is  
13 estimated at 2.9%. *Statistical methods and analysis*

14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29 To determine efficacy of the APS intervention, we will use generalized estimating equations  
30 (GEE) models with a Poisson link using the following variables and offsets: 1) rate of HIV and  
31 HCV testing of partners: number of individuals tested for HIV or HCV, offset by the number of  
32 partners located with locator information provided by the index participant; 2) prevalence of HIV  
33 and HCV infection: number of individuals identified as HIV or HCV-positive, offset by the  
34 number of individuals who were HIV tested; and 3) rate of linkage to HIV and HCV care:  
35 individuals who test HIV or HCV-positive and link to care, offset by the total number of  
36 individuals who test HIV or HCV-positive.

37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 Additionally, using both GEE and phylogenetic analysis, we will determine the following: 1)  
50 identifiable and individual risk factors linked to high rates of HIV and HCV transmission, 2) risk  
51 factors linked to both needle-sharing and sexual transmission, and 3) identification of transmission  
52 clusters among PWID for both HIV and HCV.

### Phylogenetic analysis

HIV and HCV gene sequencing are attempted for all study participants who test positive for either virus. Sequencing will be performed at the KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP) at the University of KwaZulu-Natal in Durban, South Africa. For HIV we will subsequently combine our data with additional, publicly available, HIV sequences from Kenya and perform phylogenetic and phylodynamic analyses to describe patterns and rates of viral transmission among key populations in Kenya and identify traits associated with relative infectiousness. For HCV we will use phylogenetic methods to characterize the modes and risk factors for onward transmission among PWID.

### **Ethics and Dissemination**

#### General ethical considerations

This study is registered at clinicaltrials.gov (NCT03447210) and has ethical approval from both the University of Washington Human Subjects Division and the Kenyatta National Hospital Ethics and Research Committee. It also has approval from Kenya's National Commission for Science, Technology and Innovation.

There are a number of potential risks to participants. Risks of conducting APS include psychological distress, social or economic hardship, criminal penalties, and loss of privacy and/or confidentiality. Study procedures, including confidentiality and counseling procedures, are specifically designed to minimize these risks to participants. While IPV has the potential to cause harm, it has not increased in other US or African studies when this intervention has been implemented in the general population.<sup>25,61,62</sup> We recognize that risks may be different when

1  
2  
3 implementing APS among key populations and study staff are highly trained in counseling about  
4 risk behaviors, implications of testing HIV-positive, and protecting confidentiality to avoid  
5 potential social harms. In addition, staff have undergone extensive training on IPV counseling and  
6 ensure that resources have been identified in all sites so we can safely refer participants who report  
7 abuse or are concerned for their safety. Participants reporting moderate IPV are monitored as  
8 described in Section 8; they are counseled and referred for services if IPV is reported at any of  
9 these follow-up visits.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19

20 A safety monitoring board composed of researchers and policy makers in both Kenya and the US  
21 reviews study safety data twice per year. The board monitors enrollments, deaths, loss to follow  
22 up, adverse events, including social harms, and IPV monitoring data and makes recommendations  
23 regarding study procedures.  
24  
25  
26  
27  
28  
29

30 Ethical considerations surrounding the use of biometric identification systems among key  
31 populations in Kenya have been discussed extensively.<sup>63</sup> Despite early opposition from the Key  
32 Populations Consortium and other organizations to the government's use of fingerprint-based  
33 biometric data collection, the organizations and individuals working with PWID communities  
34 continued to report no opposition to iris scanning for research purposes among PWID. In  
35 November 2019, Kenya passed the Data Protection Bill, rendering it legal to collect biometric data  
36 as long as the use of such data does not violate the subjects' rights.<sup>64</sup> The use of biometrics is now  
37 standard practice in many research and clinical settings, and has been found to be acceptable to  
38 participants.<sup>65</sup> Our participants have not reported any concerns, fears, or hesitations regarding the  
39 use of an iris scanning biometric identification system.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

#### 54 Dissemination plan

55  
56  
57

1  
2  
3 Results from the study and changes to the study are presented on an ongoing basis at Kenya's  
4 quarterly MoH harm reduction and key population technical working group meetings, and  
5 discussed at biannual meetings by the Community Advisory Board that was established for this  
6 study. Our study team includes several collaborators from the MoH. Ongoing study analyses are  
7 also presented at national conferences annually. Additionally, study results are presented in at least  
8 one international conference per year. Finally, the study team reviews data on a weekly basis and  
9 any changes in data trends or other concerns are discussed directly with the organizations through  
10 which study procedures take place.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### **Authors' contributions**

22  
23  
24  
25

26 CF and JH conceived of the study; AMW, BG, BC, MD, PM, BSi, JH and CF contributed to the  
27 study design and data collection structure; AMW, LM, DB, BSa, BC, JS, PC, HM, RB, PM, SM,  
28 EW, TDO, BSi, JH and CF contributed to data collection; AMW, LM, BG, DB, BSa, PC, HM,  
29 RB, SM, EW, TDO, NLB, JH and CF contributed to data analysis and dissemination; AMW, BG,  
30 JH and CF wrote the manuscript; all authors reviewed the manuscript for content.  
31  
32  
33  
34  
35  
36  
37

### **Funding**

38  
39  
40  
41

42 This work was supported by the Division of AIDS, National Institute of Drug Abuse, grant number  
43 R01 DA043409. 301 North Stonestreet Ave, Bethesda, MD 20892. +1 301-443-1124.  
44  
45  
46

### **Competing interests**

47  
48  
49

50 All authors state that they have no competing interests.  
51  
52

53 Figure 1. Map of Study Sites  
54  
55  
56  
57



1  
2  
3 Figure 2. Study Flow Diagram  
4  
5  
6  
7  
8

9 **References**  
10

- 11  
12 1. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be  
13 achieved? A systematic analysis of national HIV treatment cascades. *BMJ Glob Health*.  
14 2016;1(2):e000010. doi:10.1136/bmjgh-2015-000010  
15  
16 2. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Published  
17 October 2014. Accessed March 7, 2018.  
18 [http://www.unaids.org/sites/default/files/media\\_asset/90-90-90\\_en.pdf](http://www.unaids.org/sites/default/files/media_asset/90-90-90_en.pdf)  
19  
20 3. Staveteig S, Croft TN, Kampa KT, Head SK. Reaching the 'first 90': Gaps in coverage of HIV testing  
21 among people living with HIV in 16 African countries. *PLOS ONE*. 2017;12(10):e0186316.  
22 doi:10.1371/journal.pone.0186316  
23  
24 4. National AIDS and STI Control Programme (NASCOP). *Preliminary KENPHIA 2018 Report.*; 2020.  
25 Accessed December 16, 2020. [https://phia.icap.columbia.edu/wp-](https://phia.icap.columbia.edu/wp-content/uploads/2020/04/KENPHIA-2018_Preliminary-Report_final-web.pdf)  
26 [content/uploads/2020/04/KENPHIA-2018\\_Preliminary-Report\\_final-web.pdf](https://phia.icap.columbia.edu/wp-content/uploads/2020/04/KENPHIA-2018_Preliminary-Report_final-web.pdf)  
27  
28 5. Brodish P, Singh K, Rinyuri A, et al. Evidence of high-risk sexual behaviors among injection drug  
29 users in the Kenya PLACE study. *Drug Alcohol Depend*. 2011;119(1-2):138-141.  
30 doi:10.1016/j.drugalcdep.2011.05.030  
31  
32 6. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV  
33 among people who inject drugs: a systematic review. *Lancet Lond Engl*. 2008;372(9651):1733-  
34 1745. doi:10.1016/S0140-6736(08)61311-2  
35  
36 7. National AIDS Control Council NS and ACP. Kenya HIV Prevention Revolution Road Map: Count  
37 Down to 2030. Published online June 2014.  
38  
39 8. Kurth AE, Cleland CM, Des Jarlais DC, et al. HIV Prevalence, Estimated Incidence, and Risk  
40 Behaviors Among People Who Inject Drugs in Kenya. *J Acquir Immune Defic Syndr* 1999.  
41 2015;70(4):420-427. doi:10.1097/QAI.0000000000000769  
42  
43 9. Ndetei, David M. A study on the linkages between drug abuse, injecting drug use and HIV/AIDS in  
44 Kenya: a rapid situation assessment. *U N Off Drugs Crime*.:45.  
45  
46 10. Odek-Ogunde M, Okoth, F, Lore, W, Owiti, F.R. Seroprevalence of HIV, HBC and HCV in Injecting  
47 Drug Users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II Findings. In:  
48 ; 2004.  
49  
50 11. National AIDS Control Council. *Kenya HIV Estimates Report 2018*. Accessed February 21, 2019.  
51 <https://nacc.or.ke/wp-content/uploads/2018/11/HIV-estimates-report-Kenya-20182.pdf>  
52  
53  
54  
55  
56  
57  
58  
59  
60

12. Tun W, Sheehy M, Broz D, et al. HIV and STI Prevalence and Injection Behaviors Among People Who Inject Drugs in Nairobi: Results from a 2011 Bio-behavioral Study Using Respondent-Driven Sampling. *AIDS Behav.* 2015;19(Suppl 1):24-35. doi:10.1007/s10461-014-0936-3
13. Lizcano, J. Testing and Linkage to Care for Injecting Drug Users. In: ; 2016.
14. Githuka G, Hladik W, Mwalili S, et al. Populations at Increased Risk for HIV Infection in Kenya: Results From a National Population-Based Household Survey, 2012. *J Acquir Immune Defic Syndr* 1999. 2014;66(Suppl 1):S46-S56. doi:10.1097/QAI.0000000000000137
15. Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. *Lancet Infect Dis.* 2019;19(11):1255-1263. doi:10.1016/S1473-3099(19)30264-6
16. Muasya T, Lore W, Yano K, et al. Prevalence of Hepatitis C Virus and its genotypes among a cohort of drug users in Kenya. *East Afr Med J.* 2008;85(7). doi:10.4314/eamj.v85i7.9649
17. Bartonjo G, Oundo J, Ng'ang'a Z. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. *Pan Afr Med J.* 2019;34. doi:10.11604/pamj.2019.34.31.17885
18. Loarec A, Carnimeo V, Molino L, et al. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. *AIDS Lond Engl.* 2019;33(2):353-355. doi:10.1097/QAD.0000000000002070
19. Litwin AH, Jost J, Wagner K, et al. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. *Contemp Clin Trials.* 2019;87:105859. doi:10.1016/j.cct.2019.105859
20. Treloar C, Hull P, Dore GJ, Grebely J. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. *Drug Alcohol Rev.* 2012;31(7):918-924. doi:10.1111/j.1465-3362.2012.00468.x
21. Enkelmann J, Gassowski M, Nielsen S, et al. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing. *Harm Reduct J.* 2020;17(1):7. doi:10.1186/s12954-019-0338-y
22. Day E, Hellard M, Treloar C, et al. Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. *Liver Int Off J Int Assoc Study Liver.* 2019;39(1):20-30. doi:10.1111/liv.13949
23. Medecins du Monde. Our Activities in Kenya. Accessed November 24, 2020. <https://www.medecinsdumonde.org/en/countries/africa/kenya>
24. Cherutich P, Kurth A, Lizcano JA, Akiyama MJ. Integration of Hepatitis C treatment services with harm reduction service centers for people who inject drugs in Kenya: experience from test and link to care for injecting drug users study. In: *Reviews in Antiviral Therapy & Infectious Diseases.* ; 2019.

- 1
- 2
- 3 25. Dalal S, Johnson C, Fonner V, et al. Improving HIV test uptake and case finding with assisted  
4 partner notification services. *AIDS Lond Engl*. 2017;31(13):1867-1876.  
5 doi:10.1097/QAD.0000000000001555  
6
- 7 26. Kahabuka C, Plotkin M, Christensen A, et al. Addressing the First 90: A Highly Effective Partner  
8 Notification Approach Reaches Previously Undiagnosed Sexual Partners in Tanzania. *AIDS Behav*.  
9 2017;21(8):2551-2560. doi:10.1007/s10461-017-1750-5  
10
- 11 27. Cherutich P, Golden MR, Wamuti B, et al. Assisted partner services for HIV in Kenya: a cluster  
12 randomised controlled trial. *Lancet HIV*. 2017;4(2):e74-e82. doi:10.1016/S2352-3018(16)30214-4  
13
- 14 28. Plotkin M, Kahabuka C, Christensen A, et al. Outcomes and Experiences of Men and Women with  
15 Partner Notification for HIV Testing in Tanzania: Results from a Mixed Method Study. *AIDS Behav*.  
16 2018;22(1):102. doi:10.1007/s10461-017-1936-x  
17
- 18 29. Sharma M, Smith JA, Farquhar C, et al. Assisted partner notification services are cost-effective for  
19 decreasing HIV burden in western Kenya. *AIDS Lond Engl*. 2018;32(2):233-241.  
20 doi:10.1097/QAD.0000000000001697  
21
- 22 30. Landis SE, Schoenbach VJ, Weber DJ, et al. Results of a randomized trial of partner notification in  
23 cases of HIV infection in North Carolina. *N Engl J Med*. 1992;326(2):101-106.  
24 doi:10.1056/NEJM199201093260205  
25
- 26 31. Myers RS, Feldacker C, Cesár F, et al. Acceptability and Effectiveness of Assisted Human  
27 Immunodeficiency Virus Partner Services in Mozambique: Results From a Pilot Program in a Public,  
28 Urban Clinic. *Sex Transm Dis*. 2016;43(11):690-695. doi:10.1097/OLQ.0000000000000529  
29
- 30 32. Brown LB, Miller WC, Kamanga G, et al. HIV partner notification is effective and feasible in sub-  
31 Saharan Africa: opportunities for HIV treatment and prevention. *J Acquir Immune Defic Syndr*  
32 1999. 2011;56(5):437-442.  
33
- 34 33. Brown LB, Miller WC, Kamanga G, et al. Predicting partner HIV testing and counseling following a  
35 partner notification intervention. *AIDS Behav*. 2012;16(5):1148-1155. doi:10.1007/s10461-011-  
36 0094-9  
37
- 38 34. World Health Organization. WHO | WHO recommends assistance for people with HIV to notify  
39 their partners. WHO. Accessed February 22, 2019. [http://www.who.int/hiv/pub/vct/who-partner-  
40 notification-policy/en/](http://www.who.int/hiv/pub/vct/who-partner-notification-policy/en/)  
41
- 42 35. Quinn C, Nakyanjo N, Ddaaki W, et al. HIV partner notification values and preferences among sex  
43 workers, fishermen, and mainland community members in Rakai, Uganda: a qualitative study. *AIDS*  
44 *Behav*. 2018;22(10):3407-3416. doi:10.1007/s10461-018-2035-3  
45
- 46 36. Rane V, Tomnay J, Fairley C, et al. Opt-Out Referral of Men Who Have Sex With Men Newly  
47 Diagnosed With HIV to Partner Notification Officers: Results and Yield of Sexual Partners Being  
48 Contacted. *Sex Transm Dis*. 2016;43(6):341-345. doi:10.1097/OLQ.0000000000000449  
49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
- 2
- 3
- 4 37. Halkitis PN, Kupprat SA, McCree DH, et al. Evaluation of the relative effectiveness of three HIV
- 5 testing strategies targeting African American men who have sex with men (MSM) in New York City.
- 6 *Ann Behav Med Publ Soc Behav Med.* 2011;42(3):361-369. doi:10.1007/s12160-011-9299-4
- 7
- 8 38. Levy JA, Fox SE. The outreach-assisted model of partner notification with IDUs. *Public Health Rep*
- 9 *Wash DC 1974.* 1998;113 Suppl 1:160-169.
- 10
- 11 39. Malik M, Jamil MS, Johnson CC, Pasha MS, Hermez J, Qureshi S ul H. Integrating assisted partner
- 12 notification within HIV prevention service package for people who inject drugs in Pakistan. *J Int*
- 13 *AIDS Soc.* 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25317
- 14
- 15 40. DeBeck K, Cheng T, Montaner JS, et al. HIV and the criminalisation of drug use among people who
- 16 inject drugs: a systematic review. *Lancet HIV.* 2017;4(8):e357-e374. doi:10.1016/S2352-
- 17 3018(17)30073-5
- 18
- 19 41. United Nations, Office on Drugs and Crime. *World Drug Report 2016.*; 2016.
- 20
- 21 42. Molinaro S, Resce G, Alberti A, et al. Barriers to effective management of hepatitis C virus in
- 22 people who inject drugs: Evidence from outpatient clinics. *Drug Alcohol Rev.* 2019;38(6):644-655.
- 23 doi:10.1111/dar.12978
- 24
- 25 43. Phillips KT. Barriers to practicing risk reduction strategies among people who inject drugs. *Addict*
- 26 *Res Theory.* 2016;24(1):62-68. doi:10.3109/16066359.2015.1068301
- 27
- 28 44. Heath AJ, Kerr T, Ti L, et al. Healthcare avoidance by people who inject drugs in Bangkok, Thailand.
- 29 *J Public Health Oxf Engl.* 2016;38(3):e301-e308. doi:10.1093/pubmed/fdv143
- 30
- 31 45. Frost SDW, Pillay D. Understanding Drivers of Phylogenetic Clustering in Molecular Epidemiological
- 32 Studies of HIV. *J Infect Dis.* 2015;211(6):856-858. doi:10.1093/infdis/jiu563
- 33
- 34 46. Brenner BG, Wainberg MA. Future of phylogeny in HIV prevention. *J Acquir Immune Defic Syndr*
- 35 *1999.* 2013;63 Suppl 2:S248-254. doi:10.1097/QAI.0b013e3182986f96
- 36
- 37 47. Jacka B, Applegate T, Kraiden M, et al. Phylogenetic clustering of hepatitis C virus among people
- 38 who inject drugs in Vancouver, Canada. *Hepatology Baltim Md.* 2014;60(5):1571-1580.
- 39 doi:10.1002/hep.27310
- 40
- 41 48. Grabowski MK, Lessler J, Redd AD, et al. The Role of Viral Introductions in Sustaining Community-
- 42 Based HIV Epidemics in Rural Uganda: Evidence from Spatial Clustering, Phylogenetics, and
- 43 Egocentric Transmission Models. Hallett T, ed. *PLoS Med.* 2014;11(3):e1001610.
- 44 doi:10.1371/journal.pmed.1001610
- 45
- 46 49. Worobey M, Gemmel M, Teuwen DE, et al. Direct Evidence of Extensive Diversity of HIV-1 in
- 47 Kinshasa by 1960. *Nature.* 2008;455(7213):661-664. doi:10.1038/nature07390
- 48
- 49 50. de Oliveira T, Pillay D, Gifford RJ. The HIV-1 Subtype C Epidemic in South America Is Linked to the
- 50 United Kingdom. *PLoS ONE.* 2010;5(2). doi:10.1371/journal.pone.0009311
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1  
2  
3 51. Hughes GJ, Fearnhill E, Dunn D, Lycett SJ, Rambaut A, Leigh Brown AJ. Molecular Phylodynamics of  
4 the Heterosexual HIV Epidemic in the United Kingdom. *PLoS Pathog.* 2009;5(9).  
5 doi:10.1371/journal.ppat.1000590  
6
- 7 52. Hué S, Clewley JP, Cane PA, Pillay D. Investigation of HIV-1 transmission events by phylogenetic  
8 methods: requirement for scientific rigour. *AIDS Lond Engl.* 2005;19(4):449-450.  
9 doi:10.1097/01.aids.0000161778.15568.a1  
10
- 11 53. Dennis AM, Hué S, Hurt CB, et al. Phylogenetic insights into regional HIV transmission. *AIDS Lond*  
12 *Engl.* 2012;26(14):1813-1822. doi:10.1097/QAD.0b013e3283573244  
13  
14
- 15 54. Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the  
16 molecular epidemiology of newly diagnosed HIV infections. *AIDS Lond Engl.* 2012;26(16):2079-  
17 2086. doi:10.1097/QAD.0b013e32835805b6  
18
- 19 55. Kouyos RD, Rauch A, Böni J, et al. Clustering of HCV coinfections on HIV phylogeny indicates  
20 domestic and sexual transmission of HCV. *Int J Epidemiol.* 2014;43(3):887-896.  
21 doi:10.1093/ije/dyt276  
22
- 23 56. Fisher M, Pao D, Brown AE, et al. Determinants of HIV-1 transmission in men who have sex with  
24 men: a combined clinical, epidemiological and phylogenetic approach. *AIDS.* 2010;24(11):1739-  
25 1747. doi:10.1097/QAD.0b013e32833ac9e6  
26  
27
- 28 57. Brenner BG, Roger M, Routy J-P, et al. High rates of forward transmission events after acute/early  
29 HIV-1 infection. *J Infect Dis.* 2007;195(7):951-959. doi:10.1086/512088  
30
- 31 58. Kramer MA, Cornelissen M, Paraskevis D, et al. HIV transmission patterns among The Netherlands,  
32 Suriname, and The Netherlands Antilles: a molecular epidemiological study. *AIDS Res Hum*  
33 *Retroviruses.* 2011;27(2):123-130. doi:10.1089/aid.2010.0115  
34
- 35 59. Henley C, Forgewei G, Welty T, et al. Scale-up and case-finding effectiveness of an HIV partner  
36 services program in Cameroon: an innovative HIV prevention intervention for developing  
37 countries. *Sex Transm Dis.* 2013;40(12):909-914. doi:10.1097/OLQ.0000000000000032  
38  
39
- 40 60. Centers for Disease Control and Prevention (CDC). Intimate Partner Violence and Sexual Violence  
41 Victimization Assessment Instruments for Use in Healthcare Settings: (410572008-001). Published  
42 online 2007. doi:10.1037/e410572008-001  
43
- 44 61. Monroe-Wise A, Maingi Mutiti P, Kimani H, Moraa H, Bukusi DE, Farquhar C. Assisted partner  
45 notification services for patients receiving HIV care and treatment in an HIV clinic in Nairobi,  
46 Kenya: a qualitative assessment of barriers and opportunities for scale-up. *J Int AIDS Soc.*  
47 2019;22(Suppl Suppl 3). doi:10.1002/jia2.25315  
48
- 49 62. Goyette MS, Mutiti PM, Bukusi D, et al. Hiv Assisted Partner Services Among Those with and  
50 Without A History of Intimate Partner Violence in Kenya. *J Acquir Immune Defic Syndr* 1999.  
51 Published online February 5, 2018. doi:10.1097/QAI.0000000000001638  
52  
53  
54  
55  
56  
57

- 1  
2  
3 63. KELIN and the Kenya Key Populations Consortium. "Everyone Said No:" *Biometrics, HIV and Human Rights – A Kenya Case Study*. KELIN; 2018. Accessed April 10, 2020.  
4 <https://www.kelinkenya.org/everyonesaidno/>  
5  
6  
7  
8 64. Gathura G. Biometrics system for identifying people living with HIV ready. *The Standard*.  
9 [https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready)  
10 [living-with-hiv-ready](https://www.standardmedia.co.ke/article/2001349675/biometrics-system-for-identifying-people-living-with-hiv-ready). Published November 17, 2019. Accessed April 10, 2020.  
11  
12 65. Anne N, Dunbar MD, Abuna F, et al. Feasibility and acceptability of an iris biometric system for  
13 unique patient identification in routine HIV services in Kenya. *Int J Med Inf*. 2020;133:104006.  
14 doi:10.1016/j.ijmedinf.2019.104006  
15  
16  
17  
18  
19  
20  
21

22 **Table 1. Inclusion and Exclusion Criteria**  
23

24

<u>Group</u>	<u>Inclusion</u>	<u>Exclusion</u>
<i>Index</i>	<ul style="list-style-type: none"> <li>• 18 years of age or older</li> <li>• Recent intravenous drug use as defined by injecting at least once in the past year</li> <li>• HIV-positive</li> <li>• Willing and able to provide locator information for sexual and/or injecting partners</li> <li>• Willing and able to provide informed consent</li> </ul>	<ul style="list-style-type: none"> <li>• Classified as at high risk for IPV (described below)</li> </ul>
<i>Partner</i>	<ul style="list-style-type: none"> <li>• 18 years of age or older</li> <li>• identified by an index as either having injected with the index in the past 3 years or had sexual intercourse with the index in the past three years</li> <li>• Willing and able to provide informed consent</li> </ul>	None

25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Map of Study Sites

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2. Study Flow Diagram

683x449mm (96 x 96 DPI)



1  
2  
3  
4  
5 APPENDIX A: PEER EDUCATOR INTRODUCTION SCRIPT  
6  
7  
8

9 Hello, I am \_\_\_\_\_, a Peer Educator from \_\_\_\_\_. Am I speaking with  
10 Ms/Mr. \_\_\_\_\_? I want to be sure I have the right person in front of me. I work at the  
11 clinic and have come to talk with you about a health matter that concerns you. This is  
12 confidential information for you. Is this a good time to talk? This will not take long and I assure  
13 you that our discussion will be confidential.  
14

15 The information I have concerns your health but it does not mean that something is wrong with  
16 your health. We have reason to believe that you may have a health problem, and that you may  
17 also be eligible for a research study. You will have to come to the clinic to get more information  
18 about both your health issue and the research study. If you agree, you can come to the clinic with  
19 me now and I will bring you to the clinician.  
20

21 Do you have any questions about what I have said so far?  
22

23 If you do not want to come to the clinic, I will return to find you again tomorrow with someone  
24 from the clinic who can talk to you about the health issue.  
25

26 Have you made a decision about whether you'd like to come with me?  
27

28 If yes, I will take you to [name of closest clinic] center for further discussions with the clinician  
29 at the clinic. If no, we will come back and find you again at a later date to discuss this issue with  
30 you further.  
31

32 Thank you.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 APPENDIX B: HEALTH ADVISOR INTRODUCTION SCRIPT  
6  
7  
8

9 Hello, I am \_\_\_\_\_, a Health Advisor from the Kenya Ministry of Health. Am I speaking  
10 with Ms/Mr. \_\_\_\_\_? I want to be sure I have the right person in front of me. I work at  
11 the clinic and have come to talk with you about a health matter that concerns you. This is  
12 confidential information for you. Is this a good time to talk? This will not take long and I assure  
13 you that our discussion will be confidential.  
14  
15

16 The information I have concerns your health but it does not mean that something is wrong with  
17 your health.  
18  
19

20 I wish to inform you that you may have been exposed to HIV infection. I do not know who gave  
21 me information on your exposure to HIV infection.  
22  
23

24 This does not mean you are infected. It just means that you have been exposed to HIV and will  
25 need to test yourself soon to see what your HIV status is.  
26  
27

28 This HIV test will help you to know your status early and if you are not infected, you can plan to  
29 avoid future infections. If you are infected, you will receive advice on how to live positively.  
30  
31

32 You can do your test anywhere you choose, but it is advisable that you do it as soon as possible.  
33  
34

35 Do you have any questions about what I have said so far?  
36  
37

38 If you choose to do your HIV test now, I will do it for you free of charge, but before doing it, I  
39 will give you more information on voluntary counseling and testing for HIV.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 If you want to do it later, I will give you more information on health facilities where you can go  
4 and do your test.  
5  
6

7  
8 I will be in touch with you for any assistance which you made need. Would you like to have my  
9 telephone number? Would you like me to call you?  
10  
11

12  
13 I have this information for you and would like you to read it carefully and discuss it with me. If it  
14 is ok with you, please sign it. I will keep it confidential. You do not have to sign it if you do not  
15 want to.  
16  
17  
18

19  
20 Have you made a decision to do the test? When and where will you like to do it?  
21  
22

23  
24 Would you like for us to test you?  
25  
26

27  
28 If yes, would you like to come to the [name of closest clinic] center for testing or where would  
29 you want us to offer the test for you? If at home or work, please arrange for a private place where  
30 we can offer the service. If no, we would still encourage you to seek services at [name of nearest  
31 clinic].  
32  
33  
34

35  
36 Thank you.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___ 1 ___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___ 21 ___
	2b	All items from the World Health Organization Trial Registration Data Set	___ Included ___
Protocol version	3	Date and version identifier	___ 1 ___
Funding	4	Sources and types of financial, material, and other support	___ 23 ___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___ 1, 23 ___
	5b	Name and contact information for the trial sponsor	_____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___ N/A ___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___ N/A ___

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention \_\_\_ 5-7 \_\_\_

4

5

6 6b Explanation for choice of comparators \_\_\_ N/A \_\_\_

7

8 Objectives 7 Specific objectives or hypotheses \_\_\_ 6-7 \_\_\_

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) \_\_\_ 8 \_\_\_

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained \_\_\_ 8 \_\_\_

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) \_\_\_ 10-11 \_\_\_

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered \_\_\_ 11-14 \_\_\_

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) \_\_\_ N/A \_\_\_

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) \_\_\_ N/A \_\_\_

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial \_\_\_ 17 \_\_\_

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended \_\_\_ 18 \_\_\_

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) \_\_\_ 15 \_\_\_

41

42

43

44

45

46

1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including \_\_\_\_\_19\_\_\_\_\_

2 clinical and statistical assumptions supporting any sample size calculations

3

4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size \_\_\_\_\_11\_\_\_\_\_

5

6 **Methods: Assignment of interventions (for controlled trials)**

7 Allocation:

8

9

10 Sequence 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any \_\_\_\_\_N/A\_\_\_\_\_

11 generation factors for stratification. To reduce predictability of a random sequence, details of any planned restriction

12 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants

13 or assign interventions

14

15

16 Allocation 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, \_\_\_\_\_N/A\_\_\_\_\_

17 concealment opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

18 mechanism

19

20 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to \_\_\_\_\_N/A\_\_\_\_\_

21 interventions

22

23

24 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome \_\_\_\_\_N/A\_\_\_\_\_

25 assessors, data analysts), and how

26

27 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's \_\_\_\_\_N/A\_\_\_\_\_

28 allocated intervention during the trial

29

30

31 **Methods: Data collection, management, and analysis**

32

33 Data collection 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related \_\_\_\_\_12\_\_\_\_\_

34 methods processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of

35 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.

36 Reference to where data collection forms can be found, if not in the protocol

37

38

39 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be \_\_\_\_\_15\_\_\_\_\_

40 collected for participants who discontinue or deviate from intervention protocols

41

42

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___ 18 ___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___ 19-20 ___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___ N/A ___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___ N/A ___
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___ N/A ___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___ N/A ___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___ 21-22 ___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___ N/A ___
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___ 21 ___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___ 22 ___
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	__12-13__
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	__12-13__
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	__16-18__
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	__23__
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	__18__
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	__17-18__
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	__22-23__
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	__23__
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	__N/A__
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	__Attached__
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	__14-15, 20__
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.  
 40  
 41  
 42